

CURRICULUM VITAE

David S. Alberts, M.D.

**Regents Professor of Medicine, Pharmacology, Public Health,
Nutritional Sciences, & BIO5 Institute
And
Director, Arizona Cancer Center**

Table of Contents

Sections	Page
Education	2
Specialty Board Certification	2
Academic Appointments	2
University of Arizona Professional Committees, Programs and Boards.....	3
National Cancer Institute/National Institutes of Health Committees	4
National Scientific Advisory Boards	5
National Academic Research Activities	6
National Academic Service Activities	7
Local, State and National Honors/Awards	8
National Honorary Lectures	10
Patents and Inventions	11
Editorial Boards	12
Professional/Honorary Societies	13
Advising and Mentoring Activities	14
Faculty Mentoring	17
Teaching Activities/Talks	17
Current Grant Funding.....	21
 <i>Publications:</i>	
A. Articles Published in Peer Reviewed Journals	22
B. Submitted/In Press Articles	55
C. Invited Journal Publications	56
D. Books	59
E. Book Chapters	59
F. Editorials	66
G. Pamphlets/Monographs	68
H. Abstracts	70

CURRICULUM VITAE

David S. Alberts, M.D.

**Regents Professor of Medicine, Pharmacology, Public Health,
Nutritional Sciences, & BIO5 Institute
And
Director, Arizona Cancer Center**

BUSINESS ADDRESS: Arizona Cancer Center
The University of Arizona College of Medicine
1515 North Campbell Avenue
PO Box 245024
Tucson, AZ 85724-5024
Phone: (520) 626-7925
Fax: (520) 626-6898
E-mail: dalberts@azcc.arizona.edu

LICENSURE: Arizona (Active); California (Inactive); Virginia (Inactive)

EDUCATION:

1955-1958 Shorewood High School, Milwaukee, WI
1958-1962 Trinity College, Hartford, CT
1962-1966 University of Virginia School of Medicine, Charlottesville, VA (MD)
1966-1967 Internship (Medicine), University of Wisconsin, Madison, WI
1967-1969 Clinical Associate (Pharmacology Lab, Dr. Nicholas Bachur) NCI, NIH, Baltimore Cancer Research Center, Baltimore, MD
1969-1971 Residency (Medicine), University of Minnesota, Minneapolis, MN
1972-1974 PMA Faculty Trainee in Clinical Pharmacology, University of California Clinical Pharmacology Program, (Dr. Malcolm Rowland, Project Supervisor), Dept. Internal Medicine, San Francisco, CA

SPECIALTY BOARD CERTIFICATION:

1973 Diplomate of American Board of Internal Medicine
1973 Diplomate of American Board of Internal Medicine, Subspecialty of Medical Oncology

ACADEMIC APPOINTMENTS:

1971-1972 Clinical Instructor of Internal Medicine (Faculty), Cancer Research Institute, University of California, San Francisco, San Francisco, CA
1972-1974 Instructor of Internal Medicine, Cancer Research Institute, University of California, San Francisco, San Francisco, CA

- 1974-1975 Assistant Professor of Internal Medicine and Radiology, Cancer Research Institute, University of California, San Francisco, San Francisco, CA
- 1975-1978 Assistant Professor of Internal Medicine, Section of Hematology-Oncology, University of Arizona College of Medicine, Tucson, AZ
- 1975-1993 Director, Clinical Pharmacology, Pharmacology Program, Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ
- 1978-1979 Associate Professor of Internal Medicine, Section of Hematology-Oncology, University of Arizona College of Medicine, Tucson, AZ
- 1979-1982 Associate Professor of Medicine and Pharmacology, University of Arizona College of Medicine, Tucson, AZ
- 1982-present Professor of Medicine and Pharmacology, Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ
- 1985-present Faculty Member, Nutritional Sciences, University of Arizona, Tucson, AZ
- 1987-1989 Director, Section of Clinical Pharmacology, Dept. Pharmacology, University of Arizona College of Medicine, Tucson, AZ
- 1988-2005 Director, Cancer Prevention and Control Program, Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ
- 1990-1996 Deputy Director, Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ
- 1996-2002 Associate Dean for Research, University of Arizona College of Medicine, Tucson, AZ
- 1998-present Clinical Professor of Medicine, School of Medicine, University of Mississippi Medical Center, Jackson, MS
- 1999-present Professor of Public Health, College of Public Health, University of Arizona, Tucson, AZ
- 2003-present Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences, and BIO5 Institute, University of Arizona, Tucson, AZ
- 2005-present Director, Arizona Cancer Center

UNIVERSITY OF ARIZONA PROFESSIONAL COMMITTEES, PROGRAMS AND BOARDS:

- 1975-1978 Pharmacy Committee, University of Arizona Health Sciences Center, Tucson, AZ
- 1976-1985 Director, Fellowship Training Program, Section of Hematology and Oncology, Dept. Medicine, University of Arizona College of Medicine, Tucson, AZ
- 1976-1988 Surgical Review Committee, University of Arizona Health Sciences Center, Tucson, AZ
- 1976-1992 Member and Chairperson (1985-1992), Human Subjects CPommittee, Dept. Medicine, University of Arizona College of Medicine, Tucson, AZ
- 1979-1983 Animal Resources Committee, University of Arizona Health Sciences Center, Tucson, AZ
- 1979-1989 Chairperson, Tumor Board, University of Arizona College of Medicine, Tucson, AZ
- 1984-1999 Institutional Cancer Research Grant Committee, Dept Microbiology and Immunology, University of Arizona College of Medicine, Tucson, AZ
- 1986-1990 Director, Clin Pharmacol Training Grant, University of Arizona College of Medicine, Tucson, AZ
- 1988-1992 Promotions & Tenure Committee, Dept Int Med, Univ Arizona College of Medicine, Tucson, AZ
- 1991-1992 Member, Dept. Pharmacology Head Search Committee, University of Arizona College of Medicine, Tucson, AZ

- 1991-1996 Member, Management Committee, Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ
- 1992-1997 Member, Strategic Planning Committee, Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ
- 1992-1996 Executive Committee Member, Arizona's Women's Cancer Network, Arizona Dept. Health Services, Phoenix, AZ
- 1993 Chairperson, Arizona Cancer Plan Subcommittee, Oncology Committee, Arizona Dept. Health Services, Phoenix, AZ
- 1994-1996 Member and Chairperson (1995-1996), Ad Hoc Committee on Clinical Drug Studies and Clinical Trials Policy, Dept. Medicine, University of Arizona College of Medicine, Tucson, AZ
- 1995-1996 Alternate Member, Human Subjects Committee, University of Arizona, Tucson, AZ
- 1996 Conference Co-chairperson, 8th International Conference on the Adjuvant Therapy of Cancer, Scottsdale, AZ, March 13-16, Sponsored by Arizona Cancer Center, Tucson, AZ
- 1996-present Member, Nutritional Sciences Faculty Committee, Univ AZ College of Medicine, Tucson, AZ
- 1998 Member, Search Committee for Vice President for Research, University of Arizona, Tucson, AZ
- 1999-2000 Member, Phoenix Planning Team Taskforce, University of Arizona, Tucson, AZ
- 1999-2000 Member, Search Committee for Executive Director of Development, Arizona Health Sciences Center, University of Arizona, Tucson, AZ
- 2000 Member, Provost Search Committee, University of Arizona, Tucson, AZ
- 2001-present Member, Board of Directors and Chair, Research Committee, Sunstone Healing Center, Tucson, Arizona
- 2004-2007 Member, Arizona Comprehensive Cancer Control Steering Committee, Arizona Department of Health Services
- 2004-2005 Dean's Faculty Advisory Committee (elected position), Univ. Arizona College of Medicine
- 2004- Member, Planning Committee for Biomedical Imaging, University of Arizona
- 2005- Member, Better Than Ever Committee, Setsuko K. Chambers, MD, Chair
- 2005-2007 Member, Executive Committee, Advanced Research Institute for Biomedical Imaging, University of Arizona Health Sciences Center, College of Medicine
- 2007- Internal Advisory Committee and Developmental Research Committee, Lymphoma SPORE, for Dr. Thomas Miller, University of Arizona, College of Medicine, Tucson, Arizona
- 2008- Vice President for Health Affairs Search Advisory Committee, University of Arizona, College of Medicine, Tucson, Arizona

NATIONAL CANCER INSTITUTE / NATIONAL INSTITUTES OF HEALTH COMMITTEES:

- 1984-1990 Reviewer, Outstanding Investigator Grant, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1986-1990 Director, NIH Clinical Pharmacology Training Grant, University of Arizona College of Medicine, Tucson, AZ
- 1990-1994 Member, Board of Scientific Counselors, Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of Health, Bethesda, MD

- 1994-1995 Member, Chemoprevention Agent Phase I Panel, Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1995-present Member, Monitoring and Advisory Panel for Prostate-Lung-Colon-Ovary Trial, Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1995-2000 Member, Cancer Prevention Working Group, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1997-present Reviewer, PDQ[®] Screening and Prevention Advisory Board, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1998-2001 Chairperson, Chemoprevention Implementation Committee, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1999-2006 Member, Board of Scientific Advisors, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 2002-present Member, National Lung Cancer Screening Trial (NLST) Oversight Committee, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 2003-present Member, Prostate, Lung, Colorectal and Ovarian (PLCO) Biorepository Scientific Advisory Panel, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 2004-2006 Member, Clinical Trials Working Group of the National Cancer Advisory Board, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 2004-present Associate Member, Early Detection Research Network (EDRN), Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 2004-2006 NCI/NCAB Clinical Trials Working Group, Planning Committee
- 2004-2006 NCI Clinical Trials Working Group, Co-Chairman of Coordination of Clinical Trials Efforts and Interactions
- 2006-2009 Member, Clinical Trials Advisory Committee (CTAC), and Ad Hoc Coordinating Committee, Guidelines Harmonization Working Group, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 2011-present Member, National Cancer Institute, Division of Extramural Activities, Special Emphasis Review Panel for Loan Repayment Program, Bethesda, MD
- 2011-present Member, Oversight Committee, The National Lung Screening Trial Research Team. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD

NATIONAL SCIENTIFIC ADVISORY BOARDS AND COMMITTEES:

- 1993-1999 External Advisor, Tulane University Cancer Center, New Orleans, LA
- 1993-2000 Chairperson, External Advisory Committee, University of Chicago Cancer Research Center, Chicago, IL
- 1994-1999 Chairperson, External Advisory Committee, Division of Cancer Prevention and Control, MD Anderson Cancer Center, Houston, TX
- 1995-1998 External Scientific Advisor, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Hanover, NH
- 1995-1996 Member, Advisory Committee, Colon Cancer Prevention Research Unit, University of Minnesota, Minneapolis, MN

- 1996-2004 Member, Data and Safety Monitoring Committee, Chemoprevention Trial of Gastric Dysplasias in Columbia, Louisiana State University Medical Center, New Orleans, LA
- 1997-1999 Member, External Advisory Committee, NIH Institutional Development Award, University of Kansas Medical Center, Kansas City, KS
- 1997-2003 Member, External Advisory Board, MD Anderson Cancer Center, University of Texas, Houston, TX
- 1998-2004 Member, External Advisory Board, “Natural Inhibitors of Carcinogenesis” Program Project (P01 CA48112), Pezzuto JM (PI), University of Illinois, Chicago, IL
- 1999-2003 Member, External Advisory Board, Johns Hopkins Oncology Center, Baltimore, MD
- 1999-2004 Member, External Advisory Committee, San Antonio Cancer Institute, University of Texas Health Science Center, San Antonio, TX
- 2002-2004 Member, APPEAL Data and Safety Monitoring Committee, Fred Hutchinson Cancer Research Center, Seattle, WA
- 2000-2004 Member, External Advisory Committee, SPORE for Melanoma, MD Anderson Cancer Center, University of Texas, Houston, TX
- 2003-2006 Member, External Advisory Committee, SPORE for Ovarian Cancer, Fox Chase Cancer Center, Philadelphia, PA
- 2003-2006 Member, Council of Scientific Advisors, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL
- 2008-present Member, C-Change Committee, Washington, DC
- 2011-2013 Member Minority Biospecimen Geographic Management Region 4 Implementation Plan – Core Service.

NATIONAL ACADEMIC RESEARCH ACTIVITIES:

- 1980-2001 Chairperson, Gynecologic Cancer Committee, Southwest Oncology Group
- 1981-1989 Chairperson, Hematologic and Neoplastic Disease Section, American Society for Clinical Pharmacology and Therapeutics
- 1982-1989 Executive Directors Committee, American Society for Clinical Pharmacology and Therapeutics
- 1985-1996 Executive Subcommittee, Gastrointestinal Cancer Committee, Southwest Oncology Group
- 1995-present Chairperson, Cancer Prevention and Control Committee, Gynecologic Oncology Group
- 2001-2003 Chairperson, Intraepithelial Neoplasia Committee, International Genome Consortium (IGC), Phoenix, AZ
- 2005-2007 Member, Translational Research Working Group, Core Services/Coordination Subcommittee, National Cancer Institute, Bethesda, MD
- 2007-2009 Co-Chair, Gynecologic Cancer Committee, Southwest Oncology Group
- 2007-2010 Member, Ad Hoc Coordinating Committee, Clinical Translational Advisory Committee, Division of Cancer Treatment and Diagnosis, National Cancer Institute
- 2010-present Member, National Call to Action on Cancer Prevention and Survivorship Committee
- 2011 Member Advisory Board, “Stand Up To Cancer, A Nationwide Approach to Chemoprevention Trials,” Huntsman Cancer Institute, Salt Lake City, UT

2013-present Member National Cancer Institute, Division of Cancer Prevention, Early Phase Prevention Consortia Executive Committee

NATIONAL ACADEMIC SERVICE ACTIVITIES:

1980-1984 Member and Chairperson (1982-1984), Oncologic Advisory Committee, U.S. Food and Drug Administration

1984-1985 Scientific Program Committee, American Society for Clinical Oncology

1984-1986 Special Consultant, Oncologic Drug Section, U.S. Food and Drug Administration

1988-1990 Member, Ad Hoc Committee for U.S. Food and Drug Administration Liaison, American Society for Clinical Oncology

1989-2004 Member, Scientific Advisory Board, Prevent Cancer Foundation, Alexandria, VA

1991-2004 Chair, Scientific Advisory Board, Prevent Cancer Foundation, Alexandria, VA

1992-1996 Member, Convention Committee, American Association for Cancer Research

1994 Faculty Member, AACR Presents: Molecular Biology in Clinical Oncology: A Workshop. The Given Institute, Aspen, CO

1994-2004 Member, Board of Directors, Prevent Cancer Foundation, Alexandria, VA

1994-2000 Chairperson, Convention Committee, American Association for Cancer Research

1995-1999 Member, Cancer Prevention and Control Committee (Oncology Training Programs), American Society for Clinical Oncology

1996 Co-organizer, AACR/ASCO Workshop: Methods in Clinical Cancer Research, Park City, UT

1996-2004 Chair, Scientific Review Panel, Prevent Cancer Foundation, Alexandria, VA

1997-1999 Member, Program Committee, ASCO/AACR Workshop: Methods in Clinical Cancer Research, Vail, CO

1998 Chairperson, Cancer Prevention Research Subcommittee, THE MARCH: Coming Together to Conquer Cancer, Washington, DC, September 25-26, 1998

1998-2004 Member, Prevention Working Group, American Association for Cancer Research

1998-2002 Member, Nominating Committee, American Association for Cancer Research

1999-present Scientific Advisory Board, Pancreatic Cancer Action Network (PANCAN)

2000-present Medical Advisory Board, National Melanoma Foundation, Philadelphia, PA

2001 Member, Epidemiology/Prevention Subsection, Scientific Retreat on New Frontiers in Cancer Research, American Association for Cancer Research, Philadelphia, PA, September 19-21, 2001

2001-2002 Member, Scientific Committee for AACR Conference "Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, and Molecular Targets," Boston, MA, October 13-17, 2002

2001-2004 Member, Scientific Advisory Committee, Cancer Genetics Network

2002 Member, Dorothy P. Landon-AACR Prize Committee for Translational Cancer Research, American Association for Cancer Research

2002-2003 Chairperson, 2003 AACR-DeWitt S. Goodman Lecture Committee, American Association for Cancer Research

2002-2003 Member, Scientific Committee for AACR Conference: "Frontiers in Cancer Prevention Research," Phoenix, AZ, October 26-30, 2003

- 2002-present Member, Arizona BioIndustry Cluster Membership Committee, Tempe, AZ
- 2002-2005 Member, Cancer Prevention Committee, American Society of Clinical Oncology, Alexandria, VA
- 2002-present Vice-Chairperson of the Board and Scientific Director Emeritus, Board of Directors, Prevent Cancer Foundation, Alexandria, VA
- 2003-present Member, American Association for Cancer Research Task Force on Cancer Prevention, Philadelphia, PA
- 2004-present Emeritus Board Member, Prevent Cancer Foundation, Alexandria, VA
- 2005 Conference Review Committee, Dialogue for Action™ in Colorectal Cancer Screening: Bringing Systems Thinking to Health Care
- 2005 AACR Centennial Advisory Committee
- 2005 Co-Chairperson, AACR Cancer Epidemiology and Prevention Awards Selection Committee.
- 2005-2009 Member, External Advisory Board, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey
- 2006- Member, Policy Advisory Board, Prevent Cancer Foundation, Alexandria, VA
- 2007-2008 Co-Chair, SWOG Gynecological Cancer Working Group
- 2012-2013 National Cancer Institute – Loan Repayment Program Grant Reviewer
- 2012-present Member, Arizona Department of Health Services, CDC-Funded Update of Arizona Cancer Plan

LOCAL, STATE AND NATIONAL HONORS/AWARDS:

- 1962-1966 Avalon Regional Scholar, University of Virginia School of Medicine, Charlottesville, VA
- 1972-1974 Faculty Training Grant in Clinical Pharmacology, Pharmaceutical Manufacturer’s Association
- 1983 Fogarty International Scholar for Study at Institute for Cancer Research, Sutton, Surrey, England (Sabbatical: Dr. Kenneth Harrap)
- 1991 Founders Day Lectureship Award, University of Arizona College of Medicine, Tucson, AZ
- 1992-present Selected for **The Best Doctors in America** (yearly selection)
- 1995-1996 Member, Dean’s Research Council, Dept. Medicine, University of Arizona College of Medicine, Tucson, AZ
- 1995-1996 Chairperson, Clinical Advisory Board, Women's Cancer Control Project, Arizona Dept. Health Services, Phoenix, AZ
- 1995-1996 Member, Advisory Board, Skin Cancer Primary Prevention Education Project, Arizona Dept. Health Services, Phoenix, AZ
- 1995-1996 Associate Member, Pharmacology and Toxicology, University of Arizona College of Medicine, Tucson, AZ
- 1999 Speaker, “American Cancer Society Award Lecture,” Special Sessions, 35th Annual ASCO Meeting, Atlanta, GA, May 15-18, 1999
- 2001 Outstanding Service Award, Cancer Care, New York, NY
- 2002-present Member, Tucson’s Top Doctors, **Tucson Lifestyle’s Magazine**
- 2001-2003 Member and Co-Chair, Mott Selection Committee, General Motors Cancer Research Foundation, Durham, NC

2003-2005 Co-Leader, Research Core, National Center of Excellence in Women's Health (CoE), University of Arizona, Tucson, AZ

2003-2008 Co-Editor-In-Chief, **Cancer Epidemiology, Biomarkers & Prevention**

2003 Eighth Annual AACR Joseph H. Burchenal Clinical Research Award, 94th Annual Meeting of the American Association for Cancer Research, Toronto, ON, Canada, April 5-9, 2003

2003-2004 Chair, Mott Selection Committee, General Motors Cancer Research Foundation, Durham, NC

2004-present Member, Sunstone Cancer Support Centers Board of Directors, Tucson, Arizona

2004 American Association for Cancer Research Award for Excellence in Cancer Prevention Research, 3rd Annual International Conference on Frontiers in Cancer Prevention Research, Seattle WA

2004 Distinguished Achievement Award, 28th Annual Meeting of the American Society of Preventive Oncology (ASPO), Bethesda, MD, March 15, 2004

2004, 2005 American Society of Clinical Oncology (ASCO) People Living with Cancer CHAT Series on Nutrition and Cancer, August 18, 2004

2003-present Tucson's Best Doctors, Pima County Medical Society, Tucson, AZ

2005 Minority Institution/Cancer Center Partnership Presidential Leadership Forum, Amer Assoc Cancer Res Annual Meeting, Anaheim, CA, April 16, 2005

2005-2006 Co-Chairperson, American Association for Cancer Research (AACR) Cancer Epidemiology and Prevention Awards Committee

2005-2007 Member, NCI Cancer Center Directors' Steering Committee, and Subcommittee on Prevention

2006 Honorary Bobcat, Bobcats Senior Honorary and Alumni, University of Arizona, Tucson, AZ

2006 Salsbury Award from the Arizona Hospital and Healthcare Association, November 2, 2006, Phoenix, AZ

2006-2009 Member, Clinical Trials Advisory Committee, Ad hoc Coordination Subcommittee, Guidelines Harmonization Working Group, National Cancer Institute

2007-2010 Member, Ad hoc Coordination Subcommittee, Clinical Translational Trials Advisory Committee, National Cancer Institute

2008-present Member, C-Change Committee, Washington, DC

2009 Chair: Gynecologic Oncology Group Symposium, "Issues in Gynecologic Cancer Prevention and Survivorship," January 22, 2009, Garden Grove, CA

2009 America's Top Doctors for Cancer, Castle Connolly Medical Ltd.

2010 Member, Board of Directors, Association of American Cancer Institutes.

2010 Outstanding Achievement in Clinical Research Award, Association of Community Cancer Centers, St. Louis, MO.

2011 Best Doctors in America (Medical Oncology), Best Doctors, Inc.

2011 America's Top Doctors for Cancer, Castle Connolly Medical Ltd.

2011-present CEO's Against Cancer

2012 Member, Honorary Board, WiRED International, Montara, CA

2012 Member, University of Arizona, Undergraduate Biology Research Program, Advisory Board

2012 Pioneer Award, AZ Bioindustry Association

2012 America's Top Doctors for Cancer, Castle Connolly Medical Ltd.

- 2013 America's Top Doctors for Cancer, Castle Connolly Medical Ltd.
- 2013 Sydney E. Salmon Distinguished Senior Investigator Award, University of Arizona Cancer Center

NATIONAL HONORARY LECTURES:

- 1992 Invited Speaker, "Diet and Colon Cancer," "Meet the Professor" Session (Ovarian Cancer), ASCO
- 1995 ASCO Abstract Selected for Plenary Session: Alberts DS, et al: Phase III study of intraperitoneal cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients with optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG Intergroup study (INT 0051). ASCO Meeting, Los Angeles, CA, May 20-23, 1995.
- 1996 "Meet the Professor" Session (Ovarian Cancer Management - Let's Discuss the Controversies), ASCO
- 1996 SGO abstract selected for Plenary Session: Alberts DS, et al: Phase III study of IP cisplatin plus IV cyclophosphamide vs IV cisplatin plus IV cyclophosphamide in optimal disease stage III ovarian cancer: An Intergroup study 0051 (SWOG-GOG-ECOG)
- 1996 Presidential Lecture, Western Association of Gynecologic Oncologists, San Diego, CA
- 1997 Panel Member (Cancer Prevention), Progress and New Hope in the Fight against Cancer: AACR Public Forum Highlighting the Latest Discoveries, San Diego, CA
- 1998 Plenary Session Speaker, "SWOG-9412 and SWOG-8501: 2 of the 3 most important recent advances in ovarian cancer management," SWOG 40th Anniversary Meeting, San Antonio, TX, Oct. 23, 1998
- 1999 Invited Speaker, "Design of Chemoprevention Trials," Sunrise Sessions, American Association for Cancer Research Annual Conference, Philadelphia, PA, April 10-14, 1999
- 2001 Invited Speaker, "What is This Thing Called Chemoprevention?," Meet-the-Expert Sunrise Session, American Association for Cancer Research Annual Conference, New Orleans, LA, March 24-28, 2001
- 2001 Invited Speaker, "Environmental Issues Related to Colon Cancer," Cancer and the Environment: Gene-Environment Interactions, Roundtable on Environmental Health Sciences, Research, and Medicine, Washington, DC, May 16-17, 2001
- 2001 Keynote Speaker, "Chemoprevention to Save Our Skins," Carcinogenesis and Cancer Prevention: Non-melanoma and Melanoma Skin Cancer, Third Annual Chao Family Comprehensive Cancer Center Symposium, University of California, Irvine, Newport Beach, CA, June 22-24, 2001
- 2002 Member, Ask the Experts Session of Forum, "Progress and New Hope in the Fight against Cancer: Sixth AACR Public Forum Highlighting the Latest Discoveries," 93rd Annual AACR Meeting, San Francisco, CA, April 6, 2002
- 2002 Forum Chairperson, "The Role of Cancer Centers and Cooperative Groups in Advancing Cancer Prevention Research," Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Behavioral Prevention Research, and Clinical Prevention Trials, AACR 1st Annual International Multidisciplinary Conference, Boston, MA, October 14-18, 2002
- 2003 "Cancer Treatment vs Cancer Prevention: Identical Disciplines with Different Wrappers," American Association for Cancer Research, Joseph H. Burchenal Clinical Research Award, Washington, DC
- 2004 Keynote Address, "Colorectal Cancer Chemoprevention: Poised to Make a Difference," Cancer Control Research Committee, Southwest Oncology Group Spring Meeting, Huntington Beach, CA, April 29, 2004
- 2004 "Trials and Tribulations of Secondary Analyses," American Association for Cancer Research (AACR), Orlando, FL
- 2004 "From the Nose to the Rectum: Cruising Down the Chemoprevention Highway," American Society of Preventive Oncology (ASPO) Distinguished Career Award Lecture, Bethesda, MD

- 2004 “Cancer Survivorship - Increasing Survival, Improving Lives,” American Society of Clinical Oncology Meet the Experts Program, New Orleans, LA, June 5-8, 2004.
- 2004 “Epidemiology and Screening for Colorectal Cancer” 21st Annual Denali Oncology Group, Kennicott, Alaska, August 20-21, 2004.
- 2004 “Chemoprevention of Colorectal Cancer” 21st Annual Denali Oncology Group, Kennicott, Alaska, August 20-21, 2004.
- 2004 Research Videoconference Symposium, Northern Arizona University and the Arizona Cancer Center, September 29, 2004.
- 2004 “Cruising Down the Chemoprevention Superhighway with my Awesome Research Colleagues,” Third Annual American Association for Cancer Research and Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research, Seattle, WA, October 17, 2004.
- 2004 “Prevention” Panel Discussion, A Supportive Care Vision for Arizona, Sunstone Healing Center, Tucson, AZ, October 30, 2004.
- 2004 “Day of Prevention Science” Roundtable Discussion, MD Anderson Cancer Center, Houston, TX, December 7, 2004.
- 2005 “Chemoprevention of Colorectal Cancer,” Oncology Grand Rounds, Georgetown Hospital, Washington, DC, June 29, 2005.
- 2006 “Primary and Secondary Prevention of Breast Cancer” and “Intraperitoneal Chemotherapy of Ovarian Cancer,” 37th Annual Tucson Seminar Focus on Women’s Cancers, Tucson, AZ, January 26-28, 2006.
- 2006 “GOG Update Session,” Society of Gynecologic Oncologists Meeting, Palm Springs, CA, March 22-26, 2006.
- 2006 “Addressing Major Barriers for Cancer Prevention Research,” Cancer Prevention Research Summit, Bethesda, MD, June 12-13, 2006.
- 2007 “Colorectal Cancer: Celebrating a Career in Prevention,” A Symposium in Honor of Bernard Levin, MD, MD Anderson Cancer Center, Houston, TX, June 21-22, 2007.
- 2008 “From the Glint in Medicinal Chemist’s Eye to Phase I/II Clinical Trials: Blood, Sweat and Cheers!” – ΛΩΛ Introduction Ceremony, University of Arizona College of Medicine, Tucson, AZ.
- 2009 “Chemoprevention of Ovarian Cancer: Is there a role for diet and physical activity interventions?” Gynecologic Oncology Group Semi-Annual Meeting, January 22, 2009, Garden Grove, CA.
- 2009 “Chemoprevention for cervical, endometrial and ovarian cancer: Fact or Fantasy?” Gynecologic Oncology Group Semi-Annual Meeting, January 22, 2009, Garden Grove, CA.
- 2009 “Diet and exercise to prevent recurrence of ovarian cancer.” National Cancer Institute, Ovarian Cancer Clinical Trials Planning Meeting, May 29, 2009, Orlando, FL.
- 2011 “Cellular and molecular biology leading to personalized chemoprevention in the skin.” American Society of Preventive Oncology Annual meeting, March 8, 2011, Las Vegas, NV.
- 2013 “Promoting Quality of Life and Increased PFS after Ovarian Cancer: The “Pioneer” GOG0225 Trial. National Cancer Institute, Division of Cancer Prevention, 3rd Annual Karen Johnson Memorial Lecture, September 30, 2013, Washington, DC.

PATENTS AND INVENTIONS:

1. Aspiration Device for a Smoking Article. Patent to Dynamic Drug Delivery Devices, U.S. Patent Serial No. 4,657,032. Inventors: Dorr RT, **Alberts DS**, April 14, 1987.

2. Anthracene Derivatives Based on Mitonafide with Antitumor Activity. Inventors: Remers W, **Alberts DS**, Dorr RT, Sami SM, June, 1987.
3. Self-Sheathing Hypodermic Needle, U.S. Patent Serial No. 4,906,236. Inventors: **Alberts DS**, Dorr, RT, March 6, 1990.
4. Tumorimeter: Instrument for Measuring Tumors, U.S. Patent Serial No. 310,044. Inventors: Dorr RT, **Alberts DS**, August 21, 1990.
5. Antineoplastic Compounds and Methods of Using Same, Arizona Board of Regents, Arizona State University, Patent 5,246,955. Inventors: Skibo E, Islam I, **Alberts D**, September 21, 1993.
6. Azamitosene Anticancer Agents, U.S. Patent No. 5,246,955. Inventors: Skibo E, Islam I, **Alberts DS**, September 21, 1993.
7. 1,2-dihydro-3H-dibenzisoquinoline-1,3-dione Anticancer Agents (Azonafide Anticancer Agents), U.S. Patent No. 5,635,506. Inventors: **Alberts DS**, Dorr RT, Remers W, Sami S, June 3, 1997.
8. Method and Composition for Deactivating HIV Infected Blood and for Deactivating and Decolorizing Anticancer Drugs, U.S. Patent No. 5,811,113. Inventors: **Alberts DS**, et al., September 22, 1998.
9. Topical Application of α -DFMO for Prevention of Skin Cancer, U.S. Patent Serial No. 5,851,537. Inventor: **Alberts DS**, et al., December 22, 1998.
10. Method for Deactivating a Contaminant, U.S. Patent Serial No. 5,985,302. Inventor: **Alberts DS**, November 16, 1999.
11. Method for Treatment of Neuro- and Nephro-Disorders and Therapeutic Toxicities Using Aminothioli Compounds. U.S. Patent Serial No. 5,994,409. Inventor: **Alberts DS**, November 30, 1999.
12. Topical DFMO Treatment for Palmar-Plantar Erythrodysesthesia, U.S. Patent Serial No. 6,060,083. Inventor: **Alberts DS**, May 9, 2000.
13. Measurement of lesion progression via mapping of chromatin texture features along regression curve, US Patent No. 6,204,064. Inventor: **Alberts DS**, March 20, 2001.
14. Tanning Induced by a Combination of Sunlight with a Superpotent Melanotropic Peptide, Nle4-D-Phe7 Alpha Melanocyte Stimulating Hormone (new disclosure). Inventors: Levine N, Dorr RT, **Alberts DS**, Ertl G, 2002.
15. Methods for the Treatment of Nephro-Disorders Using Aminothioli Compounds. U.S. Patent Serial No. 6,586,476. Inventor: **Alberts DS**, July 1, 2003.
16. Method of Stimulation of Melanin Production and Induction of Skin Tanning. Univ AZ Disclosure No. UA-02-037, U.S. Patent Serial No. 2005/0142078 A1; U.S. Patent #10/504492. Inventors: Dorr R, Levine N, Ertl G, and **Alberts DS**, June 30, 2005.
17. Methods for the Treatment of Nephro-Disorders Using Aminothioli Compounds. U.S. Patent Serial No. 7,105,575. Inventor: **Alberts DS**, September 12, 2006.
18. Karyometry-based method for prediction of cancer event recurrence. U.S. Patent Serial No: 7,769,547 B2. Inventors: Bartesl PH, Montironi, R. Assignee: **Alberts DS**, August 3, 2010.

EDITORIAL BOARDS:

- 1975-present Consultant Reviewer, **Journal of the National Cancer Institute**
- 1978-1985 Editor, **Monthly Medical Oncology Column – Arizona Medicine**
- 1978-1990 Consultant Reviewer, **Cancer Chemotherapy and Pharmacology**
- 1978-1990 Consultant Reviewer and Editorial Advisory Board (1990-1993), **European Journal of Cancer Prevention**
- 1979-present Consultant Reviewer, **Journal of Clinical Pharmacology and Experimental Therapeutics**

1982-1988 Editorial Board, **Investigational New Drugs**
 1987-1997 Editorial Board, **Journal of Drug Development and Clinical Practice**
 1987-present Editorial and Advisory Board, **Journal of Regional Cancer Treatment**
 1989-2002 Associate Editor, **Cancer Research**
 1990-present Editorial Board, **Les Cahiers De Cancerologie**
 1990-present Editorial Board, **Anti-cancer Drugs**
 1990-present Editorial Board, **Cancer Chemotherapy and Pharmacology**
 1991-2000 International Advisory Board, **Clinical Oncology**
 1992-1994 Editorial Advisory Board, **Cahiers d'Oncologie**
 1993-present Editorial Academy, **International Journal of Oncology**
 1994-1996 Associate Editor, **Clinical Cancer Research**
 1997-2000 Chemoprevention Editorial Group, **Journal of Cellular Biochemistry**
 1997-2002 Senior Editor (Prevention), **Cancer Epidemiology, Biomarkers & Prevention**
 1998-2008 Scientific Editor, Editorial Board, **Neoplasia**
 2002-2008 Co-Editor-in-Chief, **Cancer Epidemiology, Biomarkers & Prevention**
 2003-present Editorial Board, **Disease Markers**
 2005-present Associate Editor, **Neoplasia**
 2010-present Associate Editor, **Cancer Prevention Research**

PROFESSIONAL/HONORARY SOCIETIES:

Alpha Omega Alpha (Medical Honor Society)
 American Association for Cancer Research (AACR)
 American Association for the Advancement of Science (AAAS)
 American Medical Association (State of Arizona)
 American Society for Clinical Pharmacology & Therapeutics (ASCPT)
 American Society for Clinical Oncology (ASCO)
 American Society of Preventive Oncology (ASPO)
 Arizona Clinical Oncology Society (TACOS)
 European Society of Gynaecological Oncology
 International Association for Vitamin and Nutritional Oncology
 International Gynecologic Oncology Society
 International Society for Cancer Chemoprevention (ISCaC)
 International Society for Preventive Oncology (ISPO)
 International Society of Regional Cancer Therapy (ISRCT)
 Phi Beta Kappa (Honorary Academic Society)
 Society Gynecologic Oncologists (SGO)

Western Association of Gynecologic Oncologists (WAGO)

National Call to Action Council of Experts (NCTA)

Bressler-Alpert Society for Internal Medicine, University of Arizona, Department of Internal Medicine

ADVISING AND MENTORING ACTIVITIES

Name	Term	Department and Project Title	Current Position
Pre-Doctoral Fellows and/or PhD Candidates:			
Robert T. Dorr, Ph.D.	1982-1984	Pharmacology: Interaction of thiols with anticancer drugs	Professor of Pharmacology and Toxicology, University of Arizona; Director, Therapeutic Development, Arizona Cancer Center
William Bellamy, Ph.D.	1984-1987	Pharmacology: Mechanisms of mitoxantrone drug resistance	Associate Professor of Pathology, University of Arizona
Nancy Shipp, Ph.D.	1987-1990	Pharmacology: Mechanisms of mitoxantrone cardiotoxicity	Senior Research Director, Biotechnology Company, Denver, CO
Kenneth Kunz, M.D., Ph.D.	1992-1995	Medicinal Chemistry: Synthesis and testing of novel mitomycin compounds college	Senior Researcher, Eli Lilly Company, Indianapolis
Mary E. Reid, Ph.D.	1995-1999	Epidemiology: The association of smoking and prevalent adenomatous polyp characteristics	Associate Professor, Roswell Park Cancer Institute, Buffalo, NY
Zhi-Ying "Jean" Zheng, Ph.D.	1996-1997	Microbiology: PCNA and p53 expression in skin carcinogenesis	
Russell D. Klein, Ph.D. (Deceased)	1996-1998	Cancer Biology: The regulation of matrilysin expression in prostate carcinoma cells by prostate interactions with stromal cells	Assistant Professor, Ohio State University
Cynthia A. Thomson, Ph.D.	1996-1998	Nutritional Sciences: The effect of a high fruit and vegetable, low fat dietary intervention on immune function, DNA adduct formation, and body composition among breast cancer survivors	Associate Professor of Nutritional Sciences, College of Agriculture, University of Arizona
Janine G. Einspahr, Ph.D.	1996-1999	Cancer Biology: Genetic mutations and alterations in cell proliferation and apoptosis in UV-induced skin cancer: application of biomarkers to human chemoprevention studies	Research Associate Professor of Medicine, University of Arizona
Ross Meyers, Ph.D.	2002-2005	Nutritional Sciences: Synthesis, Testing and Mechanisms of Nordihydroguaretic Acid Analogs as Anticancer and Chemopreventive Agents (doctoral thesis)	Project Manager, Pharmaceutical Products Development, McArdle Laboratory for Cancer Research, Milwaukee, WI
Amit Algotar, Ph.D.	2004-present	Epidemiology	Graduate Assistant, Arizona Cancer Center
Karen Taraszka Hastings, M.D., Ph.D.	2007-2012		Assistant Professor, Basic Medical Sciences, University of Arizona
Mary J. Picchioni, Ph.D.	2008-2009	Nutritional Sciences: Targeted Oral L-Glutamine Treatment of Grades 1, 2, and 3 Oral Mucositis in Adults with Diagnosed Primary Gastrointestinal Malignancy Receiving 5-Fluorouracil (5-FU): A Feasibility Pilot Study	Graduate Assistant, Dept. of Nutritional Sciences

Masters Degree Candidates:			
Lester Melnick, M.S.	1979-1981	Pharmacology/Toxicology: HPLC assay and metabolism of melphalan	Anesthesiologist at Teaching Hospital
Thomas Evans, M.S.	1980-1983	Pharmacology/Toxicology: Metabolism and pharmacokinetics of melphalan	Senior Investigator, Biotechnology Company, Palo Alto, CA
Gary Bignami, M.S.	1981-1983	Pharmacology/Toxicology: Pharmacokinetics and metabolism of cyclophosphamide	Senior Investigator, Biotechnology Company, Honolulu, HI
Janine G. Einspahr, M.S.	1979-1981	Pharmacology/Toxicology: Pharmacokinetics and <i>in vitro</i> stability of retinyl palmitate	Research Assistant Professor of Medicine, University of Arizona
Karen Bozak, M.S.	1984-1986	Pharmacology/Toxicology: Development of neonatal rat heart cell drug toxicity assay	Teaching Staff, University of California–Davis
Thomas McCloskey, M.S.	1988-1991	Pharmacology/Toxicology: Markers of hepatic metabolism of anti-cancer drugs	Pharm. D., University of Arizona
Mercedes Arguelles, M.S.	1997-2002	Nutritional Sciences: Cruciferous vegetables, GSTs, and adenoma recurrence	Past R25 Pre-Doctoral Fellow
Li Tang, M.S.	2001-2003	Nutritional Sciences: Selected isothiocyanates rapidly induce growth inhibition of cancer cells	Pre-Doctoral Fellow, Roswell Park Cancer Institute, Buffalo, NY
Carolyn Waltmire, M.S.	1998-2000	Sequence dependency of bleomycin added to paclitaxel anticancer activity	Research Specialist, Principal, Univ. Arizona
Daphnie Zhao, M.S.	2000-2002	Pharmacology/Toxicology	University of Arizona
Laura Mary Crowley, M.S.	2002-2004	Pharmacology/Toxicology: Characterization of 7-oxo-7H-Benzo[e]perimidine-4-carboxylic acid and analogues to treat breast cancer	Development Asst., Protein Design Labs, Minneapolis, MN
Post-Doctoral Fellows:			
Gary Goodman, M.S., M.D.	1979-1981	Pharmacology: Clinical pharmacology of vitamin A and 13-cis-retinoic acid	Assoc. Prof., Univ. WA; Member, Fred Hutchinson Cancer Center
William Dalton, M.D., Ph.D.	1981-1983	Pharmacology: Clinical pharmacology of carboplatin; reversal of multi-drug resistance	Director, Lee Moffitt Cancer Center, Tampa, FL
Scott Lippman, M.D.	1985-1990	Phase I Studies of 13-cis-retinoic Acid in Patients with Cancer and Precancerous Lesions	Prof. and Dir. Cancer Prevention, Univ. TX - MD Anderson Cancer Center
David Clark, D.V.M., Ph.D.	1993-1995	Role of bombesin/gastrin releasing peptide in small cell lung cancer	
Ana Maria Lopez, M.D.	1995-1997	Dean's Physician Career Development Award: Telecoscopy in rural Arizona; Minority Supplement to Colon PPG	Associate Dean for Outreach, Multicultural Affairs; Assoc. Prof. Clinical Medicine, Dept. Medicine, University of Arizona
Steven P. Stratton, Ph.D.	1997-2000	Pharmacology/Toxicology: Oxidative pathways in skin carcinogenesis: effects of antioxidant polyphenols; KO7 Trainee	Research Assistant Prof. Dept. Medicine, University of Arizona

M. Elena Martinez, Ph.D.	1996-2000	Minority Supplement to Colon Cancer Prevention Program Project; NCI KO7 Career Development Award	Prof., Epidemiology; Co-Dir., Cancer Prevention and Control, Arizona Cancer Center, Univ. Arizona
Cynthia A. Thomson, Ph.D.	1999-2002	Nutritional Sciences: Effect of a high fruit and vegetable, low fat dietary intervention on immune function, DNA adduct formation, and body composition among breast cancer survivors; R25 Trainee	Assistant Professor of Nutritional Sciences, College of Agriculture, University of Arizona
Maria Lluria-Prevatt, Ph.D.	2001-2002	Cancer Biology: Signal transduction pathways and targets for chemoprevention in transgenic melanoma	Consultant, Chemoprevention of Skin Cancer PPG, Arizona Cancer Ctr, Univ. Arizona
Rebecca Sedjo, Ph.D.	2001-2002	Role of retinoic acid in skin cancer prevention; T32 Trainee	Consultant, Mattson Jack Group, St. Louis, MO
Francisco Garcia, M.D.	2000-2004	NCI/NIH K23 Award: Karyometric analysis of atypical endometrial hyperplasia	Associate Professor, Dept. OB/GYN, College of Medicine, Univ. Arizona
Jesse Nodora, Ph.D.	2005-2008	Minority Supplement to Chemoprevention of Skin Cancer Program Project (Tobacco Effect on Skin Cancer)	Research Asst. Professor of Family and Community Medicine, Univ. Arizona
Elizabeth T. Jacobs, Ph.D.	2001-2003	Nutritional Sciences: Effect of cereal fiber intervention on nutrient intake and adenoma recurrence in the wheat bran fiber trial; R25 Trainee	Associate Prof., College of Public Health, University of Arizona
M. Suzanne Stratton, Ph.D.	2001-2003	Cancer Biology: Matrix metalloproteins in prostate carcinogenesis	VP Research, Carle Fdn. Hosp.; Affiliate Prof., Inst. for Genomic Biol., Univ. Illinois Urbana-Champaign
Lois Loescher, R.N., M.S., Ph.D.	2001-2003	Nursing and Genetics: Perception of breast cancer risk theory; R25 Trainee	Asst. Prof. Nursing, College of Nursing, Univ. Arizona
Joanne Jeter, M.D.	2005-2008	Topical chemoprevention of non-melanoma skin cancer	R25T Post-doctoral Cancer Prevention Fellowship, Univ. Arizona
Jesse Nodora, Dr.P.H.	2006-2009	Behavioral aspects of non-melanoma skin cancer	NCI Cancer Disparities Supplement
Yira Bermudez, Ph.D.	2009-2011	Defining a skin receptor for nicotinic acid	R25T Post-doctoral Cancer Prevention Fellowship, Univ. Arizona
Current and Post-Doctoral Fellows:			
Galen Hostetter, M.D.	2004-present	CGH in Paraffin-embedded Colorectal Adenoma Tissue; KO7	Assoc. Res. Investig. TGen; Asst. Prof. Clinical Pathology, Univ. AZ
Daniel Holterman	2005-2008	Biomarkers of Cancer Risk (e.g., alpha-defensin)	T32 Post-doctoral Fellowship

FACULTY MENTORING

Robert T. Dorr, Ph.D.	1978-1982
William S. Dalton, M.D., Ph.D.	1981-1985
Antonio Buzaid, M.D.	1985-1988
Scott M. Lippman, M.D.	1985-1989
Robin Harris, Ph.D.	1991-1995
Mark Nelson, Ph.D.	1992-1996
Ana Maria Lopez, M.D.	1995-1997
M. Elena Martinez, Ph.D.	1996-2000
Janine Einspahr, Ph.D.	1999-2002
Steve Stratton, Ph.D.	2000-2005
M. Suzanne Stratton, Ph.D.	2001-2003
Cyndi Thomson, Ph.D.	2001-2006
Benjamin M. Craig, Ph.D.	2005-2006
Joanne Jeter, M.D., MPH	2005-2008
Jesse Nodora, Dr. P.H.	2005-2009
Clara Curiel, M.D.	2005-2009
Karen Taraszka Hastings, M.D., Ph.D.	2006-2008
Francine Gachupin, Ph.D.	2013-present

TEACHING ACTIVITIES/TALKS

December 8, 2004	“Chemoprevention” - Talk for Cancer Prevention Epidemiology EPI615A - Fall 2004.
January 12, 2005	“Cruising Down the Chemoprevention Superhighway with all of my Awesome Research Colleagues” - Talk for Cancer Prevention and Control Grand Rounds.
January 25, 2005	“New Strategies for the Chemoprevention of Skin Cancer” - Frontiers in Medical Research Seminar series, Spring 2005, University of Arizona College of Medicine Research Office and the General Clinical Research Center.
October 19, 2005	“Chemoprevention” - Talk for Cancer Prevention Epidemiology EPI615A - Fall 2005.
October 20-21, 2005	“Nutrient Prevention of Cancer: Fact or Fantasy” - Research Frontiers in Nutritional Sciences, University of Arizona, Tucson, AZ.
March 20, 2006	“Ovarian Cancer, Overview and Updates in Treatment” – ‘Ask the Doctor’ series sponsored by Sunstone Cancer Support Centers. Arizona Cancer Center, Tucson, AZ.
May 1, 2006	“Nutrient Prevention of Cancer: Fact or Fantasy?” – Plenary Session, Public Forum on Nutrition and Health: Food, Politics and Society, New York, NY, April 30-May 3, 2006.
May 1-2, 2006	“Prevention” – NCI Cancer Center Directors Retreat, Washington, DC.
January 30, 2007	“Nutrient and Physical Activity Prevention of Cancer: Fact or Fantasy” – MD Anderson Cancer Center, Houston, TX.
February 21, 2007	“Chemoprevention of Skin Cancer” – Cancer Biology & Genetics Program, University of Arizona College of Medicine, Tucson, AZ.
February 2, 2007	“Nutrition and Cancer” – Arizona Science Center Adults Night Out Program, Phoenix, AZ.

February 8, 2007 “Gynecologic Malignancies” – Cancer 2007 Preferred Treatment and Management Options Meeting, Balboa Bay Club, Newport Beach, CA.

May 14, 2007 “Nutritional Strategies for Cancer Prevention” – Plenary Session, 4th Annual Nutrition and Health Conference, San Diego, CA.

August 2, 2007 “Reducing Neurological Toxicities Associated with Cancer Chemotherapeutic Agents” – Cytoprotection Institute for Education: CME for the Cancer Care Team, Denver, CO.

August 22, 2007 “Physical Activity and Nutrient Prevention of Cancer: Fact or Fantasy?” – Medicine Grand Rounds, University of Arizona College of Medicine, Tucson, AZ.

August 25, 2007 “Nutrient and Physical Activity Prevention of Cancer: Fact or Fantasy” – Coaches vs Cancer, Spokane, WA.

November 1, 2007 “Striving for Excellence in Cancer Treatment, Research and Education” – Mayo Clinic Community Leadership Breakfast, Paradise Valley, AZ.

November 7, 2007 “Physical Activity and Dietary Prevention of Cancer: Fact or Fantasy” – Mini-Medical School Lecture Series, University of Arizona College of Medicine, Tucson, AZ.

November 10, 2007 “Skin Cancer Institute – Introductory Remarks” – The 2007 Tucson Melanoma Update, Tucson, AZ.

February 7, 2008 “The Arizona Cancer Center” – Arizona Senior Academy, Tucson, AZ.

February 16, 2008 “IP Therapy for Ovarian Cancer: There Should be no Controversy!” – Regional Cancer Therapies, Palm Desert, California.

March 13, 2008 “Clinical Trial Design” – Rethinking FDA Oversight of Oncology Drug Development and Commercialization, Washington, DC.

April 18, 2008 “Teal Team Studies” – Clinical Cancer Research Conference, Arizona Cancer Center, Tucson, AZ.

November 19-21, 2008 “Primary and Secondary Prevention of Skin Cancer” – AACR-NCI Think Tank: Charting the Future of Cancer Prevention, National Harbor, MD.

April 21, 2009 “State of the Arizona Cancer Center.” – Hematology/Oncology Faculty & Fellows Friday Section Meeting, Tucson, AZ

June 1, 2009 “Primary and Secondary Chemoprevention of Skin Cancer: Emphasis on Translational Research” – American Society of Clinical Oncology Education Session Lecture, Orlando, FL

November 20-21, 2009 “Can diet and physical activity enhance PFS in women in clinical CR?” and “What is the role of hormone manipulation in ovarian cancer prevention?” First Global Workshop on Ovarian Cancer, Chicago, IL

January 26, 2010 “From the Glint in the Medicinal Chemist’s Eye to Phase II Clinical Trials: Blood, Sweat and Cheers!” Arizona Cancer Center Clinical Studies Workshop, Tucson, AZ

March 3, 2010 Plenary Session Lecture. “Karyometric Analysis: An Integrating Biomarker for Risk Stratification and Chemoprevention Efficacy.” 20th Early Detection Research Network Steering Committee Meeting, Tempe, AZ

March 15, 2010 National Call to Action (Against Cancer). Canyon Ranch Institute, Washington, DC

September 17, 2010 “Update on Ovarian Cancer,” The Ovarian Cancer National Alliance Breakfast, Phoenix Hyatt Regency, Phoenix, AZ

September 21, 2010 “Can diet and physical activity prevent cancer?” Arizona Cancer Center, Hematology/Oncology Section Weekly Scientific Conference, Tucson, AZ

September 28, 2010 “Research in the Arizona Cancer Center, 2010”, Arizona Cancer Center meeting with Chief Executive Officers of St. Joseph’s Hospital, Scottsdale Healthcare, St. Luke’s Hospital.

October 1, 2010 “Can Diet and Physical Activity Prevent Cancer?,” Association of Community Cancer Centers Meeting, Clinical Research Award Lecture, Hyatt Regency St. Louis at the Arch Hotel, MO

October 6, 2010 “Can diet and physical activity prevent cancer? University of Arizona, Department of Medicine, Grand Rounds, Tucson, AZ

October 6, 2010 “Dawn of the Pan Pacific Skin Cancer Consortium” Arizona Cancer Center/Queensland Institute for Medical Research Consortium Meeting, Tucson, AZ

November 5, 2010 “Attacking Skin Cancer Through Clinical Translational Research,” Cancer Biology Chairs and Directors Retreat, Hilton Tucson El Conquistador Resort, Oro Valley, AZ

November 21, 2010 “Can Diet and Physical Activity Prevent Cancer,” University of Arizona, Alpha Epsilon Delta Society Annual Banquet.

March 8, 2011 “Cellular and Molecular Biology Leading to Personalized Chemoprevention in the Skin.” American Society of Prevention Oncology Annual Meeting, Las Vegas, NV.

March 29, 2011 “Future Directions.” Pan-Pacific Skin Cancer Consortium Meeting, Brisbane, Australia.

June 7, 2011 “Can Diet and Physical Activity Prevent Cancer,” University of Arizona Extension, Elderhostel Meeting, Tucson, AZ.

July 10, 2011 “Chemoprevention of Ovarian Cancer: Evaluating the Role of Diet and Physical Activity,” Ovarian Cancer National Alliance, Washington, DC.

July 12, 2011 “Partnership Sustainability” Cancer Health Disparities Program Meeting, Bethesda, MD.

September 14, 2011 “Can Diet and Physical Activity Prevent Cancer?” The University of Arizona, College of Medicine-Phoenix. Science Café Lecture.

November 17, 2011 “Patient Success Story,” Collaborating for Customized Care. Greater Phoenix Economic Council, Personalized Medicine Summit. Phoenix, AZ

December 2, 2011 “Machine Visit of Nuclear Abnormality to Predict Tumor Behavior,” University of Arizona Department of Surgery, Scientific Research Meeting in honor of Dr. Hugo V. Villar.

January 18, 2012 “Can Diet and Physical Activity Prevent Cancer?” The University of Arizona Retirees Association, Tucson, AZ

June 23, 2012 “Quantitative Histopathology to Accurately Predict the Natural History of Newly Resected Skin Squamous Cell Carcinomas. 10th International Skin Carcinogenesis Conference, The Ohio State University, Columbus, OH

September 1, 2012 “Diet, Physical Activity and Ovarian Cancer,” The National Ovarian Cancer Coalition, University of Arizona, Tucson, AZ

November 9, 2012 “LIVES Study & Quality of Life,” National Ovarian Cancer Coalition Conference, Las Vegas, NV

December 7, 2012 “A randomized trial of lifestyle intervention to promote progression-free survival after ovarian cancer.” University of Arizona Cancer Center, Collaborative Cancer Grand Rounds, Tucson, AZ

January 15, 2013 “Karyometric Analysis to Predict Lesion Aggressiveness,” University of Arizona Hematology/Oncology Weekly Scientific Conference, Tucson, AZ

January 25, 2013 “Case-Based Discussion: Frontline and Maintenance Therapy Options for Ovarian Cancer,” Gynecologic Oncology Group Meeting, Educational Concepts Group, San Diego, CA

January 30, 2013 “Can Diet & Physical Activity Prevent Cancer?” Cancer Prevention & Control Seminar Series, University of Arizona Cancer Center, Tucson, AZ

February 14, 2013 Introduction of University of Arizona Cancer Center/U54 Partnership to “R4-G/BMaP Bioinformatics to Mine Human Biospecimens Data Workshop,” Tucson, AZ

February 15, 2013 University of Arizona, Center on Aging, Geriatric Grand Rounds, “Can Diet and Physical Activity Prevent Cancer?,” Tucson, AZ

March 1, 2013 University of Arizona, Southwest Border Issues Forum – El Otro Lado. “Can physical activity and diet prevent cancer?,” Tucson, AZ

May 30, 2013 Barbara Ann Karmanos Cancer Institute, Wayne State University. “Diet, Physical Activity and Ovarian Cancer?” Detroit, MI

July 19, 2013 Gynecologic Oncology Group, Data Management Committee Meeting, “Promoting Quality of Life and Increased Progression-Free Survival After Ovarian Cancer: The “Pioneer” GOG 0225 Study. San Antonio, TX

September 12, 2013 US Oncology Annual Research Forum 2013, “Antiemetic Guidelines, Dallas, TX

CURRENT GRANT FUNDING:

Grant #	Grant Period	P.I.	Title	Direct Costs for Current Year
PO1 CA27502 NCI/NIH	07/01/11-06/30/16	D. Alberts	Chemoprevention of Skin Cancer PPG (Alberts - Project IV/Cores A & C) (20% effort)	\$997,300
P30 CA023074 NCI/NIH	07/01/09-06/30/14	D. Alberts	Cancer Center Support Grant: Cancer Prevention & Control Program Director (10% effort)	\$2,756,230
P50 CA95060 NCI/NIH	06/01/08-05/30/13	E. Gerner	SPORE in Gastrointestinal Cancer (1% effort)	\$1,634,437
NSABP PFED 15-ARZ-01 (P2)	06/01/08-05/31/11	D. Alberts	Study of Tamoxifen and Raloxifene for the Prevention of Breast Cancer (STAR) (1% effort)	\$25,000
CCOP GOG	6/1/07-5/31/12	P. DiSaia	Gynecologic Oncology Group Support for Committee Chair (D. Alberts 1%)	\$224,335
2R25 CA078447 NIH/NCI	09/21/10-08/31/15	D. Alberts	Cancer Prevention and Control Training Grant	\$463,050
1U54 CA143924	09/28/09-08/31/14	D. Alberts	The Partnership for Native American Cancer Prevention	\$862,184
6U10 CA32102 SWOG	01/01/09 – 12/31/09	L. Baker	2009 Southwest Oncology Subcontract Vice-Chair	\$18,726

COMPLETED GRANTS:

Grant #	Grant Period	P.I.	Title	Direct Costs for Current Year
PO1 CA41108 NCI/NIH	8/3/05-7/31/10	D. Alberts	Colon Cancer Prevention Program Project (Alberts - Projects I, II, III/Cores A & C) (10% effort)	\$3,019,232
NO1 CN35158 NCI/NIH	09/30/03-09/29/10	S. Chow	Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive Agents (2% effort)	\$2,315,203
6U10 CA32102 SWOG	01/01/09 – 12/31/09	L. Baker	2009 Southwest Oncology Subcontract Vice-Chair	\$18,726

A. ARTICLES PUBLISHED IN PEER REVIEWED JOURNALS

1. **Alberts DS**, Bachur NR, Holtzman JL. The pharmacokinetics of daunomycin in man. *Clin Pharmacol Ther* 12:96-104, 1971.
2. Holtzman JL, **Alberts DS**. Estimation of pentobarbital hydroxylase activity by gas-liquid chromatography. *Anal Biochem* 43:48-56, 1971.
3. **Alberts DS**, Golde DW. DNA synthesis in multiple myeloma cells following cell cycle-nonspecific chemotherapy. *Cancer Res* 34:2911-4, 1974.
4. **Alberts DS**, Salmon SE. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. *Cancer Chemother Rep* 59:345-50, 1975.
5. **Alberts DS**, Serpick AA, Thompson WL. Hypocalcemia complicating acute leukemia. *Med Pediatr Oncol* 1:289-95, 1975.
6. **Alberts DS**. Current concepts in the management of ovarian carcinoma. *Ariz Med* 32:951-4, 1975.
7. **Alberts DS**, van Daalen Wetters T. The effect of phenobarbital on cyclophosphamide antitumor activity. *Cancer Res* 36:2785-9, 1976.
8. **Alberts DS**, van Daalen Wetters T. The effect of allopurinol on cyclophosphamide antitumor activity. *Cancer Res* 36:2790-4, 1976.
9. **Alberts DS**, van Daalen Wetters T. Rubidazole vs. adriamycin: an evaluation of their differential toxicity in the spleen colony assay system. *Br J Cancer* 34:64-8, 1976.
10. **Alberts DS**, Durie BGM, Salmon SE. Doxorubicin/BCNU chemotherapy for multiple myeloma in relapse. *Lancet* 1:926-8, 1976.
11. **Alberts DS**, Durie BGM, Salmon SE. Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. *Cancer Treat Res* 61:381-8, 1977.
12. **Alberts DS**, Coulthard SW. Chemotherapy of head and neck cancer. *Ariz Med* 34:695-7, 1977.
13. **Alberts DS**, Peng YM, Moon TE, Bressler R. Carnitine prevention of adriamycin toxicity in mice. *Biomed* 29:265-8, 1978.
14. Chang SY, **Alberts DS**, Melnick LR, Walson PD, Salmon SE. High-pressure liquid chromatographic analysis melphalan in plasma. *J Pharm Sci* 67:679-82, 1978.
15. Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, **Alberts DS**, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. *N Engl J Med* 298:1321-7, 1978.
16. **Alberts DS**, Peng YM, Moon TE. α -tocopherol pretreatment increases adriamycin bone marrow toxicity. *Biomed* 29:189-91, 1978.
17. Chang SY, Evans TL, **Alberts DS**, Sipes IG. The stability of L-phenylalanine mustard in bile. *Life Sci* 23:1697-702, 1978.
18. Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, **Alberts DS**, Moon TE. Quantitation of differential sensitivity of human tumor stem cell to anticancer drugs. *Bull Cancer* 65:457-64, 1978.
19. **Alberts DS**, Woolfenden JM, Haber K, Giles HR, Galindo J. Comparison of ultrasonic and indium-III-bleomycin scanning of gynecologic tumors. *Gynecol Oncol* 6:145-51, 1978.
20. Chang SY, **Alberts DS**, Farquhar D, Melnick LR, Walson PD, Salmon SE. Hydrolysis and protein binding of melphalan. *J Pharm Sci* 67:682-4, 1978.
21. **Alberts DS**, Chen HSG, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, Gross JF, Moon T, Broughton A, Salmon SE. Bleomycin pharmacokinetics in man: I. intravenous administration. *Cancer Chemother Pharmacol* 1:177-81, 1978.

22. **Alberts DS**, Ignoffo R. Adriamycin-cyclophosphamide treatment of squamous cell carcinoma of the cervix. *Cancer Treat Rep* 62:143-4, 1978.
23. Rainey JM, **Alberts DS**. Safe, rapid administration schedule for cis-platinum-mannitol. *Med Pediatr Oncol* 4:371-5, 1978.
24. **Alberts DS**, Lynch P. Cutaneous plasmacytomas in myeloma: Relationship to tumor cell burden. *Arch Dermatol* 114:1784-7, 1978.
25. **Alberts DS**, Peng YM, Chen HSG, Struck RF. Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse. *Br J Cancer* 38:316-24, 1978.
26. Hamburger AW, Salmon SE, Kim MB, Trent JM, Soehnlen BJ, **Alberts DS**, Schmidt HJ. Direct cloning of human ovarian carcinoma cells in agar. *Cancer Res* 38:3438-44, 1978.
27. Nash CH, **Alberts DS**. Non-invasive scanning techniques for gynecologic cancer. *Ariz Med* 36:119-20, 1979.
28. **Alberts DS**, Chen HSG, Mayersohn M, Perrier D, Moon TE, Gross JF. Bleomycin pharmacokinetics in man. II. Intracavitary administration. *Cancer Chemother Pharmacol* 2:127-32, 1979.
29. **Alberts DS**, Hilgers RD, Moon TE, Martimbeau PW, Rivkin S. Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial. *Cancer Treat Rep* 63:301-5, 1979.
30. **Alberts DS**, Moon TE, Stephens RA, Wilson H, Oishi N, Hilgers RD, O'Toole R, Thigpen JT. Randomized study of chemo-immunotherapy for advanced ovarian carcinoma: a preliminary report of a Southwest Oncology Group study. *Cancer Treat Rep* 63:325-31, 1979.
31. **Alberts DS**. Advances in the management of ovarian cancer. *Ariz Med* 36:197-201, 1979.
32. Woolfenden JM, **Alberts DS**, Hall JN, Patton DD: Cobalt-57 bleomycin for imaging head and neck tumors. *Cancer* 43:1652-7, 1979.
33. **Alberts DS**, Chen HSG, Woolfenden JM, Moon TE, Chang SY, Hall JN, Himmelstein KJ, Gross JF, Salmon SE: Pharmacokinetics of bleomycin in man: III. bleomycin Co-57 vs. bleomycin. *Cancer Chemother Pharmacol* 3:33-40, 1979.
34. Nash CH, **Alberts DS**, Suci TN, Giles HR, Tobias DA, Waldman RS. Comparison of B-mode ultrasonography and computed tomography in gynecologic cancer. *Gynecol Oncol* 8:172-9, 1979.
35. Chang SY, Evans TL, **Alberts DS**. The stability of melphalan in the presence of chloride ion. *J Pharm Pharmacol* 31:853-4, 1979.
36. **Alberts DS**, Chang SY, Chen HSG, Evans TL, Moon TE. Oral melphalan kinetics. *Clin Pharmacol Ther* 26:737-45, 1979.
37. **Alberts DS**, Chang SY, Chen HSG, Larcom BJ, Jones SE. Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report. *Cancer Treat Rev* 6(Suppl 5):9-17, 1979.
38. **Alberts DS**, Chang SY, Chen HSG, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF. Kinetics of intravenous melphalan. *Clin Pharmacol Ther* 26:73-80, 1979.
39. Stephens R, Coltman C, Rossof A, Samson M, Panettiere F, Al-Sarraf M, **Alberts D**, Bonnet J. cis-Dichlorodiammineplatinum (II) in adult patients: Southwest Oncology Group studies. *Cancer Treat Rep* 63:1609-10, 1979.
40. Chang SY, Larcom BJ, **Alberts DS**, Larsen B, Walson PD, Sipes IG. Mass spectrometry of chlorambucil, its degradation products, and its metabolite in biological samples. *J Pharm Sci* 69:80-4, 1980.
41. Dorr RT, **Alberts DS**, Chen HSG. Experimental model of doxorubicin extravasation in the mouse. *Pharmacol Methods* 4:237-50, 1980.

42. **Alberts DS**, Peng YM, Chen HSG, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. *J Natl Cancer Inst* 65:455-61, 1980.
43. Peng YM, **Alberts DS**, Chen HSG, Mason N, Moon TE. Antitumor activity and plasma kinetics of bleomycin by continuous and intermittent administration. *Br J Cancer* 41:644-647, 1980.
44. Dorr RT, **Alberts DS**, Chen HSG. The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. *Cancer Chemother Pharmacol* 5:17-20, 1980.
45. **Alberts DS**, Griffith KS, Goodman GE, Herman TS, Murray E. Phase I clinical trial of mitoxantrone: a new anthracenedione anticancer drug. *Cancer Chemother Pharmacol* 5:11-5, 1980.
46. **Alberts DS**, Salmon SE, Chen HSG, Surwit EA, Soehnlen B, Young L, Moon TE. *In vitro* clonogenic assay for predicting response of ovarian cancer to chemotherapy. *Lancet* 2:340-2, 1980.
47. **Alberts DS**, Chen HS, Chang SY, Peng YM. The disposition of intraperitoneal bleomycin, melphalan and vinblastine in cancer patients. *Recent Results Cancer Res* 74:293-9, 1980.
48. **Alberts DS**, Manning MR, Coulthard SW, Koopman CF Jr, Herman TS. Adriamycin/cisplatinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. *Cancer* 47:645-8, 1981.
49. Dana BW, **Alberts DS**. Combination chemoimmunotherapy for advanced renal carcinoma with adriamycin, bleomycin, vincristine, cyclophosphamide, plus BCG. *Cancer Clin Trials* 4:205-7, 1981.
50. **Alberts DS**, Chen HSG, Benz D, Mason NL. Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. *Br J Cancer* 43:330-4, 1981.
51. Salmon SE, Meyskens FL Jr, **Alberts DS**, Soehnlen B, Young L. New drugs in ovarian cancer and malignant melanoma: *in vitro* phase II screening with the human tumor stem cell assay. *Cancer Treat Rep* 65:1-12, 1981.
52. **Alberts DS**, Martimbeau PW, Surwit EA, Oishi N. Mitomycin-C, bleomycin, vincristine, cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix. *Cancer Clin Trials* 4:313-6, 1981.
53. Von Hoff DD, **Alberts DS**, Mattox DE, Coulthard SW, Dana B, Manning M, Myers JW, Griffin CB. Combination chemotherapy with cisplatin, bleomycin and methotrexate in patients with advanced head and neck cancer. *Cancer Clin Trials* 4:215-8, 1981.
54. Moon TE, Salmon SE, White CS, Chen HSG, Meyskens FL, Durie BGM, **Alberts DS**. Quantitative association between the *in vitro* human tumor stem cell assay and clinical response to cancer chemotherapy. *Cancer Chemother Pharmacol* 6:211-8, 1981.
55. **Alberts DS**, Salmon SE, Chen HSG, Moon TE, Young L, Surwit EA. Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. *Cancer Chemother Pharmacol* 6:253-64, 1981.
56. Dorr RT, **Alberts DS**. Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compounds. *Cancer Res* 41:2428-32, 1981.
57. **Alberts DS**, Chen HSG, Salmon SE, Surwit EA, Young L, Moon TE, Meyskens FL Jr, and Co-investigators from the Arizona-New Mexico Tumor Cloning Group. Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. *Cancer Chemother Pharmacol* 6:279-85, 1981.
58. Dorr RT, **Alberts DS**: Pharmacologic antidotes to experimental doxorubicin skin toxicity. a suggested role for β -adrenergic compounds. *Cancer Treat Rep* 65: 1001-6, 1981.
59. Peng YM, Davis TP, **Alberts DS**. High performance liquid chromatography of a new anticancer drug, ADCA -- physicochemical properties and pharmacokinetics. *Life Sci* 29:361-9, 1981.
60. Aapro MS, **Alberts DS**. High-dose dexamethasone for prevention of cis-platin-induced vomiting. *Cancer Chemother Pharmacol* 7:11-4, 1981.

61. Strohm GH, Payne CM, **Alberts DS**, Peng YM, Moon TE, Bahl JJ, Bressler R. Cardiotoxic effects of doxorubicin with and without carnitine usefulness of the mouse model in assessment. *Arch Pathol Lab Med* 106:181-5, 1982.
62. Evans TL, Chang SY, **Alberts DS**, Sipes IG, Brendel K. *In vitro* degradation of L-phenylalanine mustard (L-PAM). *Cancer Chemother Pharmacol* 8:175-8, 1982.
63. Davis TP, Peng YM, Goodman GE, **Alberts DS**. HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid. *J Chromatogr Sci* 20:511-6, 1982.
64. Dorr RT, **Alberts DS**: Cimetidine enhancement of cyclophosphamide antitumor activity. *Br J Cancer* 45:35-43, 1982.
65. Goodman GE, Einspahr JG, **Alberts DS**, Davis TP, Leigh SA, Chen HSG, Meyskens FL. Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. *Cancer Res* 42:2087-91, 1982.
66. Goodman GE, McLean A, **Alberts DS**, Chang SY. Inhibition of human tumour clonogenicity by chlorambucil and its metabolites. *Br J Cancer* 45:621-3, 1982.
67. **Alberts DS**, Mackel C, Pocelinko R, Salmon SE. Phase I clinical investigation of 9,10 anthracenedicarboxaldehyde bis [(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride (Bisantrene) with correlative *in vitro* human tumor clonogenic assay. *Cancer Res* 42:1170-5, 1982.
68. Dorr RT, Peng YM, **Alberts DS**. Bleomycin compatibility with selected intravenous medications. *J Med* 13:121-30, 1982.
69. Meyskens FL Jr, Gilmartin E, **Alberts DS**, Levine NS, Brooks R, Salmon SE, Surwit EA. Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. *Cancer Treat Rep* 66:1315-9, 1982.
70. Dorr RT, Surwit EA, Meyskens FL, Droegemueller W, **Alberts DS**, Chvapil M. *In vitro* retinoid binding and release from a collagen sponge material in a simulated intravaginal environment. *J Biomed Mater Res* 16:839-50, 1982.
71. Surwit EA, Graham V, Droegemueller W, **Alberts D**, Chvapil M, Dorr RT, Davis JR, Meyskens FL Jr. Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. *Am J Obstet Gynecol* 143:821-3, 1982.
72. Peng YM, Ormberg D, **Alberts DS**. Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone. *J Chromatogr* 233:235-47, 1982.
73. Bowden GT, Garcia D, Peng YM, **Alberts DS**. Molecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxyaldehyde bis [(4,5dihydro-1H-imidazol-2-yl)hydrazone] dihydro-chloride (CL 216,942). *Cancer Res* 42:2660-5, 1982.
74. Peng YM, Beaudry J, **Alberts DS**, Davis TP. High-performance liquid chromatography of the provitamin A β -carotene in plasma. *J Chromatogr* 273:410-4, 1983.
75. Surwit EA, **Alberts DS**, Crisp W, Jackson RA, Grozea PN, Leigh S. Multiagent chemotherapy in relapsing ovarian cancer. *Am J Obstet Gynecol* 146:613-6, 1983.
76. Aapro MS, **Alberts DS**, Salmon SE. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. *Cancer Chemother Pharmacol* 10:161-6, 1983.
77. Hilgers RD, Legha SS, Panetti FJ, **Alberts DS**. m-AMSA in epithelial carcinoma of the ovary: a Southwest Oncology Group study. *Am J Clin Oncol* 6:277-9, 1983.
78. Garewal HS, Ahmann FR, **Alberts DS**. Lack of inhibition by oxipurinol of 5-FU toxicity against human tumor cell lines. *Cancer Treat Rep* 67:495-8, 1983.
79. Goodman GE, **Alberts DS**, Earnest DL, Meyskens FL. Phase I trial of retinol in cancer patients. *J Clin Oncol* 1:394-9, 1983.

80. Dorr RT, **Alberts DS**. Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. *Cancer Treat Rep* 67:499-501, 1983.
81. Dorr RT, **Alberts DS**. Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents. *Invest New Drugs* 1:151-9, 1983.
82. Aapro MS, **Alberts DS**, Woolfenden JM, and Mackel C. Prospective study of left ventricular function using radionuclide scans in patients receiving mitoxantrone. *Invest New Drugs* 1:341-7, 1983.
83. Meyskens FL Jr, **Alberts DS**, Salmon SE. Effect of 13-cis-retinoic acid and 4-hydroxyphenyl-all-trans-retinamide on human tumor colony formation in soft agar. *Int J Cancer* 32:295-9, 1983.
84. Meyskens FL Jr, Graham VE, Chvapil M, Dorr RT, **Alberts DS**, Surwit EA. A phase I trial of β -all-trans retinoic acid delivered via a collagen sponge and cervical for mild or moderate intraepithelial cervical neoplasia. *J Natl Cancer Inst* 71:921-5, 1983.
85. Aapro MS, **Alberts DS**, Serokman R. Lack of dexamethasone effect on the antitumor activity of cisplatin. *Cancer Treat Rep* 67:1013-7, 1983.
86. **Alberts DS**, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in patients. *Cancer Treat Rev* 10(Suppl B):23-7, 1983.
87. Ludwig CU, Bowden GT, Roberts RA, **Alberts DS**. Reduced bisantrene-induced cytotoxicity and protein-associated DNA strand breaks under hypoxic condition. *Cancer Treat Rep* 68:367-72, 1984.
88. Ludwig R, **Alberts DS**, Miller TP, Salmon SE. Evaluation of anticancer drug schedule dependency using an *in vitro* human tumor clonogenic assay. *Cancer Chemother Pharmacol* 12:135-41, 1984.
89. Miller TP, Jones SE, **Alberts DS**, Mackel C. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas. *Invest New Drugs* 2:75-7, 1984.
90. Villar HV, **Alberts DS**. Colorectal carcinoma: new Approaches for advanced disease. *Ariz Med* 41:313-7, 1984.
91. Aapro MS, **Alberts DS**. Phase II trial of mitoxantrone in head and neck cancer. *Invest New Drugs* 2:329-30, 1984.
92. Hilgers RD, **Alberts DS**, Standefer JC, Skipper BE, Miles NJ, Borst J. Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy: a Southwest Oncology Group trial. *Gynecol Oncol* 18:62-70, 1984.
93. Garewal HS, Robertone A, Salmon SE, Jones SE, **Alberts DS**, Brooks R. Phase I trial of esorubicin (4'-deoxydoxorubicin). *J Clin Oncol* 2(9):1034-9, 1984.
94. Goodman GE, **Alberts DS**, Peng YM, Beaudry J, Leigh SA, Moon TE. Plasma kinetics of oral retinol in cancer patients. *Cancer Treat Rep* 68:1125-33, 1984.
95. Aapro MS, Plezia PM, **Alberts DS**, Graham V, Jones SE, Surwit EA, Moon TE. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. *J Clin Oncol* 2(5):466-71, 1984.
96. Peng YM, **Alberts DS**, Salmon SE, Davis TP. A method for the simultaneous measurement of the new anthracycline derivative 4'-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography. *Invest New Drugs* 2:277-80, 1984.
97. **Alberts DS**, Einspahr JG, Struck R, Bignami G, Young L, Surwit EA, Salmon SE. Comparative *in vitro* cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z7557 (INN mafosfamide). *Invest New Drugs* 2:141-8, 1984.
98. Hilgers RD, Legha SS, Johnston GA Jr, **Alberts DS**, Stephens RL, Trantum BL, Hannigan EV: m-AMSA and adenocarcinoma of the endometrium. a Southwest Oncology Group study. *Invest New Drugs* 2:335-8, 1984.

99. **Alberts DS**, Einspahr JG, Ludwig R, Salmon SE. Pharmacologic pitfalls in the human tumor clonogenic assay. *Recent Results Cancer Res* 94:184-190, 1984.
100. Ludwig R, **Alberts DS**. Chemical and biological stability of anticancer drugs used in a human tumor clonogenic assay. *Cancer Chemother Pharmacol* 12:142-5, 1984.
101. Takasugi BJ, Robertone AB, Salmon SE, Jones SE, **Alberts DS**. Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors. *Invest New Drugs* 2:387-90, 1984.
102. Surwit EA, **Alberts DS**, Christian CD, Graham VE Poor-prognosis gestational trophoblastic disease: an update. *Obstet Gynecol* 64:21-6, 1984.
103. Dorr RT, Peng YM, **Alberts DS**. Bisantrone solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote. *Invest New Drugs* 2:351-7, 1984.
104. Dalton WS, **Alberts DS**. Mitoxantrone: a promising new chemotherapeutic agent. *Ariz Med* 41:96-8, 1984.
105. Hilgers RD, Rivkin SE, Von Hoff DD, **Alberts DS**. Mitoxantrone in epithelial carcinoma of the ovary: a Southwest Oncology Group study. *Am J Clin Oncol* 7:499-501, 1984.
106. Struck RF, **Alberts DS**. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after IV or oral administration. *Cancer Treat Rep* 68:765-70, 1984.
107. Plezia PM, **Alberts DS**, Kessler J, Aapro MS, Graham V, Surwit EA. Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen. *Cancer Treat Rep* 68:1493-5, 1985.
108. Dorr RT, **Alberts DS**. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. *J Natl Cancer Inst* 74:113-20, 1985.
109. Peng YM, **Alberts DS**, Davis TP. *In vivo* and *in vitro* metabolism of the new anticancer drug bisantrene. *Cancer Chemother Pharmacol* 14:15-20, 1985.
110. **Alberts DS**, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in cancer patients. *Cancer Res* 45:1879-84, 1985.
111. Bowden GT, Roberts R, **Alberts DS**, Peng YM, Garcia D. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. *Cancer Res* 45:4915-20, 1985.
112. Dorr RT, Bowden GT, **Alberts DS**, Liddil JD. Interactions of mitomycin C with mammalian DNA detected by alkaline elution. *Cancer Res* 45:3510-6, 1985.
113. Minor D, Allen RE, **Alberts D**, Peng YM, Tardelli G, Hutchinson J. A clinical and pharmacokinetic study in isolated limb perfusion with heat and melphalan for melanoma. *Cancer* 55:2638-44, 1985.
114. **Alberts DS**, Peng YM, Bowden GT, Dalton WS, Mackel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. *Invest New Drugs* 3:101-7, 1985.
115. Meyskens FL Jr, Goodman GE, **Alberts DS**. 13-cis-retinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer. *Crit Rev Oncol Hematol* 3:75-101, 1985.
116. **Alberts DS**, Balcerzak SP, Bonnet JD, Stephens RL. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group study. *Cancer Treat Rep* 69:1321-3, 1985.
117. Dorr RT, **Alberts DS**, Stone A. Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. *Cancer Treat Rep* 69:431-7, 1985.
118. Ho EE, **Alberts DS**. Fiber and colon cancer prevention. *Boswell Hospital Proc* XI:4-12, 1985.
119. Miller TP, Ahmann FR, Mackel C, Greenberg BR, **Alberts DS**. Phase II trial of bisantrene in non-small cell lung cancer. *Invest New Drugs* 3:393-5, 1985.

120. Campbell MA, Perrier DG, Dorr RT, **Alberts DS**, Finley PR. Methotrexate: bioavailability and pharmacokinetics. *Cancer Treat Rep* 69:833-8, 1985.
121. **Alberts D**, Mason N, Surwit E, Weiner S, Hammond N, Deppe G. Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study. *Cancer Treat Rev* 12(Suppl A):83-92, 1985.
122. Piccart MJ, Speyer JL, Markman M, ten Bokkel Huinink WW, **Alberts D**, Jenkins J, Muggia F. Intraperitoneal chemotherapy: technical experience at five institutions. *Semin Oncol* 12(Suppl 4):90-6, 1985.
123. Kessler JF, **Alberts DS**, Plezia PM, Wilson V, Chase J, Aapro M, Surwit EA. An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting: experience in 84 patients. *Cancer Chemother Pharmacol* 16:282-6, 1986.
124. **Alberts DS**, Coulthard SW, Meyskens FL Jr. Regression of aggressive laryngeal papillomatosis with 13-cis-retinoic acid (Acutane). *J Biol Response Modifiers* 5:124-8, 1986.
125. Watson RR, Jackson JC, **Alberts DS**, Hicks MJ. Cellular immune functions of adults treated with a daily, long-term, low dose of 13-cis-retinoic acid. *J Leukoc Biol* 39:567-77, 1986.
126. Dorr RT, Soble MJ, **Alberts DS**. Interaction of cimetidine but not ranitidine with cyclophosphamide in mice. *Cancer Res* 46:1795-9, 1986.
127. Cowan JD, Surwit EA, **Alberts DS**, Boutselis JG, Neilan BA. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group study. *Cancer Treat Rep* 70:423-4, 1986.
128. Dorr RT, **Alberts DS**, Soble MJ. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. *Cancer Chemother Pharmacol* 16:91-4, 1986.
129. Edwards L, **Alberts DS**, Levine N. Clinical toxicity of low-dose isotretinoin. *Cancer Treat Rep* 70:663-4, 1986.
130. Peng YM, **Alberts DS**, Xu MJ, Watson RR, Gensler HL, Bowden GT. Effects of high dietary retinyl palmitate and selenium on tissue distribution of retinoid in mice exposed to tumor initiation and promotion. *J Nutr Growth Cancer* 3:33-40, 1986.
131. Braich TA, Salmon SE, Robertone AB, **Alberts DS**, Jones SE, Miller TP, Garewal HS. Phase II trial of esorubicin (4'deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. *Invest New Drugs* 4:269-74, 1986.
132. Mackel C, Meyskens FL Jr, **Alberts DS**. Phase II trial of bisantrene in patients with metastatic melanoma. *Cancer Treat Rep* 70:1037-8, 1986.
133. Laufman LR, Green JB, **Alberts DS**, O'Toole R, Hilgers RD, Young DC, Lin F, Rivkin SE. Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study. *J Clin Oncol* 4(9):1374-9, 1986.
134. Dalton WS, Durie BGM, **Alberts DS**, Gerlach JH, Cress AE. Characterization of new drug-resistant human myeloma cell line that expresses P-glycoprotein. *Cancer Res* 46:5125-30, 1986.
135. Peng YM, **Alberts DS**, Graham V, Surwit EA, Weiner S, Meyskens FL Jr. Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia. *Invest New Drugs* 4:245-9, 1986.
136. Brock J, **Alberts DS**. Safe, rapid administration of cisplatin in the outpatient clinic. *Cancer Treat Rep* 70:1409-14, 1986.
137. Meyers EF, **Alberts DS**, Gordon MO. Perioperative control of blood glucose in diabetic patients: a two-step protocol. *Diabetes Care* 9:40-5, 1986.

138. Surwit EA, **Alberts DS**, O'Toole RV, Graham V, Hannigan EV, Stephens RL, Boutselis JG. Phase II trial of vinblastine in previously treated patients with ovarian cancer: a Southwest Oncology Group study. *Gynecol Oncol* 27:214-9, 1987.
139. Surwit EA, **Alberts DS**, O'Toole RV, Graham V, Hannigan EV, Stephens RL, Boutselis JG. Phase II trial of vinblastine in previously treated patients with ovarian cancer: a Southwest Oncology Group study. *Gynecol Oncol* 28:14-9, 1987.
140. Dorr RT, **Alberts DS**, Einspahr J, Mason-Liddil N, Soble M. Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes. *Cancer Treat Rep* 71:267-72, 1987.
141. **Alberts DS**, Mason NL, O'Toole RV, Hilgers RD, Rivkin SE, Boutselig JG, Pugh RP, Vaitkevicius VK, Green JB, Oishi N. Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: a Southwest Oncology Group study. *Gynecol Oncol* 26:193-201, 1987.
142. **Alberts DS**, Mason-Liddil N, Green SJ, Cowan JD, Fletcher WS, Neilan B, Guy JT, Epstein RB. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma: a Southwest Oncology Group study. *Invest New Drugs* 5:289-92, 1987.
143. Peng YM, Xu MJ, **Alberts DS**. Analysis and stability of retinol in plasma. *J Natl Cancer Inst* 78:95-9, 1987.
144. Struck RF, **Alberts DS**, Horne K, Phillips JG, Peng YM, Roe DJ. Plasma pharmaco-kinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, cross-over trial. *Cancer Res* 47:2723-6, 1987.
145. Weiner SA, **Alberts DS**, Surwit EA, Davis J, Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. *Gynecol Oncol* 27:208-13, 1987.
146. Greenberg B, Ahmann F, Garewal H, Koopmann C, Coulthard S, Berzes H, **Alberts DS**, Shimm D, Slymen D. Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cis-platin: A phase I-II study. *Cancer* 59:1860-5, 1987.
147. Wunz TP, Dorr RT, **Alberts DS**, Tunget CL, Einspahr J, Milton S, Remers WA. New antitumor agents containing the anthracene nucleus. *J Med Chem* 30:1313-21, 1987.
148. **Alberts DS**, Kronmal R, Baker LH, Stock-Novack DL, Surwit EA, Boutselis JG, Hannigan EV. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. *J Clin Oncol* 5(11):1791-5, 1987.
149. Weiner SA, Aristizabal S, **Alberts DS**, Surwit EA, Deatherage-Deuser K. A phase II trial of mitomycin, vincristine, bleomycin, cisplatin (MOBP) as neoadjuvant therapy in high- risk cervical carcinoma. *Gynecol Oncol* 30:1-6, 1988.
150. Xu MJ, **Alberts DS**. Potentiation of platinum analogue cytotoxicity by hyperthermia. *Cancer Chemother Pharmacol* 21:191-196, 1988.
151. Lippman SM, **Alberts DS**, Slymen DJ, Weiner S, Aristizabal SA, Luditch A, Davis JR, Surwit EA. Second-look laparotomy in epithelial ovarian carcinoma: prognostic factors associated with survival duration. *Cancer* 61:2571-7, 1988.
152. Von Hoff DD, Kronmal R, O'Toole RV, Surwit EA, Hutton JJ, **Alberts DS**. Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced ovarian cancer: a Southwest Oncology Group study. *Am J Clin Oncol* 11:146-8, 1988.
153. Dorr RT, **Alberts DS**. Quantitation of ellipsoid tumor surface areas using a circumferential measuring device. *Med Oncol Tumor Pharmacother* 5:249-51, 1988.
154. Dorr RT, Bozak KA, Shipp NG, Hendrix M, **Alberts DS**, Ahmann F. *In vitro* rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios. *Cancer Res* 48:5222-7, 1988.

155. Lippman SM, Kessler JF, Al-Sarraf M, **Alberts DS**, Itri LM, Mattox D, Von Hoff DD, Loeschler L, Meyskens FL. Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial. *Invest New Drugs* 6:51-6, 1988.
156. Davis LE, **Alberts DS**, Plezia PM, Roe DJ, Griswold DP. Predictive model for plasma concentration-versus-time profiles of investigational anticancer drugs in patients. *J Natl Cancer Inst* 80:815-9, 1988.
157. Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, **Alberts DS**. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. *Cancer Res* 48:6365-70, 1988.
158. **Alberts DS**, Einspahr J, Bregman MD. Additive activity of mitoxantrone and doxorubicin *in vitro* against human breast cancer. *J Drug Dev* 1:15-21, 1988.
159. Dalton WS, Cress AE, **Alberts DS**, Trent JM. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. *Cancer Res* 48:1882-8, 1988.
160. Bellamy WT, Dorr RT, Dalton WS, **Alberts DS**. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. *Cancer Res* 48:6360-4, 1988.
161. **Alberts DS**, Surwit EA, Peng YM, McCloskey T, Rivest R, Graham V, McDonald L, Roe D. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. *Cancer Res* 48:5874-7, 1988.
162. Dorr RT, **Alberts DS**, Liddil JD. Mitomycin C toxicity and pharmacokinetics in mice given sulfur nucleophiles. *Anticancer Res* 8:733-8, 1988.
163. **Alberts DS**, McDonald L, Edwards L, Peng YM, Xu MJ, Slymen DJ, Earnest DL, Ritenbaugh C. Pharmacokinetics and metabolism of retinol administered at a chemopreventive level to normal subjects. *Cancer Detect Prev* 13:55-64, 1988.
164. Dorr RT, Soble M, **Alberts DS**: Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse. *Cancer Chemother Pharmacol* 22:299-302, 1988.
165. Bellamy WT, **Alberts DS**, Dorr RT. Daily variation in non-protein sulfhydryl levels of human bone marrow. *Eur J Cancer Clin Oncol* 24:1759-62, 1988.
166. Garewal HS, Sampliner R, Gerner E, Steinbronn K, **Alberts DS**, Kendall O. Ornithine decarboxylase activity in Barrett's Esophagus: a potential marker for dysplasia. *Gastroenterology* 94:819-21, 1988.
167. Garewal HS, Sampliner R, **Alberts D**, Steinbronn K: Increase in ornithine decarboxylase activity associated with development of dysplasia in Barrett's Esophagus. *Dig Dis Sci* 34:312-4, 1989.
168. Peng YM, Dalton WS, **Alberts DS**, Xu MJ, Lim H, Meyskens FL Jr. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. *Int J Cancer* 43:22-6, 1989.
169. Plezia PM, **Alberts DS**, Peng YM, Xu MJ, Sayers S, Davis TP, Surwit EA, Meyskens FL Jr. The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. *Prev Med* 18:680-7, 1989.
170. **Alberts DS**, Mason-Liddil N. The role of cisplatin in the management of advanced squamous cell cancer of the cervix. *Semin Oncol* 16(Suppl 6):66-78, 1989.
171. **Alberts DS**, Mason-Liddil N, O'Toole RV, Abbott TM, Kronmal R, Hilgers RD, Surwit EA, Eyre HJ, Baker LH. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: a Southwest Oncology Group study. *Gynecol Oncol* 32:8-15, 1989.
172. **Alberts DS**, Mason-Liddil N, O'Toole RV, Abbott TM, Kronmal R, Hilgers RD, Surwit EA, Eyre HJ, Baker LH. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: a Southwest Oncology Group study. *Gynecol Oncol* 32:16-21, 1989.

173. Harari PM, Shimm DS, Gerner EW, **Alberts DS**. Intraperitoneal chemotherapy plus regional/systemic hyperthermia in the treatment of advanced ovarian cancer. *Reg Cancer Treat* 2:54-8, 1989.
174. Pettit GR, Singh SB, Hamel E, Lin CM, **Alberts DS**, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. *Experientia* 45:209-11, 1989.
175. Buzaid AC, **Alberts DS**, Einspahr J, Mosley K, Peng YM, Tutsch K, Spears CP, Garewal HS. Effect of dipyridamole on fluorodeoxyuridine cytotoxicity *in vitro* and in cancer patients. *Cancer Chemother Pharmacol* 25:124-30, 1989.
176. Xu MJ, **Alberts DS**, Liu R, Leibovitz A, Liu Y. *In vitro* evaluation of cisplatin interaction with doxorubicin or 4-hydroperoxycyclophosphamide against human gynecologic cancer cell lines. *Cancer Chemother Pharmacol* 25:89-94, 1989.
177. Taylor CW, **Alberts DS**, Ketcham MA, Satterlee WG, Holdsworth MT, Plezia PM, Peng YM, McCloskey TM, Roe DJ, Hamilton M, Salmon SE. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. *J Clin Oncol* 7(11):1733-40, 1989.
178. Plezia PM, **Alberts DS**, Kessler JF, Berens PL, Chase JL, Roe DJ. Randomized crossover comparison of high-dose intravenous metoclopramide versus a five-drug antiemetic regimen. *J Pain Sympt Manage* 5:101-8, 1990.
179. Green JB, Green S, **Alberts DS**, O'Toole R, Surwit EA, Noltmier JW. Carboplatin therapy in advanced endometrial cancer. *Obstet Gynecol* 75:696-700, 1990.
180. Canfield LM, Corrigan JJ, Plezia PM, Jeter M, Sayers S, **Alberts DS**. Effects of chronic β -carotene supplementation on vitamin K status in adults. *Nutr Cancer* 13:263-9, 1990.
181. Taylor CW, Salmon SE, Satterlee WG, Robertone AB, McCloskey TM, Holdsworth MT, Plezia PM, **Alberts DS**. A phase I and pharmacokinetic study of intravenous vinzolidine. *Invest New Drugs* 8(Suppl 1):S51-7, 1990.
182. Von Hoff DD, Green S, Surwit EA, Hannigan E, **Alberts DS**. Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer: a Southwest Oncology Group Study. *Am J Clin Oncol* 13:433-5, 1990.
183. Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, **Alberts DS**. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: A Southwest Oncology Group trial. *Gynecol Oncol* 37:354-8, 1990.
184. **Alberts DS**, Einspahr J, Rees-McGee S, Ramanujam P, Buller MK, Clark L, Ritenbaugh C, Atwood J, Pethigal P, Earnest D. Effects of dietary wheat bran fiber on rectal epithelium proliferation rates in patients with resection for colorectal cancers. *J Natl Cancer Inst* 82:1280-5, 1990.
185. Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, **Alberts DS**. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. *Gynecol Oncol* 39:332-6, 1990.
186. Boros L, Peng YM, **Alberts DS**, Asbury RF, Goodman TL, Penn TE, Hickox DE. Pharmacokinetics of very high-dose oral melphalan in cancer patients. *Am J Clin Oncol* 13:19-22, 1990.
187. Smaldone L, Plezia P, **Alberts DS**, Aapro M, Sartiano G, Dorn M, Brady M, Comerski C, Schwartz SE, Fairchild C: Batanopride (BMY-25801). A new 5-HT₃ receptor antagonist for the prevention of cancer chemotherapy-induced emesis. *Cancer Treat Rev* 17:319-27, 1990.
188. Watson RR, Prabhala RH, Plezia PM, **Alberts DS**. Effect of β -carotene on lymphocyte subpopulations in elderly humans: Evidence for a dose response relationship. *Am J Clin Nutr* 53:90-4, 1991.
189. Von Hoff DD, Kronmal R, Salmon SE, Turner J, Green JB, Bonorris JS, Moorhead EL, Hynes HE, Pugh RE, Belt RJ, **Alberts DS**. A Southwest Oncology Group Study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. *Cancer* 67:20-7, 1991.

190. Ho EE, Atwood JR, Benedict J, Ritenbaugh C, Sheehan ET, Abrams C, **Alberts DS**, Meyskens FL Jr. A community-based feasibility study using wheat bran fiber supplementation to lower colon cancer risk. *Prev Med* 20:213-25, 1991.
191. Von Hoff DD, Green S, **Alberts DS**, Stock-Novack DL, Surwit EA, Miller TP, Stephens RL. Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer: a Southwest Oncology Group study. *Am J Clin Oncol* 14:193-4, 1991.
192. Kunz KR, Iyengar BS, Dorr RT, **Alberts DS**, Remers WA. Structure-activity relationships for mitomycin C and mitomycin A analogues. *J Med Chem* 34:2281-6, 1991.
193. Green JB, Green S, O'Toole RV, **Alberts DS**, Nahhas WA, Wallace DL. Etorubicin in advanced endometrial cancer: An ineffective and potentially toxic therapy: a Southwest Oncology Group study. *Invest New Drugs* 9:191-3, 1991.
194. **Alberts DS**, Dorr RT, Wunz TP, Remers WA, Einspahr J, Liu R, Salmon SE. *In vitro* cytotoxicity against fresh human tumors and P388 leukemia predicts the differential *in vivo* activity of a series of anthracene anticancer drugs. *Anticancer Drugs* 2:69-77, 1991.
195. Bhuyan BK, Folz SJ, DeZwaan J, Northcott SE, **Alberts DS**, Garcia D, Wallace TL, Li LH. Cytotoxicity of tetraplatin and cisplatin for human and rodent cell lines cultured as monolayers and multicellular spheroids. *Cancer Commun* 3:53-9, 1991.
196. Kreisle WH, **Alberts DS**, List AF, McCloskey T, Plezia P, Peng YM, George M. A phase I trial of 14-day continuous intravenous infusion mitoxantrone. *Anticancer Drugs* 2:251-9, 1991.
197. **Alberts DS**, Dorr RT. Case Report: Topical DMSO for mitomycin-C-induced skin ulceration. *Oncol Nurs Forum* 18:693-5, 1991.
198. Atwood JR, Buller MK, Sheehan ET, Benedict JA, Giordano L, **Alberts DS**, Earnest D, Meyskens FL Jr. Acceptability, satisfaction and cost of a model-based newsletter for elders in a cancer prevention adherence promotion strategy. *Patient Ed Counsel* 18:211-21, 1991.
199. **Alberts DS**, Mason-Liddil N, Plezia PM, Roe DJ, Dorr RT, Struck RF, Phillips JG. Lack of ranitidine effects on cyclophosphamide bone marrow toxicity or metabolism: a placebo controlled clinical trial. *J Natl Cancer Inst* 83:1739-43, 1991.
200. Weiss G, Green S, **Alberts DS**, Thigpen JT, Hines HE, Hanson K, Pierce HI, Baker LH, Goodwin JW. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. *Eur J Cancer* 27:135-8, 1991.
201. Fossella FV, Lippman SM, Seitz DE, **Alberts DS**, Taylor CW, Wiltshaw E, Hardy J, O'Brein M, Haynes TR, Wolen RL. Hypoprothrombinemia from coadministration of sulofenur (LY 186641) and warfarin: Report of three cases. *Invest New Drugs* 9:357-9, 1991.
202. Advanced Ovarian Trialists Group (**Alberts DS**, et al). Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. *Br Med J* 303:884-93, 1991.
203. Islam I, Skibo EB, Dorr RT, **Alberts DS**. Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents. *J Med Chem* 34:2954-61, 1991.
204. Earnest DL, Hixson LJ, Fennerty B, Emerson SS, **Alberts DS**. Inhibition of prostaglandin synthesis: Potential for chemoprevention of human colon cancer. *Cancer Bull* 43:561-8, 1991.
205. Plezia PM, Peng YM, Xu MJ, **Alberts DS**. Pharmacokinetic issues in cancer chemoprevention. *Cancer Bull* 43:504-6, 1991.
206. Vargas PA, **Alberts DS**, Ritenbaugh C, Atwood JR, Sampliner R, Earnest D, Ramanujan P, McGee D, Clark L, Emerson S. Dietary fiber and colon cancer prevention. *Cancer Bull* 43:549-54, 1991.

207. Malviya VK, Liu PY, **Alberts DS**, Surwit EA, Craig JB, Hannigan EV. Evaluation of amonafide in cervical cancer, phase II: A SWOG Study. *Am J Clin Oncol* 15:41-4, 1992.
208. Poplin E, Smith H, Behrens B, Redman B, Flaherty L, Neidhart J, **Alberts D**. SWOG 8825: Melphalan GM-CSF: a phase I study. *Gynecol Oncol* 44:66-70, 1992.
209. Lam KS, **Alberts DS**, Peng YM, Brodar F, Matias B, Modiano M, Tuttle R, Sol Lucas V, Wargin W. Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients. *Anticancer Drugs* 3:219-24, 1992.
210. **Alberts DS**, Mason-Liddil N, Stock-Novack D, O'Toole RV, Abbott TM, Salmon SE. A phase II evaluation of esorubicin in ovarian cancer: a Southwest Oncology Group study. *Am J Clin Oncol* 15:146-9, 1992.
211. **Alberts DS**, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malviya VK, Nahhas WA, Jolles CJ. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. *J Clin Oncol* 10(5):706-17, 1992.
212. Cain JM, Liu PY, **Alberts DS**, Gallion HH, Laufman L, O'Sullivan J, Weiss G, Bickers JN. Phase II trial of didemnin-B in advanced epithelial ovarian cancer: a Southwest Oncology Group study. *Invest New Drugs* 10:23-4, 1992.
213. Weiss GR, Liu PY, **Alberts DS**, Brown TD, Neefe JR, Barlogie B. A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial. *Gynecol Oncol* 45:303-6, 1992.
214. Taylor CW, **Alberts DS**, Peng YM, McCloskey TM, Matzner M, Roe DJ, Plezia PM, Grindey GB, Hamilton M, Seitz D. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer. *J Natl Cancer Inst* 84:1798-802, 1992.
215. Gallion HH, Liu PY, **Alberts DS**, O'Toole RV, O'Sullivan J, Mills G, Smith HO, Hynes HE. Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study. *Gynecol Oncol* 46:230-2, 1992.
216. Xu MJ, Plezia PM, **Alberts DS**, Emerson SS, Peng YM, Sayers SM, Liu Y, Ritenbaugh C, Gensler HL. Reduction in plasma or skin alpha-tocopherol concentration with long-term oral administration of beta-carotene in humans and mice. *J Natl Cancer Inst* 84:1559-64, 1992.
217. Dorr RT, **Alberts DS**. Topical absorption and inactivation of cytotoxic anticancer agents in vitro. *Cancer Suppl* 70:983-7, 1992.
218. Meakem TJ, Unger EC, Pond GD, Modiano MR, **Alberts DS**. CT findings after hepatic chemoembolization. *J Comput Assist Tomogr* 16:916-20, 1992.
219. Atwood JR, Aickin M, Giordano L, Benedict J, Bell M, Ritenbaugh C, Rees-McGee S, Sheehan E, Buller M, Ho EE, Meyskens FL, **Alberts D**. The effectiveness of adherence intervention in a colon cancer prevention field trial. *Prev Med* 21:637-55, 1992.
220. Atwood JR, Haase J, Rees-McGee S, Blackwell G, Giordano L, Earnest D, **Alberts DS**, Sheehan E, Benedict J, Aickin M, Meyskens F. Reasons related to adherence in community-based field studies. *Patient Ed Counsel* 19:251-9, 1992.
221. Leong SPL, Xu MJ, **Alberts DS**, Wang TF, Peng YM, Hersh EM, Taylor CW, Fanta P, Salmon SE. Chemosensitivity of human melanoma to cisplatin and heat at pharmacokinetic doses achievable by isolated hyperthermic perfusion. *Reg Cancer Treat* 4:216-9, 1992.
222. Earnest DL, Hixson LJ, **Alberts DS**. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. *J Cell Biochem Suppl*. 161:156-66, 1992.
223. Shipp NG, Dorr RT, **Alberts DS**, Dawson BV, Hendrix M. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. *Cancer Res* 53:550-6, 1993.

224. Emerson S, McGee D, Fennerty B, Hixson L, Garewal H, **Alberts DS**. Design and analysis of studies to reduce the incidence of colon polyps. *Stat Med* 12:339-51, 1993.
225. Markman M, **Alberts D**, Rubin S, Hakes T, Lewis J, Reichman B, Jones W, Curtin J, Barakat R, Brodar F, Peng YM, Pennie K, Almadrones L, Hoskins W. Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery. *Gynecol Oncol* 48:185-8, 1993.
226. **Alberts DS**, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R, Stock-Novack D, Surwit EA, Malviya VK, Jolles CJ. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. a Southwest Oncology Group study. *Cancer Suppl* 71:618-27, 1993.
227. Sami SM, Dorr RT, **Alberts DS**, Remers WA. 2-substituted-1,2-dihydro-3H-dibenz [de,h]isoquinoline-1,3-diones. A new class of antitumor agent. *J Med Chem* 36:765-70, 1993.
228. Garewal H, Meyskens F Jr, Friedman S, **Alberts D**, Ramsey L. Oral cancer prevention: the case for carotenoids and anti-oxidant nutrients. *Prev Med* 22:701-11, 1993.
229. Feldman EJ, **Alberts DS**, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. *J Clin Oncol* 11(10):2002-9, 1993.
230. Hannigan EV, Green S, **Alberts DS**, O'Toole R, Surwit E. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. *Oncology* 50(Suppl 2):2-9, 1993.
231. Peng YS, Peng YM, McGee DL, **Alberts DS**. Carotenoids, tocopherols and retinoids in human buccal mucosal cells: intra- and interindividual variability and storage stability. *Am J Clin Nutr* 59:636-43, 1994.
232. Thompson FH, Emerson J, **Alberts D**, Liu Y, Guan XY, Burgess A, Fox S, Taetle R, Weinstein R, Makar R, Powell D, Trent J. Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. *Cancer Genet Cytogenet* 73:33-45, 1994.
233. Malviya VK, Liu PY, O'Toole R, **Alberts DS**, Surwit E, Rosenoff S, Ward JH, Yu A, O'Sullivan J, Craig JB. Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma: a Southwest Oncology Group study. *Am J Clin Oncol* 17:37-40, 1994.
234. Stiff PJ, McKenzie RS, **Alberts DS**, Sosman JA, Dolan JR, Rad N, McCloskey T. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. *J Clin Oncol* 12(1):176-83, 1994.
235. Poplin EA, **Alberts DS**, Rinehart JJ, Smith HO, Neidhart JA, Hersh EM. GM-CSF, carboplatin, doxorubicin: a phase I study. *Cancer Chemother Pharmacol* 33:340-6, 1994.
236. **Alberts D**, Hannigan E, Canetta R, O'Toole R, Malviya V, Surwit E, Nahhas W, Jolles C, Jacobs J, Pashko S. Cisplatin versus carboplatin in advanced ovarian cancer: an economic analysis. *Pharmacol Ther* 19:692-706, 1994.
237. **Alberts DS**, Einspahr J, Aickin M, Hixson L, Earnest D, Roe D, Powell M. Validation of proliferation indices as surrogate endpoint biomarkers. *J Cell Biochem Suppl* 19:76-83, 1994.
238. Shamdas GJ, **Alberts DS**, Modiano M, Wiggins C, Power J, Kasunic DA, Elfring GL, Earhardt RH. Phase I study of adozelesin (U-73, 975) in patients with solid tumors. *Anticancer Drugs* 5:10-4, 1994.
239. Thompson FH, Liu Y, Emerson J, Weinstein R, Makar R, Trent JM, Taetle R, **Alberts DS**. Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma. *Genes Chromosom Cancer* 10:262-6, 1994.
240. Hixson LJ, **Alberts DS**, Krutzsch M, Einspahr J, Brendel K, Gross PH, Paranka NS, Baier M, Emerson S, Pamukcu R, Burt R. Antiproliferative effect of nonsteroidal anti-inflammatory drugs against human colon cancer cells. *Cancer Epidemiol Biomarkers Prev* 3:433-8, 1994.

241. Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, Johnson CS, **Alberts DS**. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-*trans*-retinoic acid: a randomized trial. *J Natl Cancer Inst* 86:539-43, 1994.
242. Meyskens FL Jr, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, **Alberts DS**, Gerner EW. Dose de-escalation chemoprevention trial of α -difluoromethylornithine in patients with colon polyps. *J Natl Cancer Inst* 86:1122-30, 1994.
243. Powis G, **Alberts DS**. Inhibiting intracellular signalling as a strategy for cancer chemoprevention. *Eur J Cancer* 30A:1138-44, 1994.
244. Nelson MA, Einspahr JG, **Alberts DS**, Balfour CA, Wymer JA, Welch KL, Salasche SJ, Bangert JL, Grogan TM, Bozzo PO. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. *Cancer Lett* 85:23-9, 1994.
245. Federico M, **Alberts DS**, Garcia DJ, Emerson J, Fanta P, Liu R, Salmon SE. *In vitro* drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of *in vitro* response and clinical outcome. *Gynecol Oncol* 55:S156-63, 1994.
246. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, **Alberts DS**, Covey JM, Doody LA, Knapp GG, Nayfield S, Parkinson DR, Prasad VK, Prorok PC, Sausville EA, Sigman CC. Strategy and planning for chemopreventive drug development: clinical development plans. *J Cell Biochem Suppl* 20:55-299, 1994.
247. Hallum AV, **Alberts DS**, Lippman SM, Inclan L, Shamdas GJ, Childers JM, Surwit EA, Modiano M, Hatch KD. Phase II study of 13-*cis*-retinoic acid plus interferon- γ 2a in heavily pretreated squamous carcinoma of the cervix. *Gynecol Oncol* 56:382-6, 1995.
248. **Alberts DS**, Garcia DJ. An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies. *J Nutr* 125:692S-7S, 1995.
249. **Alberts DS**, Hixson L, Ahnen D, Bogert C, Einspahr J, Paranka N, Brendel K, Gross PH, Pamukcu R, Burt RW. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? *J Cell Biochem Suppl* 22:18-23, 1995.
250. Childers JM, Chu J, Voigt LF, Feigl P, Tamimi HK, Franklin EW, **Alberts DS**, Meyskens FL Jr. Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group intergroup study. *Cancer Epidemiol Biomarkers Prev* 4:155-9, 1995.
251. Finley PR, Bogert CL, **Alberts DS**, Einspahr J, Earnest DL, Blackwell G, Girodias K. Measurement of prostaglandin E₂ in rectal mucosa in human subjects: a method study. *Cancer Epidemiol Biomarkers Prev* 4:239-44, 1995.
252. Albain KS, Liu PY, Hantel A, Poplin EA, O'Toole RV, Wade JL, Maddox AM, **Alberts DS**. A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904. *Gynecol Oncol* 57:407-11, 1995.
253. **Alberts DS**, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented? *Anticancer Drugs* 6:369-83, 1995.
254. Einspahr J, **Alberts D**, Xie T, Ritchie J, Earnest D, Hixson L, Powell M, Roe D, Grogan T. Comparison of proliferating cell nuclear antigen *versus* the more standard measures of rectal mucosal proliferation rates in subjects with a history of colorectal cancer and normal age-matched controls. *Cancer Epidemiol Biomarkers Prev* 4:359-66, 1995.
255. Powell MB, Hyman P, Bell OD, Balmain A, Brown K, **Alberts D**, Bowden GT. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-*ras* gene regulated by mouse tryosinase promoter. *Mol Carcinog* 12:82-90, 1995.

256. Sami SM, Dorr RT, Solyom AM, **Alberts DS**, Remers WA. Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[*de,h*]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure-activity relationship. *J Med Chem* 38:983-93, 1995.
257. Piazza GA, Kulchak Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, **Alberts DS**, Pamukcu R, Ahnen DJ. Antineoplastic drugs sulindac sulfide and sulfone inhibit growth by inducing apoptosis. *Cancer Res* 55:3110-6, 1995.
258. Moon TE, Levine N, Cartmel B, Bangert J, Rodney S, Schreiber M, Peng YM, Ritenbaugh C, Meyskens F, **Alberts D**, Southwest Skin Cancer Prevention Study Group. Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. *Cancer Epidemiol Biomarkers Prev* 4:661-9, 1995.
259. Brooks DJ, Srinivas NR, **Alberts DS**, Thomas T, Igwemzie LM, McKinney LM, Randolph J, Schacter L, Kaul S, Barbhaiya RH. Phase I and pharmacokinetic study of etoposide phosphate. *Anticancer Drugs* 6:637-44, 1995.
260. Kochevar DT, Middendorf DL, Mealey KL, Meyers RO, Rogers KS, Barton CL, Habron J, **Alberts DS**, Polzer JP. Pharmacokinetics and haematological effects of a single intravenous dose of mitoxantrone in cats. *J Vet Pharmacol Ther* 18:471-5, 1995.
261. **Alberts DS**, Ritenbaugh C, Story JA, Aickin M, Rees-McGee S, Buller MK, Atwood J, Phelps J, Ramanujam PS, Bellapralu S, Patel J, Bettinger L, Clark L. Randomized, double-blind, placebo-controlled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps. *J Natl Cancer Inst* 88:81-92, 1996.
262. Thompson FH, Nelson MA, Trent JM, Guan XY, Liu Y, Yang JM, Emerson J, Adair L, Wymer J, Balfour C, Massey K, Weinstein R, **Alberts DS**, Taetle R. Amplification of 19q13.1-q13.2 sequences in ovarian cancer: G-band, FISH, and molecular studies. *Cancer Genet Cytogenet* 87:55-62, 1996.
263. Atwood JR, Giordano L, Vargas P, Blackwell GG, Earnest DL, Meyskens F, **Alberts D**. Adherence enhancers in pill-related clinical trials: a health behavior in cancer prevention model-based approach. *Patient Ed Counsel* 28:15-23, 1996.
264. Einspahr J, **Alberts DS**, Aickin M, Welch K, Bozzo P, Levine N, Grogan T: Evaluation of proliferating cell nuclear antigen as a surrogate end point biomarker in actinic keratosis and adjacent, normal-appearing, and non-sun-exposed human skin samples. *Cancer Epidemiol Biomarkers Prev* 5:343-8, 1996.
265. **Alberts DS**, Lipkin M, Levin B. Genetic screening for colorectal cancer and intervention. *Int J Cancer* (Pred Oncol) 69:62-3, 1996.
266. Tricot G, **Alberts DS**, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. *Clin Cancer Res* 2:947-52, 1996.
267. Roe DJ, **Alberts DS**, Wargovich MJ, Bostick RM, Garewal HS, Einspahr J, Fosdick L, Ramsey L, Woods C, McGee DL. Reproducibility of the measurement of colonic proliferation using bromodeoxyuridine across laboratories. *Cancer Epidemiol Biomarkers Prev* 5:349-53, 1996.
268. **Alberts DS**, Speicher LA, Krutzsch M, Wymer J, Capizzi RL, Conlon J, Barrett A, Aickin M. WR-1065, the active metabolite of amifostine (Ethyol[®]), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. *Eur J Cancer* 32A(Suppl 4):S17-S20, 1996.
269. Muggia FM, Liu PY, **Alberts DS**, Wallace DL, O'Toole RV, Terada KY, Franklin EW, Harrer GW, Goldberg DA, Hannigan EV. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy - A randomized phase II study by the Southwest Oncology Group. *Gynecol Oncol* 61:395-402, 1996.

270. Sami SM, Dorr RT, Solyom AM, **Alberts DS**, Iyengar BS, Remers WA. 6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[*de,h*]isoquinoline-1,3-diones: synthesis, nucleo-philic displacements, antitumor activity, and quantitative structure-activity relationships. *J Med Chem* 39:1609-18, 1996.
271. Aickin M, **Alberts DS**. The measurement of adenoma occurrence. *Eur J Cancer Prev* 5:43-8, 1996.
272. Gensler HL, Timmermann BN, Valcic S, Wächter GA, Dorr R, Dvorakova K, **Alberts DS**. Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea. *Nutr Cancer* 26:325-35, 1996.
273. **Alberts DS**, Goldman R, Xu MJ, Dorr RT, Quinn J, Welch K, Guillen-Rodriguez J, Aickin M, Peng YM, Loescher L, Gensler H. Disposition and metabolism of topically administered α -tocopherol acetate: a common ingredient of commercially available sunscreens and cosmetics. *Nutr Cancer* 26:193-201, 1996.
274. Malviya VK, Liu PY, Goldberg DA, Hantel A, O'Toole RV, Roach RW, Conrad ME, **Alberts DS**. A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group Study 8918. *Anticancer Drugs* 7:527-30, 1996.
275. Surwit E, Childers J, Atlas I, Nour M, Hatch K, Hallum A, **Alberts D**. Neoadjuvant chemotherapy for advanced ovarian cancer. *Int J Gynecol Cancer* 6:356-61, 1996.
276. Valcic S, Timmermann BN, **Alberts DS**, Wächter GA, Krutzsch M, Wymer J, Guillén JM. Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. *Anticancer Drugs* 7:461-8, 1996.
277. **Alberts DS**, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. *N Engl J Med* 335:1950-5, 1996.
278. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Leshner JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR, **Alberts DS**, Dalkin BL, Allison RJ Jr, Bradshaw JC, Curtis D, Deal DR, Dellasega M, Hendrix JD, Herlong JH, Hixson LJ, Kight F, Moore J, Rice JS, Rogers AI, Schuman B, Smith EH Jr, Woodward JC. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized clinical trial. *J Am Med Assoc* 276:1957-63, 1996.
279. Sami SM, Dorr RT, **Alberts DS**, Solyom AM, Remers WA. 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[*de,h*]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships. *J Med Chem* 39:4978-87, 1996.
280. Dorr RT, Dvorakova K, Snead K, **Alberts DS**, Salmon SE, Pettit GR. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. *Invest New Drugs* 14:131-7, 1996.
281. Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang JM, Guan XY, Trent J, **Alberts DS**, Taetle R. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. *Br J Cancer* 74:1518-25, 1996.
282. Brooks DJ, **Alberts DS**. A phase I study of etoposide phosphate plus paclitaxel. *Sem Oncol* 23(Suppl 13):30-3, 1996.
283. Ritenbaugh C, Peng YM, Aickin M, Graver E, Branch M, **Alberts DS**. New carotenoid values for foods improve relationship of food frequency questionnaire intake estimates to plasma values. *Cancer Epidemiol Biomarkers Prev* 5:907-12, 1996.
284. Yeilding A, Bertoli L, Eisenberg P, Plezia P, Modiano MR, **Alberts DS**, Khojasteh A, Cramer MB, Hahne WF. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. *Am J Clin Oncol* 19:619-23, 1996.

285. Einspahr JG, **Alberts DS**, Gapstur SM, Bostick RM, Emerson SS, Gerner EW. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. *Cancer Epidemiol Biomarkers Prev* 6:37-48, 1997.
286. **Alberts DS**, Fanta PT, Running KL, Adair LP Jr, Garcia DJ, Liu-Stevens R, Salmon SE. *In vitro* phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. *Cancer Chemother Pharmacol* 39:493-7, 1997.
287. **Alberts DS**, Einspahr J, Ritenbaugh C, Aickin M, Rees-McGee S, Atwood J, Emerson S, Mason-Liddil N, Bettinger L, Patel J, Bellapravalu S, Ramanujam PS, Phelps J, Clark L. The effect of wheat bran fiber and calcium supplementation on rectal mucosal proliferation rates in patients with resected adenomatous colorectal polyps. *Cancer Epidemiol Biomarkers Prev* 6:161-9, 1997.
288. Ritenbaugh C, Aickin M, Taren D, Teufel N, Graver E, Woolf K, **Alberts DS**. Use of a food frequency questionnaire to screen for dietary eligibility in a randomized cancer prevention phase III trial. *Cancer Epidemiol Biomarkers Prev* 6:347-54, 1997.
289. Piazza GA, **Alberts DS**, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. *Cancer Res* 57:2909-15, 1997.
290. Einspahr J, **Alberts DS**, Aickin M, Welch K, Bozzo P, Grogan T, Nelson M. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin. *Cancer Epidemiol Biomarkers Prev* 6:583-7, 1997.
291. Thompson FH, Taetle R, Trent JM, Liu Y, Massey-Brown K, Scott KM, Weinstein RS, Emerson JC, **Alberts DS**, Nelson MA. Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. *Cancer Genet Cytogenet* 96:106-10, 1997.
292. Remers WA, Dorr RT, Sami SM, **Alberts DS**, Bear S, Mayr CA, Solyom AM. A new class of antitumor agent: 2-substituted-1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. *Curr Top Med Chem* 2:45-61, 1997.
293. Moon TE, Levine N, Cartmel B, Bangert JL, Rodney S, Dong Q, Peng YM, **Alberts DS**. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. *Cancer Epidemiol Biomarkers Prev* 6:949-56, 1997.
294. Levine N, Moon TE, Cartmel B, Bangert JL, Rodney S, Dong Q, Peng YM, **Alberts DS**. Trial of retinol and isotretinoin in skin cancer prevention. *Cancer Epidemiol Biomarkers Prev* 6:957-61, 1997.
295. Iyengar BS, Dorr RT, **Alberts DS**, Solyom AM, Krutzsch M, Remers WA. 1,4-disubstituted anthracene antitumor agents. *J Med Chem* 40:3734-8, 1997.
296. Chen W, Barthelman M, Martinez J, **Alberts D**, Gensler HL. Inhibition of cyclobutane pyrimidine dimer formation in epidermal p53 gene of UV-irradiated mice by α -tocopherol. *Nutr Cancer* 29:205-11, 1997.
297. Macdonald JS, Benedetti JK, Modiano M, **Alberts DS**. Phase II evaluation of topotecan in patients with advanced colorectal cancer: a Southwest Oncology Group trial (SWOG-9241). *Invest New Drugs* 15:357-9, 1997.
298. **Alberts DS**, Slattery ML, Giovannucci E, Shike M, Garcia DJ. Primary prevention of colon cancer with dietary and micronutrient interventions. *Cancer* 83:1734-9, 1998.
299. Bozzo PD, Vaught LC, **Alberts DS**, Thompson D, Bartels PH. Nuclear morphometry in solar keratosis. *Analyt Quant Cytol Histol* 20:21-8, 1998.
300. **Alberts DS**, Dorr RT. New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. *Oncologist* 3:15-34, 1998.
301. Batta AK, Salen G, Holubec H, Brasitus TA, **Alberts D**, Earnest DL. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. *Cancer Res* 58:1684-7, 1998.

302. Batta AK, Salen G, Rapole KR, Batta M, Earnest D, **Alberts D**. Capillary gas chromatographic analysis of serum bile acids as the *n*-butyl ester-trimethylsilyl ether derivatives. *J Chromatogr B* 706:337-41, 1998.
303. Monk BJ, **Alberts DS**, Burger RA, Fanta PT, Hallum AV, Hatch KD, Salmon SE. *In vitro* phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers. *Gynecol Oncol* 71:308-12, 1998.
304. Martinez ME, Reid ME, Guillen-Rodriguez J, Marshall JR, Sampliner R, Aickin M, Ritenbaugh C, van Leeuwen B, Mason-Liddil N, Giuliano A, Vargas PA, **Alberts DS**. Design and baseline characteristics of study participants in the wheat bran fiber trial. *Cancer Epidemiol Biomarkers Prev* 7:813-6, 1998.
305. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, and other National Surgical Adjuvant Breast and Bowel Project Investigators (includes **Alberts D**). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 90:1371-88, 1998.
306. Weiss GR, Liu PY, **Alberts DS**, Peng YM, Fisher E, Xu MJ, Scudder SA, Baker LH, Moore DF Jr, Lippman SM. 13-*cis*-retinoic acid or all-*trans*-retinoic acid plus interferon- α in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. *Gynecol Oncol* 71:386-90, 1998.
307. Advanced Ovarian Cancer Trialists' Group: Aabo K, Adams M, Adnitt P, **Alberts DS**, Athanazziou A, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Colombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D, Kaye SB, Laing AH, Landoni F, Leonard RC, Lewis C, Liu PY, Mangioni C, Marsoni S, Meerpohl H, Omura GA, Parmar MKB, Pater J, Pecorelli S, Presti M, Sauebrei W, Skarlos DV, Smalley RV, Solomon HJ, Stewart LA, Sturgeon JFG, Tattersall MHN, Wharton JT, ten Bokkel Huinink WW, Tomirotti M, Torri W, Trope C, Turbow MM, Vermorken JB, Webb MJ, Wilbur DW, Williams CJ, Wiltshaw E, Yea. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. *Br J Cancer* 78:1479-87, 1998.
308. Levine N, Dorr RT, Ertl GA, Brooks C, **Alberts DS**. Effects of a potent synthetic melanotropin, Nle⁴-D-Phe⁷- α -MSH (Melanotan-I) on tanning: a dose-ranging study. *J Dermatol Treat* 10:127-32, 1999.
309. Dvorakova K, Dorr RT, Valcic S, Timmermann B, **Alberts DS**. Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin. *Cancer Chemother Pharmacol* 43:331-5, 1999.
310. Earnest DL, Einspahr JG, **Alberts DS**. Protective role of wheat bran fiber: data from marker trials. *Am J Med* 106:32S-7S, 1999.
311. Earnest DL, Sampliner RE, Roe DJ, van Leeuwen B, Guillen J, Reid M, Martinez ME, Marshall JR, **Alberts DS**. Progress report: the Arizona phase III study of the effect of wheat bran fiber on recurrence of adenomatous colon polyps. *Am J Med* 106:43S-5S, 1999.
312. Taetle R, Aickin M, Yang JM, Panda L, Emerson J, Roe D, Adair L, Thompson F, Liu Y, Wisner L, Davis JR, Trent J, **Alberts DS**. Chromosome abnormalities in ovarian adenocarcinoma: I. Non-random chromosome abnormalities in 244 cases. *Gene Chromosom Cancer* 25:290-300, 1999.
313. Taetle R, Aickin M, Panda L, Emerson J, Roe D, Thompson F, Davis J, Trent J, **Alberts D**. Chromosome abnormalities in ovarian adenocarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases. *Gene Chromosom Cancer* 25:46-52, 1999.
314. Iyengar BS, Dorr RT, **Alberts DS**, Hersh EM, Salmon SE, Remers WA. Novel antitumor 2-cyanoaziridine-1-carboxamides. *J Med Chem* 42:510-4, 1999.
315. Martinez ME, Heddens D, Earnest DL, Bogert CL, Roe D, Einspahr J, Marshall JR, **Alberts DS**. Physical activity, body mass index, and prostaglandin E₂ levels in rectal mucosa. *J Natl Cancer Inst* 91:950-3, 1999.

316. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, **Alberts DS**. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. *Cancer Chemother Pharmacol* 44:303-6, 1999.
317. Batta AK, Salen G, Rapole KR, Batta M, Batta P, **Alberts D**, Earnest D: Highly simplified method for gas-liquid chromatographic quantitation of bile acids and sterols in human stool. *J Lipid Res* 40:1148-54, 1999.
318. Martinez ME, Maltzman T, Marshall JR, Einspahr J, Reid ME, Sampliner R, Ahnen DJ, Hamilton SR, **Alberts DS**. Risk factors for ki-ras protooncogene mutation in sporadic colorectal adenomas. *Cancer Res* 59:5181-5, 1999.
319. Poplin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF Jr, Potkul RK, Fine BA, Hannigan EV, **Alberts DS**. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a Southwest Oncology Group study. *Gynecol Oncol* 74:432-5, 1999.
320. Cheng L, Guan Y, Li L, Legerski RJ, Einspahr J, Bangert J, **Alberts DS**, Wei Q. Expression in normal human tissue of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction. *Cancer Epidemiol Biomarkers Prev* 8:801-7, 1999.
321. Marshall JR, Martinez ME, **Alberts DS** Wheat bran as a means of cancer chemoprevention. *Asia Pacific J Clin Nutr* 8(Suppl):S47-S53, 1999.
322. Sridhara R, Sharma M, Canetta RM, Swenerton KD, **Alberts DS**, Egorin MJ. Predicting grade 3 or greater myelotoxicity to carboplatin in advanced ovarian cancer patients. *Cancer Ther* 2:83-93, 1999.
323. Martinez ME, Marshall JR, Graver E, Whitacre RC, Woolf K, Ritenbaugh C, **Alberts DS**. Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. *Cancer Epidemiol Biomarkers Prev* 8:941-6, 1999.
324. Einspahr JG, **Alberts DS**, Warneke JA, Bozzo P, Basye J, Grogan TM, Nelson MA, Bowden GT. Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. *Neoplasia* 1:468-5, 1999.
325. Garewal HS, Katz RV, Meyskens F, Pitcock J, Morse D, Friedman S, Peng Y, Pendry DG, Mayne S, **Alberts D**, Kiersch T, Graver E. β -carotene produces sustained remissions in oral leukoplakia: results of a multicenter prospective clinical trial. *Arch Otolaryngol Head Neck Surg* 125:1305-10, 1999.
326. Batta AK, Datta SC, Tint GS, **Alberts DS**, Earnest DL, Salen G. A convenient synthesis of dinorbile acids: Oxidative hydrolysis of norbile acid nitriles. *Steroids* 64:780-4, 1999.
327. Monsky WL, Heddens DK, Clark GM, Von Hoff DD, Coltman CA Jr, Dorr RT, **Alberts DS**. Comparison of young clinical investigators' accuracy and reproducibility when measuring pulmonary and skin surface nodules using a circumferential measurement versus a standard caliper measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Workshop. *J Clin Oncol* 18(2):437-44, 2000. PMID 10637260.
328. Simon R, Desper R, Papadimitriou CH, Peng A, **Alberts DS**, Taetle R, Trent JM, Schaffer AA. Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis. *Gene Chromosom Cancer* 28:106-20, 2000.
329. **Alberts DS**, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, Reid ME, Ritenbaugh C, Vargas PA, Bhattacharyya AB, Earnest DL, Sampliner RE: Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. *N Engl J Med* 342:1156-62, 2000.
330. Chow HH, Earnest DL, Clark D, Mason-Liddil N, Kramer CB, Einspahr JG, Guillen-Rodriguez JM, Roe DJ, Malone W, Crowell JA, **Alberts DS**. Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E₂ levels in healthy subjects with a history of resected polyps. *Cancer Epidemiol Biomarkers Prev* 9:351-6, 2000.

331. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, **Alberts DS**, Howell SB. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. *Clin Cancer Res* 6:1415-21, 2000.
332. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, **Alberts DS**. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *J Clin Oncol* 18(8):1606-13, 2000. PMID 10764420.
333. Stratton SP, Dorr RT, **Alberts DS**. The state-of-the-art in chemoprevention of skin cancer. *Eur J Cancer* 36:1292-7, 2000.
334. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, **Alberts D**, Sondak V, Hayward N, Trent J. Molecular classification of cutaneous malignant melanoma by gene expression profiling. *Nature* 406:536-40, 2000.
335. Lopez AM, Ketchum M, Nichols H, Xu MJ, Peng YM, Dorr R, **Alberts DS**. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies. *Cancer Chemother Pharmacol* 46:411-5, 2000.
336. Stratton SP, Bangert JL, **Alberts DS**, Dorr RT. Dermal toxicity of topical (-)epigallocatechin-3-gallate in BALB/c and SKH1 mice. *Cancer Lett* 158:47-52, 2000.
337. Cartmel B, Moon TE, Levine N, Rodney S, **Alberts D**. Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study. *Cancer Epidemiol Biomarkers Prev* 9:999-1002, 2000.
338. Sami SM, Dorr RT, **Alberts DS**, Solyom AM, Remers WA. Analogues of amonafide and azonafide with novel ring systems. *J Med Chem* 43:3067-73, 2000.
339. Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, **Alberts DS**. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle⁴-D-Phe⁷]- α -MSH in humans. *Photochem Photobiol* 72:526-32, 2000.
340. **Alberts DS**, Dorr RT, Einspahr JG, Aickin M, Saboda K, Xu MJ, Peng YM, Goldman R, Foote JA, Warneke JA, Salasche S, Roe DJ, Bowden GT. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. *Cancer Epidemiol Biomarkers Prev* 9:1281-6, 2000.
341. Calaluce R, Earnest DL, Heddens D, Einspahr JG, Roe D, Bogert CL, Marshall JR, **Alberts DS**. Effects of piroxicam on prostaglandin E₂ levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial. *Cancer Epidemiol Biomarkers Prev* 9:1287-92, 2000.
342. Chow HH, Cai Y, **Alberts DS**, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, Hara Y. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. *Cancer Epidemiol Biomarkers Prev* 10:53-8, 2001.
343. Markman M, Bundy BN, **Alberts DS**, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sichel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. *J Clin Oncol* 19(4):1001-7, 2001. PMID 11181662.F
344. Bartels PH, Garcia FA, Davis J, da Silva VD, Bartels HG, Thompson D, **Alberts DS**. Progression curves for endometrial lesions. *Analyt Quant Cytol Histol* 23:1-8, 2001.
345. Foote JA, Harris RB, Giuliano AR, Roe DJ, Moon TE, Cartmel B, **Alberts DS**. Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults. *Int J Cancer* 95:7-11, 2001.

346. Martinez ME, Sampliner R, Marshall JR, Bhattacharyya AK, Reid ME, **Alberts DS**. Adenoma characteristics as risk factors for recurrence of advanced adenomas. *Gastroenterology* 120:1077-83, 2001.
347. Garcia FA, Davis JR, **Alberts DS**, Hatch K, Weyn B, Thompson D, Bartels PH. Nuclear chromatin patterns in normal, hyperplastic and atypical endometrium. *Analyt Quant Cytol Histol* 23:144-50, 2001.
348. **Alberts DS**, Hallum AV III, Stratton-Custis M, Garcia DJ, Gleason-Guzman M, Salmon SE, Santabarbara P, Niesor EJ, Floret S, Bentzen CL. Phase I pharmacokinetic trial and correlative *in vitro* phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. *Clin Cancer Res* 7:1246-50, 2001.
349. Dorr RT, Liddil JD, Sami SM, Remers W, Hersh EM, **Alberts DS**. Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. *Anticancer Drugs* 12:213-20, 2001.
350. Hakim IA, Hartz V, Harris RB, Balentine D, Weisgerber UM, Graver E, Whitacre R, **Alberts D**. Reproducibility and relative validity of a questionnaire to assess intake of black tea polyphenols in epidemiological studies. *Cancer Epidemiol Biomarkers Prev* 10:667-78, 2001.
351. Damle B, Ravandi F, Kaul S, Sonnichsen D, Ferreira I, Brooks D, Stewart D, **Alberts D**, Pazdur R. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. *Clin Cancer Res* 7:517-23, 2001.
352. Bozzo P, **Alberts DS**, Vaught L, da Silva VD, Thompson D, Warneke J, Miller RC, Einspahr J, Bartels PH. Measurement of chemopreventive efficacy in skin biopsies. *Analyt Quant Cytol Histol* 23:300-12, 2001.
353. Maltzman T, Knoll K, Martinez ME, Byers T, Stevens BR, Marshall JR, Reid ME, Einspahr J, Hart N, Bhattacharyya AK, Kramer CB, Sampliner R, **Alberts DS**, Ahnen DJ. Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. *Gastroenterology* 121:302-9, 2001.
354. Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, **Alberts DS**. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). *Gynecol Oncol* 82:317-22, 2001.
355. Xu XC, Wong WY, Goldberg L, Baer SC, Wolf JE, Ramsdell WM, **Alberts DS**, Lippman SM, Lotan R. Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. *Cancer Res* 61:4306-10, 2001.
356. Waltmire CN, **Alberts DS**, Dorr RT. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer. *Anticancer Drugs* 12:595-602, 2001.
357. Frank DH, Davis JR, **Alberts DS**, Thompson D, Liu Y, Bartels PH. Nuclear chromatin characteristics of breast solid pattern ductal carcinoma *in situ*. *Analyt Quant Cytol Histol* 23:418-26, 2001.
358. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, **Alberts DS**, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Recommendations of the American Association for Cancer Research Task Force on the treatment and prevention of intraepithelial neoplasia. *Clin Cancer Res* 8:314-46, 2002.
359. Einspahr JG, Nelson MA, Saboda K, Warneke J, Bowden GT, **Alberts DS**. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. *Clin Cancer Res* 8:149-55, 2002.
360. Martinez ME, Marshall JR, Sampliner R, Wilkinson J, **Alberts DS**. Calcium, vitamin D, and risk of adenoma recurrence (United States). *Cancer Causes Control* 13:213-20, 2002.

361. Garcia FA, Davis JR, Hatch K, **Alberts DS**, Thompson D, Bartels PH. Karyometry in endometrial adenocarcinoma of different grades. *Analyt Quant Cytol Histol* 24:93-102, 2002.
362. Lluria-Prevatt M, Morreale J, Gregus J, **Alberts DS**, Kaper F, Giaccia A, Powell MB. Effects of perillyl alcohol on melanoma in the TPras mouse model. *Cancer Epidemiol Biomarkers Prev* 11:573-9, 2002.
363. Heddens D, **Alberts DS**, Hannigan EV, Williams SD, Garcia D, Roe DJ, Bell J, Alvarez RD. Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. *Gynecol Oncol* 86:239-43, 2002.
364. Bartels PH, Ranger-Moore J, Stratton MS, Bozzo P, Einspahr J, Liu Y, Thompson D, **Alberts DS**. Statistical analysis of chemopreventive efficacy of vitamin A in sun-exposed, normal skin. *Analyt Quant Cytol Histol* 24:185-97, 2002.
365. Batta AK, Salen G, Batta P, Stephen Tint G, **Alberts DS**, Earnest DL. Simultaneous quantitation of fatty acids, sterols and bile acids in human stool by capillary gas-liquid chromatography. *J Chromatogr B* 775:153-61, 2002.
366. Clifford JL, Walch E, Yang X, Xu X, **Alberts DS**, Clayman GL, El-Naggar AK, Lotan R, Lippman SM. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. *Clin Cancer Res* 8:2067-72, 2002.
367. Jacobs ET, Giuliano AR, Roe DJ, Guillen-Rodriguez JM, Hess LM, **Alberts DS**, Martinez ME. Intake of supplemental and total fiber and risk of colorectal adenoma recurrence in the wheat bran fiber trial. *Cancer Epidemiol Biomarkers Prev* 11(9):906-14, 2002.
368. Hawes D, Liu PY, Muggia FM, Wilczynski S, Cote R, Felix J, Terada K, Belt RJ, **Alberts DS**. Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. *Gynecol Oncol* 87:17-23, 2002.
369. Jacobs ET, Giuliano AR, Roe DJ, Guillen-Rodriguez JM, **Alberts DS**, Martinez ME. Baseline dietary fiber intake and colorectal adenoma recurrence in the Wheat Bran Fiber Randomized Trial. *J Natl Cancer Inst* 94:1620-5, 2002.
370. Bair WB 3rd, Hart N, Einspahr J, Liu G, Dong Z, **Alberts D**, Bowden GT. Inhibitory effects of sodium salicylate and acetylsalicylic acid on UVB-induced mouse skin carcinogenesis. *Cancer Epidemiol Biomarkers Prev* 11:1645-52, 2002.
371. Markman M, Glass T, Smith HO, Hatch KD, Weiss GR, Taylor SA, Goodwin JW, **Alberts DS**. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial. *Gynecol Oncol* 88:282-8, 2003.
372. **Alberts DS**, Einspahr JG, Earnest DL, Krutzsch MF, Lin P, Hess LM, Heddens DK, Roe DJ, Martinez ME, Salen G, Batta AK. Fecal bile acid concentrations in a subpopulation of the wheat bran fiber colon polyp trial. *Cancer Epidemiol Biomarkers Prev* 12(3):197-200, 2003.
373. Chu DZ, Chansky K, **Alberts DS**, Meyskens FL Jr, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Goodman GE, Abbruzzese JL, Lippman SM. Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. *Ann Surg Oncol* 10:870-5, 2003.
374. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, **Alberts DS**, Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. *J Lab Clin Med* 142:46-51, 2003.
375. Rothenberg ML, Liu PY, Braly PS, Wilczynski SP, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, **Alberts DS**. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. *J Clin Oncol* 21(7):1313-9, 2003. PMID 12664730

376. Thomson CA, LeWinn K, Newton TR, **Alberts DS**, Martinez ME. Nutrition and diet in the development of gastrointestinal cancer. *Curr Oncol Rep* 5:192-202, 2003.
377. Wiese FW, Thompson PA, Warneke J, Einspahr J, **Alberts DS**, Kadlubar FF. Variation in cyclooxygenase expression levels within the colorectum. *Mol Carcinog* 37:25-31, 2003.
378. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, **Alberts DS**, Gerner EW. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. *Proc Natl Acad Sci U S A* 100:7859-64, 2003.
379. Gold MA, Walker JL, Berek JS, Hallum AV 3rd, Garcia DJ, **Alberts DS**. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. *Gynecol Oncol* 90:325-30, 2003.
380. Anderson N, Houghton J, Kirk SJ, Frank D, Ranger-Moore J, **Alberts DS**, Thompson D, Bartels PH. Malignancy-associated changes in lactiferous duct epithelium. *Analyt Quant Cytol Histol* 25:63-72, 2003.
381. Bozzo P, Saboda K, Einspahr JG, Ranger-Moore J, Farmer ER, Cockerell CJ, Elder DE, Bangert JL, Hart N, Kramer CB, **Alberts DS**. Reliability and validity of a histologic score as a marker for skin cancer chemoprevention studies. *Analyt Quant Cytol Histol* 25:285-92, 2003.
382. Einspahr JG, Krouse RS, Yochim JM, Danenberg PV, Danenberg KD, Bhattacharyya AK, Martinez ME, **Alberts DS**. Association between cyclooxygenase expression and colorectal adenoma characteristics. *Cancer Res* 63:3891-3, 2003.
383. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, **Alberts D**. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. *J Clin Oncol* 21(13):2460-5, 2003.
384. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, **Alberts DS**. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. *Clin Cancer Res* 9:3312-9, 2003.
385. Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, **Alberts DS**, Marshall JR, Ahmann FR. Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study. *Anticancer Drugs* 14:589-94, 2003.
386. Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, **Alberts DS**, Marshall JR, Ahmann FR. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the "Watchful Waiting" Study. *Anticancer Drugs* 14:595-600, 2003.
387. Reid ME, Marshall JR, Roe D, Lebowitz M, **Alberts D**, Battacharyya AK, Martinez ME. Smoking exposure as a risk factor for prevalent and recurrent colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 12:1006-11, 2003.
388. Goulet AC, Einspahr JG, **Alberts DS**, Beas A, Burk C, Bhattacharyya A, Bangert J, Harmon JM, Fujiwara H, Koki A, Nelson MA. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. *Cancer Biol Ther* 2:713-8, 2003.
389. Barton JK, Gossage KW, Xu W, Ranger-Moore JR, Saboda K, Brooks CA, Duckett LD, Salasche SJ, Warneke JA, **Alberts DS**. Investigating sun-damaged skin and actinic keratosis with optical coherence tomography: a pilot study. *Technol Cancer Res Treat* 2:525-35, 2003.
390. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, **Alberts DS**. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal ³²P or intravenous cyclophosphamide and cisplatin—a Gynecologic Oncology Group study. *J Clin Oncol* 21(23):4350-5, 2003. PMID 14645424.

391. Samimi G, Varki NM, Wilczynski S, Safaei R, **Alberts DS**, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. *Clin Cancer Res* 9:5853-9, 2003.
392. Garcia FA, Davis JR, **Alberts DS**, Liu Y, Thompson D, Bartels PH. A karyometric approach to the characterization of atypical endometrial hyperplasia with and without co-occurring adenocarcinoma. *Analyt Quant Cytol Histol* 25:339-46, 2003.
393. Ranger-Moore J, Bozzo P, **Alberts D**, Einspahr J, Liu Y, Thompson D, Stratton S, Stratton MS, Bartels P. Karyometry of nuclei from actinic keratosis and squamous cell cancer of the skin. *Analyt Quant Cytol Histol* 25:353-61, 2003.
394. Chow HH, Anavy N, Salazar D, Frank DH, **Alberts DS**. Determination of celecoxib in human plasma using solid-phase extraction and high-performance liquid chromatography. *J Pharm Biomed Anal* 34:167-74, 2004.
395. Frank DH, Roe DJ, Chow HH, Guillen JM, Choquette K, Gracie D, Francis J, Fish A, **Alberts DS**. Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial. *Cancer Epidemiol Biomarkers Prev* 13(2):299-303, 2004.
396. Jacobs ET, Giuliano AR, Roe DJ, Guillen-Rodriguez JM, Hartz VL, Whitacre RC, **Alberts DS**, Martinez ME. Dietary change in an intervention trial of wheat bran fiber and colorectal adenoma recurrence. *Ann Epidemiol* 14(4):280-6, 2004.
397. **Alberts DS**, Jiang C, Liu PY, Wilczynski S, Markman M, Rothenberg ML. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. *Int J Gynecol Oncol* 14:224-8, 2004.
398. **Alberts D**, Ranger-Moore J, Einspahr J, Saboda K, Bozzo P, Liu Y, Xu XC, Lotan R, Warneke J, Salasche S, Stratton S, Levine N, Goldman R, Islas M, Duckett L, Thompson D, Bartels P. Safety and efficacy of dose intensive oral vitamin A in subjects with sun-damaged skin. *Clin Cancer Res* 10:1875-80, 2004.
399. Martinez ME, Henning S, **Alberts DS**. Folate and colorectal neoplasia: review of the literature and relationship between plasma and dietary markers of folate and adenoma recurrence. *Am J Clin Nutr*, 79:691-7, 2004.
400. Martinez ME, Reid M, Jiang R, Einspahr J, **Alberts DS**. Accuracy of self-reported smoking status among participants in a chemoprevention trial. *Prev Med* 38:492-7, 2004.
401. Hess LM, Krutzsch MF, Guillen J, Chow HH, Einspahr J, Batta AK, Salen G, Reid ME, Earnest DL, **Alberts DS**. Results of a phase I multiple-dose clinical study of ursodeoxycholic acid. *Cancer Epidemiol Biomarkers Prev* 13(5):861-7, 2004.
402. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, Humphrey S, **Albers DS**. Effects of a superpotent melanotropic peptide in combination with solar ultraviolet radiation on tanning of the skin in human volunteers. *Arch Dermatol* 140:827-35, 2004.
403. Thomson CA, Rock CL, Giuliano AR, Newton TR, Cui H, Reid PM, Green TL, **Alberts DS**. Longitudinal changes in body weight and body composition among women previously treated for breast cancer consuming a high-vegetable, fruit and fiber, low-fat diet. *Eur J Nutr*, Online First, pgs 1-8, March 5, 2004.
404. Stiff PJ, Shpall EJ, Liu PY, Wilczynski SP, Callander NS, Scudder SA, Jazieh AR, Samlowski W, McCoy J, **Alberts DS**. Randomized phase II trial of two high dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. *Gynecol Oncol* 94(1):98-106, 2004.
405. Lavey RS, Liu PY, Greer BE, Robinson WR, Pui CC, Wynn RB, Conrad ME, Jiang C, Markman M, **Alberts DS**. Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. *Gynecol Oncol* 95:145-51, 2004.

406. Jacobs ET, Jiang R, **Alberts DS**, Greenberg ER, Gunter EW, Karagas MR, Lanza E, Ratnasinghe L, Reid ME, Schatzkin A, Smith-Warner SA, Wallace K, Martinez ME. Selenium and colorectal adenoma: results of a pooled analysis. *J Natl Cancer Inst* 96(22):1669-75, 2004.
407. Prentice RL, Willett WC, Greenwald P, **Alberts D**, Bernstein L, Boyd NF, Byers T, Clinton SK, Fraser G, Freedman L, Hunter D, Kipnis V, Kolonel LN, Kristal BS, Kristal A, Lampe JW, McTiernan A, Milner J, Patterson RE, Potter J, Riboli E, Schatzkin A, Yates A, Yetley E. Nutrition, physical activity and chronic disease prevention: research strategies and recommendations. *J Natl Cancer Inst* 96(17):1276-87, 2004.
408. Brewer MA, Ranger-Moore J, Baruche A, **Alberts DS**, Greene M, Thompson D, Liu Y, Davis J, Bartels PH. Exploratory study of ovarian intraepithelial neoplasia. *Cancer Epidemiol Biomarkers Prev* 14(2):299-305, 2005.
409. Ranger-Moore J, Bartels P, Bozzo P, Einspahr J, Liu Y, Saboda K, **Alberts DS**. Karyometric analysis of actinic damage in unexposed and sun-exposed skin, and in actinic keratoses in untreated individuals. *Anal Quant Cytol Histol* 26(3):155-65, 2004.
410. Garcia FA, Ranger-Moore J, Barker B, Davis J, Brewer M, Lozevski J, Vinyak S, Liu Y, Yemane J, Hatch KD, **Alberts DS**, Bartels HG, Bartels PH. Karyometric image analysis for intraepithelial and invasive cervical lesions. *Anal Quant Cytol Histol* 26(3):141-50, 2004.
411. Brewer MA, Ranger-Moore J, Greene MH, **Alberts DS**, Liu Y, Bartels HG, Baruch AC, Bartels PH. Preneoplastic changes in ovarian tissues. *Anal Quant Cytol Histol* 26(4):207-16, 2004.
412. Sedjo RL, Ranger-Moore J, Foote J, Craft NE, **Alberts DS**, Xu MJ, Giuliano AR. Circulating endogenous retinoic acid concentrations among participants enrolled in a randomized placebo-controlled clinical trial of retinyl palmitate. *Cancer Epidemiol Biomarkers Prev* 13(11):1687-92, 2004.
413. Chen Z, Stini WA, Marshall JR, Martinez ME, Guillen-Rodriguez JM, Roe D, **Alberts DS**. Wheat bran fiber supplementation and bone loss among older people. *Nutrition* 20(9):747-51, 2004.
414. Edwards ET, Jiang R, **Alberts DS**, Greenberg ER, Gunter EW, Karagas MR, Lanza E, Ratnasinghe L, Reid ME, Schatzkin A, Smith-Warner SA, Wallace K, Martinez ME. Selenium and colorectal adenoma: a pooling project. *J Natl Cancer Inst* 96(22):1645-7, 2004.
415. Thigpen JT, Aghajanian CA, **Alberts DS**, Campos SM, Gordon AN, Markman M, McMeekin S, Monk BJ, Rose PG. Role of pegylated liposomal doxorubicin in ovarian cancer. *Gynecol Oncol* 96(1):10-18, 2005.
416. Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV 3rd, Smith GB, Hannigan EV, Markman M, **Alberts DS**. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. *Gynecol Oncol* 96:610-5, 2005.
417. Harris RB, Foote JA, Hakim IA, Bronson DL, **Alberts DS**. Fatty acid composition of red blood cell membranes and risk of squamous cell carcinoma of the skin. *Cancer Epidemiol Biomarkers Prev* 14(4):906-12, 2005.
418. Wilczynski SP, Chen Y-Y, Chen W, Howell SB, Shivley JE, **Alberts DS**. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFR α and PDGFR β in ovarian cancers. *Hum Pathol* 36(3):242-9, 2005.
419. Chow H-HS, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, Celaya CA, Rodney R, Hara Y, **Alberts DS**. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. *Clin Cancer Res* 11(12):4627-33, 2005.
420. **Alberts DS**, Martinez ME, Hess L, Einspahr J, Green S, Bhattacharya A, Guillen J, Krutzsch M, Batta A, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. *J Natl Cancer Inst* 97(11):846-53, 2005.

421. Ranger-Moore J, Frank D, Lance P, **Alberts D**, Yozwiak M, Bartels HG, Einspahr J, Bartels PH. Karyometry in rectal mucosa of patients with previous colorectal adenomas. *Anal Quant Cytol Histol* 27(3):134-42, 2005.
422. Bartels PH, Ranger-Moore J, Bartels HG, **Alberts D**. Second order discriminant analysis in chemopreventive efficacy measurement. *Anal Quant Cytol Histol* 27(1):15-26, 2005.
423. Monk BJ, Wang J, Im S, , Stock RJ, Peters WA, Liu PY, Barrett, RJ, Berek JS, Souhami L, Grigsby PW, Gordon W, **Alberts DS**. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of SWOG 8797/GOG 109 by the Gynecologic Oncology Group/Radiation Therapy Oncology Group Trial. *Gynecol Oncol* 96(3):721-8, 2005.
424. Thomson CA, Giuliano AR, Shaw JW, Rock CL, Ritenbaugh CK, Hakim IA, Hollenbach KA, **Alberts DS**, Pierce JP. Diet and biomarkers of oxidative damage in women previously treated for breast cancer. *Nutr Cancer* 51(2):146-54, 2005.
425. Frank DH, Davis JR, Ranger-Moore J, Liu Y, Bartels HG, **Alberts DS**, Bartels PH: Karyometry of infiltrating breast lesions. *Anal Quant Cytol Histol* 27(4):195-201, 2005.
426. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, **Alberts DS**, Hamilton SR, Issa J-PJ: MGMT promoter methylation and field defect in sporadic colorectal cancer. *J Natl Cancer Inst* 97(18):1330-8, 2005.
427. Hess LM, Saboda K, Malone DC, Salasche S, Warneke, J, **Alberts DS**. Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer. *Cancer Epidemiol Biomarkers Prev* 14(11):2579-83, 2005.
428. Bartels PH, Descour M, **Alberts DS**, Ranger-Moore J. The evolution of scanning microphotometry: an historical review. *Anal Quant Cytol Histol* 27(6):323-36, 2005.
429. Ranger-Moore J, **Alberts DS**, Montironi R, Garcia F, Davis J, Frank D, Brewer M, Mariuzzi GM, Bartels HG, Bartels PH: Karyometry in the early detection and chemoprevention of intraepithelial lesions. *Eur J Cancer* 41(13):1875-88, 2005.
430. **Alberts DS**, Hannigan EV, Liu PY, Jiang C, Wilczynski S, Copeland L, Markman M. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. *Gynecol Oncol* 100(1):133-8, 2006.
431. Smith HO, Jiang CS, Weiss GR, Hallum AV III, Liu PY, Robinson WR III, Cheng PC, Scudder SA, Markman M, **Alberts DS**. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: A Southwest Oncology Group Study. *Int J Gynecol Cancer* 16(1):298-305, 2006.
432. Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, **Alberts DS**. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. *J Clin Oncol* 24(9):1454-8, 2006. PMID 16549840.
433. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke II JJ, **Alberts D**, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group Study. *Cancer* 106(4):812-9, 2006.
434. Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, **Alberts DS**, Weems G, Cullen M, McGuire III WP. A phase II study of iriflufen in women with recurrent and heavily pretreated ovarian cancer. *Gynecol Oncol* 101(1):55-61, 2006.
435. Reid ME, Duffield-Lillico AJ, Sunga A, **Alberts DS**, Marshall J. Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. *Int J Cancer* 118(7):1777-81, 2006.
436. Jacobs ET, Lanza E, **Alberts DS**, Hsu C-H, Jiang R, Schatzkin A, Thompson PA, Martinez ME. Fiber, sex, and colorectal adenoma: results of a pooled analysis. *Am J Clin Nutr* 83:343-9, 2006.
437. Einspahr JG, Xu MJ, Warneke J, Saboda K, Ranger-Moore J, Bozzo P, Duckett L, Goldman R, Lin P, Buckmeier J, **Alberts DS**. Reproducibility and expression of skin biomarkers in sun-damaged skin and actinic keratoses. *Cancer Epidemiol Biomarkers Prev* 15(10):1841-8, 2006.

438. Einspahr JG, Martinez ME, Jiang R, Hsu CH, Rashid A, Bhattacharya AK, Ahnen DJ, Jacobs ET, Houlihan PS, Webb CR, **Alberts DS** and Hamilton SR. Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics. *Cancer Epidemiol Biomarkers Prev* 15:1443-50, 2006.
439. Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman S, Lieberman R, **Alberts D**, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford D. Design and progress of a trial of selenium to prevent prostate cancer among men with high grade prostatic intraepithelial neoplasia. *Cancer Epidemiol Biomarkers Prev* 15:1479-84, 2006.
440. Martinez ME, Giovannucci E, Jiang R, Henning SM, Jacobs ET, Thompson P, Smith-Warner SA, **Alberts DS**. Folate fortification of the US food supply, plasma folate and homocysteine, and colorectal adenoma recurrence. *Int J Cancer* 119(6):1440-6, 2006.
441. Clouser MC, Harris RB, Roe DJ, Saboda K, Ranger-Moore J, Duckett L, **Alberts DS**. Risk group, skin lesion history and sun sensitivity reliability in squamous cell skin cancer progression. *Cancer Epidemiol Biomarkers Prev* 15(11):2292-7, 2006.
442. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, **Alberts DS**. Effects of repeated green tea catechin administration on human cytochrome P450 activity. *Cancer Epidemiol Biomarkers Prev* 15(12):2473-6, 2006.
443. Ganz PA, Kwan L, Somerfield MR, **Alberts D**, Garber JE, Offit K, Lippman S. The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology (ASCO) members. *J Clin Oncol* 24(18):2946-57, 2006.
444. Markman M, Federico M, Liu PY, Hannigan E, **Alberts D**..Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. *Gynecol Oncol* 103:195-8, 2006.
445. Martinez ME, Thompson P, Jacobs ET, Giovannucci E, Jiang R, Klimecki, **Alberts DS**. Dietary factors and biomarkers involved in the methylenetetrahydrofolate reductase genotype-colorectal adenoma pathway. *Gastroenterology* 131(6):1706-16, 2006.
446. Bartels PH, Ranger-Moore J, **Alberts D**, Hess L, Scarpelli M, Montironi R. Carcinogenesis and the hypothesis of phylogenetic reversion. *Anal Quant Cytol Histol* 28(5):243-52, 2006.
447. **Alberts DS**, Delforge A. Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life. *Sem Oncol Supplement* 33(12):8-17, 2006.
448. Hess LM, **Alberts DS**. The role of intraperitoneal therapy in advanced ovarian cancer. *Oncology* 21(2):227-32, 2007.
449. Jacobs ET, **Alberts DS**, Benuzillo J, Holis BW, Thompson PA, Martinez ME. Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. *J Steroid Biochem Mol Biol* 103:752-6, 2007.
450. Montironi R, Scarpelli M, Lopez-Beltran A, Mazzucchilli R, **Alberts D**, Ranger-Moore J, Bartels HG, Hamilton PW, Einspahr J, Bartels PH. Chromatin phenotype karyometry can predict recurrence in papillary urothelial neoplasms of low malignant potential. *Cell Oncol* 29:47-58, 2007.
451. Bartels PH, Fabian CJ, Kimler BF, Ranger-Moore JR, Frank DH, Yozwiak ML, **Alberts DS**. Karyometry of breast epithelial cells acquired by random periareolar fine needle aspiration in women at high risk for breast cancer. *Anal Quant Cytol Histol* 29(2):63-70, 2007. PMID: 17484269.
452. Jacobs ET, Martinez ME, **Alberts DS**, Jiang R, Lance P, Lowe KA, Thompson PA. Association between body size and colorectal adenoma recurrence. *Clin Gastroenterol Hepatol* 5(8):982-90, 2007. PMID: 7553754.
453. **Alberts DS**, Liu PY, Wilczynski S, Jang A, Moon J, Ward JH, Beck JT, Clouser M, Markman M. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer: a Southwest Oncology Group Study (S0211). *Int J Gynecol Oncol* 17(4):784-8, 2007.

454. Martinez EM, Jacobs B, Ashbeck E, Sinha R, Lance P, **Alberts DS**, Thompson P. Meat intake, preparation methods, mutagens and colorectal adenoma recurrence. *Carcinogenesis* 28(9):2019-27, 2007. PMID: 7690112.
455. Chow HH, Hakim IA, Vining DR, Crowell JA, Tome ME, Ranger-Moore J, Cordova CA, Mikhael DM, Briehl MM, **Alberts DS**: Modulation of human glutathione S-transferases by polyphenol e intervention. *Cancer Epidemiol Biomarkers Prev* 16:1662-6, 2007. PMID: 17684143.
456. Mitchell A, Newton JM, Brite K, Einspahr J, Ellis M., Davis J, Nuno T, **Alberts D**, Garcia F. Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer. *J Lower Genital Tract Dis* 11(2):80-5, 2007. PMID: 17415111.
457. Hess LM, Barakat R, Tian C, Ozols RF and **Alberts DS**. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. *Gynecol Oncol* 107(2):260-5, 2007. PMID: 17675142.
458. Hess LM, Benham-Hutchins M, Herzog TJ, Hsu P, Malone DC, Skrepnek GH, Slack MK, **Alberts DS**. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. *Int J Gynecol Cancer* 17(3):561-70, 2007. PMID: 17504373.
459. **Alberts DS**, Einspahr JG, Krouse RS, Prasad A, Ranger-Moore J, Hamilton P, Ismail A, Lance P, Goldschmid S, Hess LM, Yozwiak M, Bartels HG, Bartels PH. Karyometry of the colonic mucosa. *Cancer Epidemiol Biomarkers Prev* 16(12):2704-16, 2007. PMID: 18086777.
460. Einspahr JG, Thomas TL, Saboda K, Nickoloff BJ, Warneke J, Curiel-Lewandrowski C, Ranger-Moore J, Duckett L, Bangert J, Fruehauf JP, **Alberts DS**. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. *Cancer* 110(11):2519-27, 2007. PMID: 17932890.
461. Liu PY, **Alberts DS**, Monk BJ, Brady M, Moon J, Markman M. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. *J Clin Oncol* 25(24):3615-20, 2007. PMID: 17704410.
462. Korde VR, Xu W, Bonnema GT, Krishnamurthy C, Xu W, Krishnamurthy C, Ranger-Moore J, Saboda KL, Slayton LD, Salasche SJ, Warneke JA, **Alberts DS**, Barton JK. Using optical coherence tomography to evaluate skin sun damage and precancer. *Lasers Surg Med* 39(9):687-95, 2007. NIHMS #48080; PMID: 17960754.
463. **Alberts DS**, Liu PY, Wilczynski S, Clouser M, Lopez A, Michelin DP, Lanzotti V, Markman M: Randomized trial of pegylated liposomal doxorubicin plus carboplatin versus carboplatin in platinum-sensitive patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy. Southwest Oncology Group Study #S0200. *Gynecol Oncol* 108(1):90-4, 2008. NIHMS #38787; PMID: 17949799.
464. Jacobs ET, Martinez ME, **Alberts DS**, Ashbeck EL, Gapstur SM, Lance P, Thompson PA. Plasma insulin-like growth factor I is inversely associated with colorectal adenoma recurrence: a novel hypothesis. *Cancer Epidemiol Biomarkers Prev* 17(2):300-5, 2008. PMID: 18250342.
465. Einspahr JG, Bowden GT, **Alberts DS**, McKenzie N, Saboda K, Warneke J, Salasche S, Ranger-Moore J, Curiel-Lewandrowski C, Nagle RB, Nickoloff BJ, Brooks C, Dong Z, Stratton SP: Cross-validation of murine UV signal transduction pathways in human skin. *Photochem Photobiol* 84:463-76, 2008. PMID: 18248498.
466. Greene MH, Piedmonte M, **Alberts DS**, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S. A prospective study risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a GOG Study. *Cancer Epidemiol Biomarkers Prev* 17(3):594-604, 2008.

467. **Alberts DS**, Marth C, Alvarez R, Johnson G, Bidzinski M, Kardatzke D, Williamson BZ, Loutit J, Kirn DM, Clouser MC, Markman M and the GRACES Clinical Trial Consortium: Randomized phase III trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. *Gynecol Oncol* 109:174-81, 2008. PMID: 18314182.
468. Reid M, Duffield-Lillico AJ, Slate E, Natarajan N, Turnbull B, Jacobs E, Combs Jr., GF, **Alberts DS**, Clark L and Marshall JR. The nutritional prevention of cancer: 400 mcg per day selenium treatment. *Nutr Cancer* 60(2):155-63, 2008. PMID: 18444146.
469. Stratton SP, Saboda KL, Myrdal PB, Gupta A, McKenzie NE, Brooks C, Salasche SJ, Warneke JA, Ranger-Moore J, Bozzo PD, Blanchard J, Einspahr JG, Dorr RT, Levine N, **Alberts DS**. Phase I study of topical perillyl alcohol cream for chemoprevention of skin cancer. *Nutr Cancer* 60(3):325-30, 2008. PMID: 18444166.
470. Hess LM, Jeter JM, Benham-Hutchins M, **Alberts DS**. Factors associated with osteonecrosis of the jaw among bisphosphonate users. *Am J Med* 121(6):475-83, 2008. PMID: 18501224.
471. Jacobs ET, **Alberts DS**, Foote JA, Green SB, Hollis BW, Yu Z, Martinez ME. Vitamin D deficiency in Southern Arizona. *Am J Clin Nutr* 87:608-13, 2008. PMID: 18326598.
472. Bartels PH, Yozwiak ML, Bartels HG, Liu Y, Hess LM, **Alberts DS**. Limits of detection of chemopreventive efficacy: karyometry of skin biopsies. *Cancer Epidemiol Biomarkers Prev* 17(7):1689-95, 2008. PMID: 18583468.
473. Mutter GL, Kauderer J, Baak JPA, **Alberts DS**. Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group Study. *Hum Pathol* 39(6):866-74, 2008.
474. Bartels PH, **Alberts DS**, Yozwiak M, Liu Y, Bartels HG. Actinic damage in histopathologically normal skin. *Anal Quant Cytol Histol* 30(6): 316-22, 2008.
475. Vale C, Thomas G, Dinshaw K, **Alberts DS**, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. *J Clin Oncol* 26 (35):5802-12, 2008.
476. Goodman GE, Alberts DS, Meyskens FL. Retinol, vitamins, and cancer prevention: 25 years of learning and relearning. *J Clin Oncol* 26 (34):5495-6, 2008.
477. Frank DH, Kimler BF, Fabian CJ, Ranger-Moore, J, Yozwiak M, Bartels HG, **Alberts DS**, Bartels PH. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months. *Breast Cancer Res Treat* 115(3):661-8, 2009.
478. Bookman MA, Brady MF, McGuire WP, Harper PG, **Alberts DS**, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. *J Clin Oncol* 27:1419-25, 2009.
479. Jacobs, ET, Jurutka, PW, Martinez ME, **Alberts DS**. Vitamin D, calcium, and colorectal neoplasia: new insights on mechanisms of action. *Cancer Prev Res* 2(3):197-9, 2009.
480. Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR, Markman M, **Alberts DS**. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: A Southwest Oncology Group Study #S-0009 *Gynecolog Oncol*, 112(3):444-9, 2009.
481. Vale C, Thomas G, Dinshaw K, Brady MF, Parmar M, Trimble T, Whitney CW, Pras E, Leborgne F, Keys H, Chen H, Roberts KB, **Alberts D**, Garipagaoglu M, Kantardzic N, Peifel, Punita L, Lanciano RM, Pearcey R, Rose P, Lorvidhaya V, Anders K, Jakobsen M, Onishi H, Tomasevic A, Tierney J, Stewart L. Reducing uncertainties about the effects of chemoradiation for cervical cancer: a systemic review and meta-analysis of individual patient data from 18 randomized trials. *J Clin Oncol*, (26) 5802-12, 2008.

482. Foote JA, Ranger-Moore JR, Einspahr JG, Saboda K, Kenyon J, Warneke J, Miller RC, Goldman R, Xu MJ, Roe DJ, **Alberts DS**. Chemoprevention of human actinic keratoses by topical dl- α -tocopherol. *Cancer Prev Res* 2: 394-400, 2009.
483. Hsu C-H, Taylor MG, Long Q, **Alberts DS**. Analysis of colorectal adenoma recurrence data subject to informative censoring. *Cancer Epidemiol Biomarkers Prev* 18(3): 712-17, 2009.
484. Bartels PH, Bartels HG, **Alberts DS**. Karyometry: correction algorithm for differences in staining. *Anal Quant Cytol Histol*, 31(2): 63-73, 2009.
485. Hostetter GH, Kim SY, Savage S, Gooden GC, Barret M, Zhang J, Lalitamba A, Watanabe A, Einspahr J, Prasad A, Nickloff BJ, Carpten J, Trent J, **Alberts D**, Bittner M. Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples. *Nucleic Acids Res* 37(19):1-12, 2009.
486. Thompson PA, Wertheim BC, Roe DJ, Ashbeck EL, Jacobs ET, Lance P, Martinez ME, **Alberts DS**. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. *Cancer Prev Res* 2(12):1023-30, 2009.
487. Bartels P, Yozwiak M, Einspahr J, Saboda K, Liu Y, Brooks C, Bartels H, **Alberts DS**. Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry. *Anal Quant Cytol Histol*, 31(6):355-66, 2009.
488. Thompson PA, Hsu, CH, Green S, Stopeck AT, Johnson K, **Alberts DA**, Chow HH. Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial. *Cancer Prev Res*, 3(1), 101-7, 2009.
489. Stratton SP, **Alberts DS**, Einspahr JG, Sagerman PM, Warneke JA, Curiel CL, Myrdal PB, Karlage KL, Nickoloff BJ, Brooks C, Saboda K, Yozwiak ML, Krutzsch MF, Hu C, Lluia-Prevatt M, Dong Z, Bowden GT, Bartels PH. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. *Cancer Prev Res*, 3(2) 160-9, 2010.
490. Tiersten AD, Moon J, Smith HO, Wilczynski SP, Robinson WR, Markman M, **Alberts DS**. Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study. *Intl J Cancer Res Treat*, 2009.
491. Bartels PH, Montironi R, Scarpelli M, Bartels HG, **Alberts DS**: Knowledge discovery processing and data mining in karyometry. *Anal Quant Cytol Histol*, 31(3), 2009.
492. Krouse R, **Alberts DS**, Prasad AR, Yozwiak M, Bartels HG, Liu Y, Bartels PH. Progression of skin lesions from normal skin to squamous cell carcinoma. *Anal Quant Cytol Histol*, 31:17-25, 2009.
493. Markman M, Liu PY, Moon J, Monk B, Copeland L, Wilczynski S, **Alberts D**. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m²) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group Phase 3 Trial. *Gynecol Oncol* 114(2):195-8, 2009.
494. Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM Jr, Michelin DP, Lanzotti VJ, Anderson GL, **Alberts DS**. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) Phase 3 randomized trial. *Gynecol Oncol* 116:323-5, 2010.
495. Martinez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza L, Winawer SJ, Zauber AG, Jiang R, Ahnen DJ, Bond JH, Church TR, Robertson D, Smith-Warner S, Jacobs ET, **Alberts D**, Greenberg ER. Advanced colorectal neoplasia diagnosed during surveillance following colonoscopic polypectomy: a pooled analysis. *Am J Epidemiol* 169:657-66, 2009.
496. Thomson CA, **Alberts DS**. Diet and survival after ovarian cancer: where are we and what's next?" *J Am Diet Assoc* 110: 3, 2010.

497. Martinez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, Zauber AG, Jiang R, Ahnen DJ, Bond JH, Church TR, Robertson DJ, Smith-Warner, SA, Jacobs ET, **Alberts DS**, Greenberg ER. A pooled analysis of advanced colorectal neoplasia diagnoses following colonoscopic polypectomy. *Gastroenterol* 136(3):832-41, 2009.
498. Wertheim BC, Martinez ME, Ashbeck EL, Roe DJ, Jacobs ET, **Alberts D**, Thompson PA. Physical activity as a determinant of fecal bile acid levels. *Cancer Epidemiol Biomarkers Prev* 18(5), 1591-8, 2009.
499. Hostetter G, Kim S, Savage S, Gooden G, Alla L, Barrett M, Zhang J, Watanabe A, Einspahr J, **Alberts D**, Prasad A, Nickoloff B, Carpten J, Trent J, Bittner M. Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples. *Nucleic Acids Res* 38(2), 2010.
500. Olson ER, Melton T, Dickinson SE, Dong Z, **Alberts DS**, Bowden GT. Quercetin potentiates UVB-induced c-Fos expression: implications for its use as a chemopreventive agent. *Cancer Prev Res*; 3(7), 876-84, 2010.
501. Chow, HH, Garland L, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, **Alberts DS**. Resveratrol modulates drug and carcinogen metabolizing enzymes in a healthy volunteer study. *Cancer Prev Res* 3(9) 1168-75, 2010.
502. Sekulic A, Kim SY, Hostetter G, Savage S, Einspahr JG, Prasad A, Sagerman P, **Alberts DS**, Pittelkow MR, DiCaudo David, Nickoloff B, Trent JM, Bittner M. Loss of inositol polyphosphate 5-phosphatase is an early event in development of cutaneous squamous cell carcinoma. *Cancer Prev Res* 3(10):1277-83, 2010.
503. Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, **Alberts DS**. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. *Clin Cancer Res* 16(21):5320-8, 2010.
504. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC; Gynecologic Cancer Intergroup/National Cancer Institute Writing Committee, Aghajanian C, **Alberts DS**, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. for the Gynecologic Cancer Intergroup/National Cancer Institute Writing Committees. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting. *Intl J Gynecol Cancer* 20(7):1290-8, 2010.
505. Darcy KM, Mannel RS, Nilsa MD, Ramirez MD, **Alberts DS**, Jelonek J, Puehn K, Birrer M. Gynecologic Oncology Group ovarian treatment trials with specimen banking and translational research. *Clin Ovarian Cancer* 3(2):98-112, 2010.
506. Clouser M, Roe D, Foote J, Harris R, **Alberts D**. Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. *Nutr Cancer*, 62(8), 1058-66, 2010. PMID: 21058193
507. Hess LM, Chambers SK, Hatch K, Hallum A, Janicek MF, Buscema J, Borst M, Johnson C, Slayton L, Chongpison Y, **Alberts DS**. Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. *J Support Oncol* 8(6), 252-58, 2011.
508. Dickinson SE, Olson ER, Zhang J, Cooper SJ, Melton T, Criswell PJ, Casanova A, Dong Z, Hu C, Saboda K, Jacobs ET, **Alberts DS**, Bowden GT. p38 MAP kinase plays a functional role in UVB-induced mouse skin carcinogenesis. *Mol Carcinog* 50(6):469-78, 2011.

509. Friedlander M, Trimble T, **Alberts D**, Avall-Lundquist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I. Recurrent ovarian cancer – consensus statements on key questions for clinical trial design. *Intl J Gynecol Cancer*, 21:771-5, 2011.
510. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 365(5):395-409, 2011.
511. Montironi R, Bartels PH, DeCensi A, Hurle R, Decobelli O, Carmignani G, Mazzucchelli R, Bartels HG, **Alberts DS**, Putoni M, Maffezzini M. A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. *Urol Oncol* Epub ahead of print, 2011.
512. Marshall J, Tangen C, Sakr W, Wood D, Berry D, Klein E, Lippman S, Parnes H, **Alberts D**, Jarrard D, Lee WR, Crawford ED, Ely B, Ray M, Davis W, Minasian L, Thompson I. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG- S9917. *Cancer Prev Res*, 4:1761-96, 2011.
513. Goldberg M, **Alberts DS**, Buckmeier JA, Prasad AR, Krouse RS, Diamond AM. Loss of heterozygosity at the glutathione peroxidase 1 locus is not an early event in colon carcinogenesis. *Genes Cancer* 2(9):910-3, 2011.
514. Glazer ES, Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, **Alberts DS**, Krouse RS. Nuclear morphometry identifies a distinct aggressive cellular phenotype in cutaneous squamous cell carcinoma. *Cancer Prev Res* 4:1770-7, 2011.
515. Bartels PH, Garcia FAR, Trimble CL, Kauderer J, Curtin J, Lim PC, Hess LM, Silverberg S, Zaino RJ, Yozwiak M, Bartels HG, **Alberts DS**. Karyometry in Atypical Endometrial Hyperplasia. A Gynecologic Oncology Group Study. *Gynecol Oncol* 125:129-135, 2012.
516. Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Bartels H, Bartels PH, **Alberts DS**, Montironi R. Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis. *Intl J Immunopathol Pharmacol* 24(2):489-497, 2011.
517. Chu, DZJ, Hussey MA, **Alberts DS**, Meyskens Jr. FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. *Clin Colorectal Cancer* 10(4):310-6, 2011.
518. Einspahr, JG, Calvert V, **Alberts DS**, Curiel-Lewandrowski C, Warneke J, Krouse R, Stratton SP, Liotta L, Longo C, Pellacani G, Prasad A, Sagerman P, Bermudez Y, Deng J, Bowden GT, Petricoin EF. Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. *Cancer Prev Res*, 5:403-13, 2012. PMID: 22389437
519. Jeter JM, Han J, Martinez ME, **Alberts DS**, Qureshi AA, Feskanich D. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. *Cancer Causes Control*, 23:9, 1451-61, 2012. PMID:22763500
520. Bartels, PH, Bartels HG, **Alberts DS**, Yozwiak M, Prasad AR, Glazer ES, Krouse RS. Karyometry of nuclear phenotypes in cutaneous squamous cell cancer. *Anal Quant Cytol Histol* 34(1):1-8, 2012. PMID: 22590813
521. Chambers SK, Chow, HH, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Hillman KS, AbuShahin N, **Alberts DS**. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. *Clin Cancer Res* 18(a):2668-78, 2012.
522. Baker AF, Roe DJ, Laughren C, Cohen JL, Wright HM, Clouser MC, Cui H, **Alberts, DS**, Chambers SK. Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer. *Invest New Drugs*, Epub ahead of print, 2012.

523. Curiel-Lewandrowski C, Swetter SM, Einspahr JG, Hsu C-H, Nagle R, Sagerman P, Tangrea J, Parnes H, **Alberts DS**, Chow H-H. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. *Cancer*, 118: 2; 5848-5856, 2012. PMID: 22605570
524. Wertheim BC, Smith JW, Fang C, **Alberts DS**, Lance P, Thompson PA. Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis. *Cancer Prev Res* 5(2):197-204, 2012. PMID: 22058145
525. Thompson P, Roe DJ, Fales L, Buckmeier J, Wang F, Hamilton SR, Bhattacharyya A, Green S, Hsu C-H, Chow H-H, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Martinez ME, Jacobs E, Ashbeck EL, **Alberts DS** and Lance P. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. *Cancer Prevention Research*, 2012. . PMID: 23060037
526. Jeter J, **Alberts D**. Difluoromethylornithine: The Proof is in the Polyamines. *Can Prev Res*, 5:1341-1344, 2012. PMID: 23221207
527. **Alberts DS**, Blessing J, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ and Ramondetta LM. Phase II Trial of Nab-Paclitaxel in the Treatment of Recurrent or Persistent Advanced Cervix Cancer: A Gynecologic Oncology Group Study. *Gynecologic Oncology*, 127:451-455, 2012. PMID: 22986144
528. **Alberts D** and Crano SL. Personalized Medicine in Oncology. *The Journal of Southern California Clinicians*, 6:32-34, 2012.
529. Tang DH, **Alberts DS**, Nevins R, Sullivan S, and Skrepnek GH. Health care expenditures, hospitalizations, and productivity associated with cancer in US employer settings. *Journal of Occupational and Environmental Medicine*, 54 (12):1453-1460, 2012. PMID:23169275

B. SUBMITTED/IN PRESS ARTICLES (alphabetically)

1. **Alberts DS**, Clouser M, Hess LM. Intraperitoneal Chemotherapy: Phase III Trials. In Press, 2009.
2. **Alberts DS**, Fabian C, Kimler B, Bartels P. Prediction of response to the chemopreventive agent Arzoxifene in individual cases. To be submitted, 2013.
3. Chase, DM, Gibson SJ, Sumner DA, Bea JW, **Alberts DS**. Appropriate use of complementary and alternative medicine approaches in gynecologic cancers. *Current Treatment Options in Oncology*, Submitted, 2013.
4. Chu DZJ, **Alberts DS**, Hussey M, Meyskens Jr. FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Goodman GE, Blanke C and Lippman SM: Reduction of recurrent neoplasms in the colon and rectum with oral calcium supplement. Submitted, *Cancer Prev Res*, 2009.
5. Crane TE, Khulpateea BR, **Alberts DS**, Basen-Enquist K, Thomson CA. Dietary intake and ovarian cancer risk: A systematic review. Accepted, *Cancer Epidemiology, Biomarkers and Prevention*, 2013.
6. Fabian C, Kimler B, **Alberts DS**, Bartels P. Efficacy of Arzoxifene as chemopreventive agent in women at risk for breast cancer. To be submitted, 2013.
7. Garcia FAR, Cornelison T, Nuno T, Mitchell AL, Greenspan DL, Byron JW, Hsu C-H, **Alberts DS**, Chow S. Results of a phase II randomized, double-blind, placebo controlled trial of Polyphenon E in women with persistent high risk HPV infection and low grade cervical intraepithelial neoplasia. Submitted, *Gynecologic Oncology*, 2013.

8. Glazer, ES, Bartels PH, Prasad AR, Yozwiak M, Bartels HG, Einspahr JG, **Alberts DS**. High proportion of an aggressive nuclear phenotype identifies aggressive cutaneous squamous cell carcinoma. Submitted, *Cancer Prevention Research*, 2013.
9. Glazer ES, Bartels PH, Lian F, Morgan SS, Da Silva VD, Yozwiak ML, Bartels HG, Cranmer LM, de Oliveira JK, **Alberts DS**, Warneke JA, Krouse RS. Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases. Submitted to *Melanoma Research*, 2013.
10. Lluria-Prevatt M, Dickinson SE and **Alberts DS**. Skin Cancer Prevention in Fundamentals of Cancer Prevention, Third Edition. Ed. David S. Alberts and Lisa Hess. Springer-Verlag Berlin Heidelberg, 2014.
11. Olson ER, Levenson C, **Alberts DS** and Bowden GT. Novel chemopreventive mechanism from traditional medicine: East Indian sandalwood oil induces autophagy and cell death in proliferating keratinocytes. Submitted, *Cancer Prevention Research*, 2013.
12. Plattner S, McCartney G, Thomson C, Balderama A, **Alberts DS**, Foote JA. Healthy Children Arizona: Early Intervention for Cancer Prevention. *J Nutri Edu and Behavior*. Submitted, 2011.
13. Raja FA, Counsell N, Colombo N, Parmar MK, Pfisterer J, Vergote IB, Gonzalez-Martin A, Alberts DS, Plante M, Torri V, Ledermann JA. Single agent platinum versus combination platinum chemotherapy in platinum-sensitive recurrent ovarian cancer: A Meta-Analysis of Randomised Trials Using Individual Patient Data. In Press, *Annals of Oncology*, 2013.
14. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauf ND, Yamada SD, Rodriguez G, Skates SL, **Alberts DS**, Walker JL, Minasian L, Lu K, Greene MH. Pathologic findings in risk-reducing salpingo oophorectomy (RRSO): Primary results from Gynecologic Oncology Group Trial GOG-0199. Submitted, *J Clin Oncol*, 2013.
15. Stratton SP, Saboda K, Brooks CA, Bozzo PD, Salasche SJ, Warneke JA, Miller RC, Dorr RT, Einspahr JG, Roe DJ, Levine NS and **Alberts DS**: Randomized, double-blind, placebo-controlled phase I trial of topical EGCG: safety, tolerance and sun protection factor. *Nutr Cancer (or Cancer Prevention Research)*, To be Submitted, 2013.
16. Thigpen JT, **Alberts D**, Birrer M, Copeland L, Coleman RL, Markman M, Bast RC, Eisenhauer EL, Fleming G, Fracasso PM, Gershenson DM, Herzog T, Monk B, Ozols RF, Rustin G, Shrader M, Ranganathan A. Current challenges and future directions in the management of ovarian cancer. *Clinical Ovarian Cancer*, 2010.
17. Thomson C, Crane TE, **Alberts D**. et al. Dietary intake and ovarian cancer risk: A systematic Review. *Cancer Epidemiology, Biomarkers & Prevention*, Submitted, 2013.
18. Trotter II, RT, Laurila K, **Alberts D** Huenneke LF. A diagnostic evaluation model for complex research partnerships with community engagement: The Native American Cancer Prevention Project. Submitted, *Journal of Evaluation and Program Planning*, 2013.

C. INVITED JOURNAL PUBLICATIONS

1. **Alberts DS**, Young L, Mason N, Salmon SE: *In vitro* evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. *Semin Oncol* 12(Suppl 4):38-42, 1985.
2. **Alberts DS**, Garcia-Kendall D, Surwit EA: Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer. *Semin Oncol* 15(Suppl 4):22-26, 1988.
3. Monk BJ, Surwit EA, **Alberts DS**, Graham V: Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. *Semin Oncol* 15(Suppl 4):27-31, 1988.
4. **Alberts DS**, Mason-Liddil N: Carboplatin in the treatment of ovarian cancer. *Semin Oncol* 16(Suppl 5):19-26, 1989.

5. **Alberts DS**, Canetta R, Mason-Liddil N: Carboplatin in the first-line chemotherapy of ovarian cancer. *Semin Oncol* 17(Suppl 2):54-60, 1990.
6. **Alberts DS**: Clinical pharmacology of carboplatin. *Semin Oncol* 17(Suppl 7):6-8, 1990.
7. **Alberts DS**, Garcia D, Mason-Liddil N: Cisplatin in advanced cancer of the cervix: An update. *Semin Oncol* 18(Suppl 3):11-24, 1991.
8. Kreisle WH, **Alberts DS**: Mitoxantrone: Advancing the standard therapeutic equation. *Contemp Oncol* 1:49-54, 1991.
9. Vargas P, **Alberts DS**: Primary prevention of colorectal cancer through dietary modification. *Cancer* 70(Suppl):1229-1235, 1992.
10. Taylor CW, Modiano MR, Woodson ME, Marcus SG, **Alberts DS**, Hersh EM: A phase I trial of fluorouracil, leucovorin, and recombinant interferon α -2b in patients with advanced malignancy. *Semin Oncol* 19(Suppl 3):185-190, 1992.
11. **Alberts DS**: Foreword: Fourth international conference on prevention of human cancer: Nutrition and chemoprevention controversies, Tucson, Arizona, June 3-6, 1992. *Prev Med* 22:629-641, 1993.
12. Vargas PA, **Alberts DS**: Colon cancer: The quest for prevention. *Oncology* 7(Suppl): 33-40, 1993.
13. **Alberts DS**, Garcia DJ: Total platinum dose versus platinum dose intensification in ovarian cancer treatment. *Semin Oncol* 21(Suppl 2):11-15, 1994.
14. **Alberts DS**, Garcia DJ: Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix. *Semin Oncol* 21(Suppl 7):37-46, 1994.
15. **Alberts DS**: Carboplatin versus cisplatin in ovarian cancer. *Semin Oncol* 22(Suppl 12):88-90, 1995.
16. **Alberts DS**, Bleyer WA: Future development of amifostine in cancer treatment. *Semin Oncol* 23(Suppl 8):90-99, 1996.
17. **Alberts DS**, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Hoskins WJ, Adelson MD, Alvarez RD, O'Sullivan J, Garcia DJ, Sparks DB, Quade J, Rothenberg ML: Phase III study of intraperitoneal cisplatin-intravenous cyclophosphamide versus intravenous cisplatin-intravenous cyclophosphamide in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG Intergroup study. *Int J Gynecol Cancer* 6(Suppl 1):28-29, 1996.
18. **Alberts DS**, Garcia DJ: Safety aspects of pegylated liposomal doxorubicin in patients with cancer. *Drugs* 54(Suppl 4):30-35, 1997.
19. **Alberts DS**, Garcia DJ: A safety review of pegylated liposomal doxorubicin in the treatment of various malignancies. *Oncology* 11(Suppl 11):54-62, 1997.
20. **Alberts DS**, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malviya VK, Nahhas WA, Jolles CJ: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. *Classic Papers Current Comments* 3:145-157, 1998.
21. **Alberts DS**: Treatment of refractory and recurrent ovarian cancer. *Semin Oncol* 26(Suppl 1):8-14, 1999.
22. **Alberts DS**: Future directions in gynecologic cancer. *Semin Oncol* 26(Suppl 7):125-128, 1999.
23. **Alberts DS**: Protection by amifostine of cyclophosphamide-induced myelosuppression. *Semin Oncol* 26(Suppl 7):37-40, 1999.
24. **Alberts DS**: A unifying vision of cancer therapy for the 21st century. *J Clin Oncol* 17(11s):13-21, 1999.
25. Chemoprevention Working Group (includes **Alberts DS**): Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. *Cancer Res* 59:4743-4758, 1999.

26. **Alberts DS:** Chemoprevention of skin cancer: In pursuit of saving our skins! Cancer Research at the Millennium Program and Abstracts (42nd Annual Clinical Conference, 52nd Annual Symposium on Fundamental Cancer Research), January 9-12, pp. 30-33, 2000.
27. **Alberts DS:** Gene/environmental interactions related to colon cancer. Cancer and the Environment: Gene-Environment Interactions, Roundtable on Environmental Health Sciences, Research, and Medicine, Washington, DC, May 16-17, pp. 29-36, 2001.
28. **Alberts DS:** The current management of ovarian cancer – primary care edition. CME Credit Course on Virtual Lecture Hall website (<http://vlh.com>), 2002.
29. **Alberts DS,** Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malviya VK, Nahhas WA, Jolles CJ: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. *Classic Papers Current Comments* 7:41-52, 2002.
30. Markman M, Bundy BN, **Alberts DS,** Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. *Classic Papers Current Comments* 7:92-99, 2002.
31. Peters WA III, Liu PY, Barrett RJ II, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, **Alberts DS:** Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *Classic Papers Current Comments* 7:174-181, 2002.
32. **Alberts DS,** Martinez ME: Gene-environment interactions related to colon cancer (talk abstract). In: *Cancer and the Environment: Gene-Environment Interaction*, Wilson S, Jones L, Coussens C, Hanna K (eds). National Academy Press: Washington DC, pp. 70-75, 2002.
33. Einspahr JG, Stratton SP, Bowden GT, **Alberts DS:** Chemoprevention of human skin cancer (invited review). *Crit Rev Oncol Hematol* 41:269-285, 2002.
34. Fish AE, **Alberts DS:** Cyclooxygenase-2 inhibitors and the chemoprevention of colorectal cancer. *Targeted Ther Oncol* 2:2-5, 12, 2002.
35. Stratton MS, Einspahr J, **Alberts DS:** Cyclooxygenase-2-specific inhibitors in chemoprevention. *Targeted Ther Oncol* 2:6-11, 2002.
36. Stratton MS, **Alberts DS:** Current application of selective COX-2 inhibitors in cancer prevention and treatment. *Oncology* 16(Suppl 4):37-51, 2002.
37. **Alberts DS:** Reducing the risk of colorectal cancer by intervening in the process of carcinogenesis: A status report. *Cancer J* 8:208-221, 2002.
38. Fruehauf JP, **Alberts DS:** Assay-assisted treatment selection for women with breast or ovarian cancer. *Recent Results Cancer Res* 161:126-145, 2003.
39. **Alberts DS:** Treating IEN, not chemoprevention. *Cancer Prevention (A National Newsletter and Web Site for Professionals from New York-Presbyterian Hospital)* 1:3, 2003.
40. Einspahr JG, Bowden GT, **Alberts DS:** Skin cancer chemoprevention: Strategies to save our skin (invited). *Recent Results Cancer Res* 163:151-164, 2003.
41. Thomson CA, LeWinn K, Newton TR, **Alberts DS,** Martinez ME: Nutrition and diet in the development of gastrointestinal cancer. *Current Oncol Reports* 5:192-202, 2003.
42. Kelloff GJ, Schilsky RL, **Alberts DS,** Day RW, Guyton KZ, Pearce HL, Peck JC, Phillips R, Sigman CC: Colorectal adenomas: a prototype for the use of surrogate endpoints in the development of cancer prevention drugs. *Clin Cancer Res, Special Review* 10:3908-3918, 2004.

43. Harris RB and **Alberts DS**: Strategies for skin cancer prevention. *Int J Dermatol* 43:243-251, 2004.
44. **Alberts DS**: Case Review: Stage IIIC ovarian cancer. *Case Studies in Oncol.* July 2004.
45. **Alberts DS**, Godley L: Clinical Trials and End-of-Life Decision Making. *Virtual Mentor, Ethics J Am Med Assoc* 6(11), 2004.
46. **Alberts DS**, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, Dibella NJ, Stewart SJ, Kavanagh JJ, and Gabizon AA: Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. *Seminars in Oncology* 31(Suppl 13):53-90, 2004.
47. Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, **Alberts DS**: Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group Study. *Gynecologic Oncology* 95(3):506-512, 2004.
48. **Alberts DS**: Nutrition and Cancer Introduction. University of Arizona Program in Integrative Medicine website (www.arizona.edu), 2005.
49. Ranger-Moore J, **Alberts DS**, Montironi R, Garcia F, Davis J, Frank D, Brewer M, Mariuzzi GM, Bartels HG, Bartels PH: Karyometry in the early detection and chemoprevention of intraepithelial lesions. *Eur J Cancer*, on line August 8, 2005 and published *Eur J Cancer* 41:1875-1888, 2005.
50. Garland LL, **Alberts DS**: Practical tips for getting through treatment. *Coping with Cancer*, in press, July-August, 2006.
51. **Alberts DS**: Recommendations from the NCI-designated Cancer Center Directors. Accelerating Successes Against Cancer. US Dept. Health and Human Services, National Institutes of Health, www.3.cancer.gov/cancercenters/Accelerating_Successes_Against_Cancer_Report.pdf, 2006.
52. Hess LM, **Alberts DS**: The role of intraperitoneal therapy in advanced ovarian cancer. *Oncology*, 21(2):227-232, 2007.
53. **Alberts DS**: Introduction, *Seminars in Oncol* 33(6):S1-S2, December 2006.
54. **Alberts DS**: Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life. *Seminars in Oncol* 33(12):S8-S17, December 2006.
55. Herberman RB, Pearch HL, Lippman S, Pyenson BS, and **Alberts DS**: C-Change Cancer Chemoprevention Summit Report: Cancer Chemoprevention and Cancer Preventive Vaccines – A call to action: Leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need. *Cancer Research* 66(24):11540-11549, December 15, 2006.
56. **Alberts DS**, Markman M, Muggia F, Ozols RF, Eldermire E, Bookman MA, Chen T, Curtin J, Hess LM, Liebes L, Young R, Trimble E: Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. *Gynecologic Oncol* 103(3):783-792, 2006.
57. **Alberts DS**: Clinical Trials Design: Our patients deserve better. *Am Enterprise Inst Publ*, In press, 2008.
58. Szabo E, **Alberts DS**, Hawk ET. AACR-NCI Think Tank: Charting the Future of Cancer Prevention, Translational Research and Clinical Prevention Trials. *Amer Assn Clin Res*, 2009.
59. **Alberts DS** and Lluria-Prevatt M. Foreword to *Bioactive Compounds and Cancer*. Editors: Romanglo D and Milner J. Springer Verlag, Berlin, 2010.
60. **Alberts DS**, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. *Gastroenterology*, Oxford Journals, 68-78, 2009.
61. Recommendations from the NCI-designated Cancer Center Directors, Accelerating Successes Against Cancer. National Institutes of Health, National Cancer Institute. 2009.

62. **Alberts DS**. Reducing the risk of colorectal cancer by intervening in the process of carcinogenesis: A status report. *The Cancer Journal*; 8 (3), 208-221, 2002.

D. BOOKS

1. **Alberts DS**, Surwit EA (eds): *Ovarian Cancer*. Martinus Nijhoff Publishers, NY, 1985.
2. Surwit EA, **Alberts DS** (eds): *Cervix Cancer*. Martinus Nijhoff Publishers, NY, 1987.
3. Surwit EA, **Alberts DS** (eds): *Endometrial Cancer*. Kluwer Academic Publishers, NY, 1989.
4. **Alberts DS** and Hess LM (eds): *The Only Proven Cure for Cancer: Prevention*. Springer-Verlag, in press, 2004.
5. **Alberts DS**, Barakat RR, Daly M, Method MW, Benbrook. *Prevention of Gynecologic Malignancies*. Elsevier, 2004.
6. **Alberts DS** and Hess LM (eds): *Fundamentals of Cancer Prevention*, Springer-Verlag, 2005.
7. **Alberts DS** and Hess LM (eds): *Fundamentals of Cancer Prevention*, 2nd Edition, Springer-Verlag, 2008.
8. **Alberts DS**, Hess LM, Clouser MC (eds). *Intraperitoneal Therapy for Ovarian Cancer*, Springer-Verlag, 2010.

E. BOOK CHAPTERS

1. **Alberts DS**: Adjuvant immunotherapy with BCG of advanced ovarian cancer: A preliminary report. In: **Adjuvant Therapy of Cancer**, Salmon SE, Jones SE (eds). Elsevier/North Holland Biomedical Press: Amsterdam, pp. 327-334, 1977.
2. **Alberts DS**, Chen HSG, Liu R, Chen J, Mayersohn M, Perrier D, Moon TE, Gross JF, Broughton A, Salmon SE: Disposition kinetics of intracavity bleomycin in man: A preliminary report. In: **The Bleomycins - Current Status and New Developments**, Carter SK, Crooke ST (eds). Academic Press: New York, pp. 131-141, 1978.
3. **Alberts DS**, Salmon SE, Moon TE: Chemoimmunotherapy for advanced ovarian carcinoma with adriamycin-cyclophosphamide + BCG: Early report of a Southwest Oncology Group study. In: **Recent Results in Cancer Research: Adjuvant Therapies & Markers of Post-Surgical Minimal Residual Disease II**, Bonadonna G, Mathe G, Salmon SE (eds). Springer Verlag: New York, 68:160-165, 1979.
4. **Alberts DS**, Moon TE, O'Toole R, Neff J, Tate T, Blessing J: BCG as an adjuvant to adriamycin-cyclophosphamide in the treatment of advanced ovarian carcinoma: An ongoing analysis of a Southwest Oncology Group study. In: **Adjuvant Therapy of Cancer II**, Jones SE, Salmon SE (eds). Grune & Stratton, Inc: New York, pp. 483-494, 1979.
5. **Alberts DS**, Chen HSG: Tabular summary of pharmacokinetic parameters relevant to *in vitro* drug assay. In: **Cloning of Human Tumor Stem Cells**, Salmon SE (ed). Alan R. Liss, Inc: New York, pp. 351-359, 1980.
6. **Alberts DS**: Gynecologic Cancers. In: **Clinical Immunotherapy**, LoBuglio A (ed). Marcel Dekker, Inc: New York, pp. 287-311, 1980.
7. **Alberts DS**, Chen HSG, Chang SY, Peng YM: The disposition of intraperitoneal bleomycin, Melphalan, and vinblastine in cancer patients. In: **Recent Results in Cancer Research**, Mathe G, Muggia F (eds). Springer-Verlag: Berlin, pp. 293-299, 1980.
8. **Alberts DS**, Chang SY, Chen HSG, Larcom BJ, Evans TL: Comparative pharmacokinetics of chlorambucil and Melphalan in man. In: **Recent Results in Cancer Research**, Mathe G, Muggia F (eds). Springer-Verlag: Berlin, pp. 124-131, 1980.

9. Salmon SE, **Alberts DS**, Durie BGM, Meyskens FL Jr, Jones SE, Soehnlen BJ, Chen HSG, Moon TE: Clinical correlations of drug sensitivity in the human tumor stem cell assay. In: **Recent Results in Cancer Research**. Paris, 74:300-305, 1980.
10. **Alberts DS**, Hilgers RD, Moon TE, O'Toole R, Mantz F, Martimbeau PW, Stevens RL, Rivkin SE, Mason NL: Cis-platinum combination chemotherapy for drug-resistant ovarian carcinoma. In: **Cisplatin: Current Status and New Developments**, Carter SK, Crooke S (eds). Academic Press: New York, pp. 393-401, 1980.
11. **Alberts DS**, Chen HSG, Salmon SE: *In vitro* drug assay: Pharmacologic considerations. In: **Cloning of Human Tumor Stem Cells**, Salmon SE (ed). Alan R. Liss, Inc: New York, pp. 197-207, 1980.
12. Salmon SE, Soehnlen BJ, **Alberts DS**: New drugs in ovarian cancer: *In vitro* phase II screening with the human tumor stem cell assay. In: **Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas**, van Oosterm AT (ed). Martinus Nijhoff Publishers: The Hague, pp. 113-128, 1980.
13. Salmon SE, **Alberts DS**, Meyskens FL Jr, Durie BGM, Jones SE, Soehnlen BJ, Young L, Chen HSG, Moon TE: Clinical correlations of *in vitro* drug sensitivity. In: **Cloning of Human Tumor Stem Cells**, Salmon SE (ed). Alan R. Liss, Inc: New York, pp. 223-245, 1980.
14. Hamburger AW, Salmon SE, **Alberts DS**: Development of a bioassay for ovarian carcinoma colony-forming cells. In: **Cloning of Human Tumor Stem Cells**, Salmon SE (ed). Alan R. Liss, Inc: New York, pp. 63-73, 1980.
15. Salmon SE, **Alberts DS**, Meyskens FL Jr, Durie BGM, Jones SE, Moon TE: Tumor stem cells and adjuvant chemotherapy: Perspectives in 1981. In: **Adjuvant Therapy of Cancer III**, Salmon SE, Jones SE (eds). Grune & Stratton, Inc: New York, pp. 13-23, 1981.
16. **Alberts DS**: Perspectives on adjuvant therapy of head and neck cancer. In: **Adjuvant Therapy of Cancer III**, Salmon SE, Jones SE (eds). Grune & Stratton, Inc: New York, pp. 191-197, 1981.
17. Jones SE, Salmon SE, **Alberts DS**, Meyskens FL Jr, Durie BGM, Chen HSG: *In vitro* phase II trial of vinca alkaloids. In: **Proceeds of the International Vinca Alkaloid Symposium - Vindesine**, Brade W, Nagel GA, Seeber S (eds). Karger Press: Frankfurt, pp. 53-58, 1981.
18. Salmon SE, Silvestrini R, **Alberts DS**, Sanfilippo O, Kaufmann M, Bonmassar E, Giovanella BC, Fostad O: Methods for testing sensitivity of human tumors to anticancer drugs. In: **Current Chemotherapy and Immunotherapy**, Periti P, Grassi GG (eds). American Society for Microbiology: Washington, DC, pp. 1230-1235, 1982.
19. **Alberts DS**, Salmon SE, Moon TE: Human tumor cloning: Drug sensitivity testing and clinical correlations. In: **Progress in Clinical Cancer**, Ariel IM (ed). Grune & Stratton, Inc: New York, pp. 147-179, 1982.
20. **Alberts DS**, Mason NL, O'Toole R, Neff J, Hilgers RD, Carlin D, Moon TE: A randomized trial of doxorubicin and cyclophosphamide plus BCG vs. doxorubicin and cyclophosphamide therapy of advanced ovarian cancer. In: **Immunotherapy of Human Cancer: Present Status of Trials in Man**, Terry W (ed). Elsevier/North Holland Press: New York, pp. 343-350, 1982.
21. Dorr RT, **Alberts DS**: Pharmacology of Doxorubicin. In: **Current Concepts in the Use of Doxorubicin Chemotherapy**, Jones SE (ed). Farmitalia Carlo Erba: Milan, pp. 3-20, 1982.
22. **Alberts DS**, Surwit EA: Mitomycin-C, bleomycin, vincristine and cisplatin combination therapy for advanced, recurrent cervix cancer: A Southwest Oncology Group Pilot Study. In: **Mitomycin-C**, Rozenweig M (ed). Raven Press: New York, pp. 127-134, 1983.
23. **Alberts DS**, Peng YM, Leigh SA, Davis TP, Woodward DL: Pharmacokinetics of mitoxantrone in cancer patients. In: **Proceeds of the 13th International Congress on Chemotherapy**, Karrer, Spitzky (eds). Verlag H. Egermann: Vienna, Austria, 1983.

24. **Alberts DS**, Peng YM, Leigh SA, Davis TP, Woodward DL: Pharmacokinetics of bisantrene in cancer patients. In: **Proceeds of the 13th International Congress on Chemotherapy**, Karrer, Spitzzy (eds). Verlag H. Egermann: Vienna, Austria, 1983.
25. **Alberts DS**, Surwit EA, Salmon SE: Pharmacologic studies in ovarian cancer using a human tumor clonogenic assay. In: **Proceeds of the 13th International Congress on Chemotherapy**, Karrer, Spitzzy (eds). Verlag H. Egermann: Vienna, Austria, 1983.
26. Aapro MS, Plezia PM, **Alberts DS**, Graham VG, Jones SE, Surwit EA, Moon TE: Double-blind crossover study of the antiemetic efficacy of high-dose oral dexamethasone versus high-dose oral metoclopramide. In: **Proceeds of the 13th International Congress on Chemotherapy**, Karrer, Spitzzy (eds). Verlag H. Egermann: Vienna, Austria, 1983.
27. **Alberts DS**, Mackel C, Peng YM, Davis TP: Phase I clinical investigation and preliminary pharmacokinetics of 9, 10 anthracenedicarboxaldehyde bis (4, 5-dihydro-1H-imidazol-2-yl) hydrazone] dihydrochloride (bisantrene) with correlative *in vitro* human tumor clonogenic assay. In: **New Anthracene Drugs**, Rozenzweig M (ed). Raven Press: New York, pp. 149-173, 1983.
28. **Alberts DS**: Doxorubicin in the management of gynecologic cancer. In: **Current Concepts in the Use of Doxorubicin Chemotherapy**, Jones SE (ed). Farmitalia Carlo Erba: Milan, pp. 343-350, 1983.
29. Surwit EA, **Alberts DS**, Salmon SE: Studies of ovarian cancer utilizing the human tumor stem cell assay. In: **Cancer of the Ovary, Cancer Campaign**, Fischer G (ed). Verlag, Stuttgart: New York, 7:59-70, 1983.
30. Meyskens FL Jr, **Alberts DS**, Aapro MS, Surwit EA: Clinical studies of vitamin A and its synthetic derivatives in cancer prevention and treatment at the University of Arizona. In: **Modulation and Mediation of Cancer by Vitamins**, Meyskens FL, Prasad K (eds). Karger: New York, pp. 306-310, 1983.
31. Goodman GE, **Alberts DS**, Peng YM, Beaudry J, Einspahr J, Leigh S, Miles NJ, Davis TP, Meyskens FL: Pharmacokinetics and phase I trial of retinol and 13-*cis*-retinoic acid. In: **Modulation and Mediation of Cancer by Vitamins**, Meyskens FL, Prasad KN (eds). Karger: New York, pp. 311-316, 1983.
32. Meyskens FL Jr, **Alberts DS**, Salmon SE: Modulation of human solid tumor colony forming units by retinoids. In: **Modulation and Mediation of Cancer by Vitamins**, Meyskens FL, Prasad K (eds). Karger: New York, pp. 223-227, 1983.
33. **Alberts DS**, Leigh SA, Surwit EA, Serokman R, Moon TE, Salmon SE: Improved survival of patients with relapsing ovarian cancer treated on the basis of drug selection following human tumor clonogenic assay. In: **Human Tumor Cloning**, Salmon SE, Trent JM (eds). Grune & Stratton, Inc: New York, pp. 509-520, 1984.
34. Surwit EA, **Alberts DS**, Salmon SE: Use of human stem cell assay in gynecologic cancer chemotherapy. In: **Chemotherapy of Gynecologic Cancer**, Deppe G (ed). Alan R. Liss, Inc: New York, pp. 301-320, 1984.
35. **Alberts DS**: Adjuvant therapy of ovarian cancer. In: **Adjuvant Therapy of Cancer IV**, Salmon SE, Jones SE (eds). Grune & Stratton, Inc, pp. 507-519, 1984.
36. Dalton WS, **Alberts DS**: The physiologic disposition and phase I studies of mitoxantrone. In: **Pharmanual - A Comprehensive Guide to the Therapeutic Use of Mitoxantrone**, Sieber & McIntyre, Inc: New Jersey, pp. 75-86, 1984.
37. Ludwig R, **Alberts DS**, Salmon SE: Pharmacology phase II studies and new drug development. In: **Recent Results in Cancer Research**, Springer-Verlag: Heidelberg 94:202-204, 1984.
38. Welander CE, **Alberts DS**: Clonogenic assay studies of tumor cells from gynecologic malignancies. In: **Cancer of the Female Reproductive System**, Williams CJ (ed). John Wiley & Sons, Ltd, 1985.

39. **Alberts DS**, Aristizabal SA, Weiner SA, Surwit EA: Cervical Cancer: Bleomycin studies - An overview. In: **Bleomycin Chemotherapy**, Sikic BI, Rozenzweig M., Carter SK (eds). Academic Press, Inc, pp. 227-237, 1985.
40. **Alberts DS**, Young L, Salmon S: Comparative activity of anticancer drugs administered by the intraperitoneal route for the treatment of advanced ovarian cancer. In: **Recent Advances in Chemotherapy. Proceeds of the 14th International Congress of Chemotherapy**, Kyoto, pp. 270-272, 1985.
41. **Alberts DS**, Coulthard SW, Meyskens FL Jr: Regression of aggressive laryngeal papillomatosis with 13-cis-retinoic acid. In: **Recent Advances in Chemotherapy. Proceeds of the 14th International Congress of Chemotherapy**, Kyoto, pp. 677-679, 1985.
42. **Alberts DS**, Peng YM, Bowden GT, Mackel C, Dalton WS: Mechanism of action and pharmacokinetics of novantrone in intravenous and intraperitoneal therapy. In: **Advances in Chemotherapy: The Current Status of Novantrone**, Coltman C (ed). Park Row Publishers: New York, 1985.
43. **Alberts DS**, Edwards L, Peng YM, Serokman R, Davis TP, Meyskens FL Jr: Clinical toxicology pharmacokinetics of 13-cis-retinoic acid administered chronically at low doses expected for cancer chemoprevention trials. In: **Vitamins and Cancer**, Prasad K, Meyskens FL Jr (eds). Humana Press: Clifton, NJ, pp. 245-255, 1985.
44. Weiner SS, Meyskens FL Jr, Surwit EA, **Alberts DS**, Levine NS: Response of human papilloma-associated diseases to retinoids (Vitamin A Derivatives). In: **Papillomavirus: Molecular and Clinical Aspects**, pp. 249-255, 1985.
45. **Alberts DS**, Surwit EA: Gynecologic Cancer. In: **Stein's Internal Medicine**, Little Brown and Co, Chapter 145, 1986.
46. Plezia PM, **Alberts DS**: Nausea and vomiting: Mechanisms and management. In: **Early and Late Effects of Cancer Treatment**, Vol. V, No. 1, WB Saunders Co: Sussex, 1986.
47. Moon TE, Rodney SR, Peng YM, **Alberts DS**, Meyskens FL: Design and compliance considerations of dietary intervention trials, Humana Press, pp. 267-281, 1986.
48. Dalton WS, **Alberts DS**: Physiologic disposition and phase I studies of mitoxantrone. In: **PharManual Novantrone II**, Sieber & McIntyre, Inc: Chicago, pp. 75-85, 1987.
49. **Alberts DS**, Aristizabal S, Surwit EA, Weiner S: Primary chemotherapy for high-risk recurrence cervix cancer. In: **Cervix Cancer**, Martinus Nijhoff Publishers: New York, pp. 161-183, 1987.
50. **Alberts DS**, Mason-Liddil N, Surwit EA, O'Toole RV, Kronmal R, Slymen DJ, Salmon SE: Stage III optimal disease ovarian cancer relatively resistant to adjuvant cisplatin chemotherapy *in vitro* and *in vivo*. In: **Adjuvant Therapy of Cancer V**, pp. 629-636, 1987.
51. Nierenberg D, Peng YM, **Alberts DS**: Methods for determination of retinoids, α -tocopherols, and carotenoids in human serum, plasma, and other tissues. In: **Nutrition and Cancer Prevention: Investigating the Role of Micronutrients**, Moon T, Micozzi M (eds). Marcel Dekker, Inc: New York, pp. 181-209, 1988.
52. **Alberts DS**, Surwit EA, Peng YM, McCloskey T, Graham V, Roe D: Phase I and pharmacokinetic study of mitoxantrone by intraperitoneal administration. In: **Die Lokoregionale Tumorthherapie - Moglichkeiten und Grenzen**, Seeber S, Aigner KR, Enghofer E (eds) (In German). Walter de Gruyter: Berlin, 1988.
53. Meyskens FL, Garewal HS, Sampliner R, **Alberts DS**: Premalignant lesions for esophagus and colon: Potential for chemoprevention. In: **Accomplishments in Oncology**, Herschowitz B (ed). JP Lippincott: Philadelphia, 13:136-148, 1988.

54. **Alberts DS**, Slymen DJ, Salmon SE: *In vitro* chemosensitivity and survival of patients with previously untreated, advanced ovarian cancer. 2nd International Symposium: Multimodality Treatment of Ovarian Cancer, Genova, Italy, EORTC Monograph, Raven Press, Sept. 24-26, 1987. In: **Multimodal Treatment of Ovarian Cancer**, Conte PF (ed). Raven Press: New York, pp. 211-217, 1989.
55. Welander CE, Jones CM, **Alberts DS**, Salmon SE: *In vitro* sensitivity of human endometrial cancer to cytotoxic and biologic agents. In: **Endometrial Cancer**, Surwit E, **Alberts D** (eds). Kluwer Academic Publishers: Boston, pp. 117-126, 1989.
56. Earnest DL, **Alberts DS**, Hixson LJ, Meyskens FL: Dietary fiber or piroxicam as potential cancer prevention agents: Effects on rectal epithelial cell proliferation in humans at increased risk of colon cancer. In: **Hereditary Colorectal Cancer**, Utsunomiya J, Lynch HT (eds). Springer-Verlag: Tokyo, pp. 275-282, 1990.
57. Ozols RF, Kavanaygh JJ, **Alberts DS**, Waltshaw E, Eisenhaur EA: Questions and Answers. In: **Carboplatin Textbook**, WB Saunders Co, Science and Medicine: New York, 1990.
58. Garewal HS, Meyskens FL Jr, **Alberts DS**, Friedman S, Pitcock J: Potential role of Vitamin A related compounds in oral cancer. In: **Adjuvant Therapy of Cancer VI**, Salmon SE (ed). WB Saunders Co, pp. 109-116, 1990.
59. Surwit EA, Childers JM, **Alberts DS**, Graham V: Short-term dose-intensive adjuvant therapy with cisplatin for advanced ovarian carcinoma. In: **Adjuvant Therapy of Cancer VI**, Salmon SE (ed). WB Saunders Co, 1990.
60. **Alberts DS**: Adjuvant therapy of epithelial ovarian cancer. In: **Adjuvant Therapy of Cancer VI**, Salmon SE (ed). WB Saunders Co, pp. 491-500, 1990.
61. **Alberts DS**, Green SJ, Hannigan EV, O'Toole R, Mason-Liddil N, Surwit EA, Stock-Novack D, Goldberg R, Malviya VK, Nahhas WA, Pugh RP, Guy JT, Dakhil SR: Improved efficacy of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Preliminary report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV suboptimal ovarian cancer. In: **Carboplatin (JM-8): Current Perspectives and Future Directions**, Bunn PA, Canetta R, Ozols RF, Rozenzweig M (eds). WB Saunders Co, pp. 163-164, 1990.
62. Green JB, Green S, **Alberts DS**, O'Toole R, Surwit EA, Noltimier JW: Carboplatin therapy in advanced endometrial cancer: A Southwest Oncology Group phase II study. In: **Carboplatin (JM-8): Current Perspectives and Future Directions**, Bunn PA, Canetta R, Ozols RF, Rozenzweig M (eds). WB Saunders Co, pp. 113-121, 1990.
63. **Alberts DS**, Roe D, Plezia P, Kuhn J, Davis L: Prospective evaluation of a predictive model for plasma concentration-versus-time profiles of investigational anticancer drugs in patients. In: **Anticancer Drug Discovery and Development**, Valeriote F, Corbett T, Baker L (eds). Kluwer Academic Publishers: Norwell, MA, 1991.
64. Plezia PM, Xu MJ, **Alberts DS**, Peng YM, Sayers S, Liu Y: The importance of serum and tissue pharmacology in the design and interpretation of chemoprevention trials. In: **Chemoimmuno Prevention of Cancer**, Pastorino U, Hong WK (eds). Thieme Medical Publishers, Inc: New York, pp. 73-77, 1991.
65. Vargas PA, **Alberts DS**: Clinical trials on colorectal cancer. In: **Macronutrients: Investigating their Role in Cancer**, Moon T, Micozzi M (eds). Marcel Dekker, Inc: New York, pp. 407-421, 1992.
66. Earnest DL, Hixson LJ, Finley PR, Blackwell GG, Einspahr J, Emerson SS, **Alberts DS**: Arachidonic acid cascade inhibitors in chemoprevention of human colon cancer: Preliminary studies. In: **Cancer Chemoprevention**, Wattenberg L, Lipkin M, Boone CW, Kelloff GJ (eds). CRC Press, pp. 165-180, 1992.
67. **Alberts DS**, Einspahr JG, McGee DL, Hixson LJ, Davidson J, Emerson S, Earnest DL: Reproducibility of [³H]-thymidine labeling index determinations in rectal mucosal crypt organ culture. In: **Calcium, Vitamin D, and Prevention of Colon Cancer**, Lipkin M, Newmark HL, Kelloff G (eds). CRC Press, pp. 327-337, 1991.

68. **Alberts DS**, Buller MK, Rosenbaum E, Dollinger M, Newell G: Cancer prevention, screening and risk assessment. In: **Everyone's Guide To Cancer Therapy**, 1991.
69. **Alberts DS**, Dorr RT, Von Hoff DD: Pharmacology and therapeutics in gynecologic cancer. In: **Principles and Practice of Gynecologic Oncology**, Hoskins W, Perez C, Young R (eds). JB Lippincott Co: Philadelphia, pp. 289-331, 1992.
70. Garewal H, Meyskens F, Katz R, Friedman S, **Alberts D**, Morse D: Beta-carotene and other antioxidant nutritional agents in oral leukoplakia. In: **Proceeds of the 4th International Conf. on Cancer Prevention**, 1993.
71. **Alberts DS**, Katsenes K, Garcia D: Adjuvant therapy of ovarian cancer. In: **Adjuvant Therapy of Cancer VII**, Salmon SE (ed). JB Lippincott Co: Philadelphia, PA, pp. 335-344, 1993.
72. Garewal H, Friedman S, Meyskens F, **Alberts D**: Emerging role of beta-carotene and antioxidant nutrients in oral cancer prevention. In: **Adjuvant Therapy of Cancer VII**, Salmon SE (ed). JB Lippincott Co: Philadelphia, pp. 72-81, 1993.
73. Dorr RT, **Alberts DS**: Multifactorial mechanisms of resistance to mitomycin C and pilot trial of megestrol acetate as a MDR modulator. In: **The Mechanism and New Approach on Drug Resistance of Cancer Cell**, Miyazaki T, Takaku F, Sakuraka K (eds). Elsevier Science Publishers: pp. 243-254, 1993.
74. **Alberts DS**, Buller MK, Rosenbaum E, Dollinger M, Newell G: Cancer prevention, screening and risk assessment. In: **Everyone's Guide To Cancer Therapy (2nd ed)**, Dollinger M, Rosenbaum EH, Cable G (eds). Andrews and McMeel: Kansas City, pp. 233-246, 1994.
75. **Alberts DS**: Carboplatin versus cisplatin in the chemotherapy of solid tumors - pro carboplatin. In: **Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2**, Pinedo HM, Schornagel JH (eds). Plenum Press: New York, pp. 303-309, 1996.
76. **Alberts DS**, Speicher LA, Garcia DJ, Dorr RT, Von Hoff DD: Pharmacology and therapeutics in gynecologic cancer. In: **Principles and Practice of Gynecologic Oncology (2nd ed)**, Hoskins WJ, Perez CA, Young RC (eds). JB Lippincott-Raven Publishers: Philadelphia, pp. 399-455, 1997.
77. **Alberts DS**, Garcia DJ: Adjuvant therapy of ovarian cancer-is there reason for optimism? In: **Adjuvant Therapy of Cancer VIII**, Salmon SE (ed). Lippincott-Raven Publishers: Philadelphia, pp. 207-216, 1997.
78. Sutton G, Piver MS, Goldberg J, **Alberts D**, Loescher L, Gallion HH, Lynch HT, Carlson J, Dunton C, Hopkins M: Family history of ovarian and breast cancer. In: **Expert Consultations in Gynecological Cancers**, Markman M, Belinson JL (eds). Marcel Dekker: New York, pp. 9-18, 1997.
79. Burger RA, Ball HG, Cagnoni PJ, Shpall EJ, **Alberts D**, Randall ME, Reichman BS: Microscopic residual ovarian cancer at second-look laparotomy. In: **Expert Consultations in Gynecological Cancers**, Markman M, Belinson JL (eds). Marcel Dekker: New York, pp. 314-326, 1997.
80. **Alberts DS**, Buller MK, Rosenbaum E, Dollinger M, Newell G: Risk assessment, cancer screening and prevention. In: **Everyone's Guide To Cancer Therapy (3rd edition)**, Dollinger M, Rosenbaum EH, Cable G (eds). Andrews McMeel Publishing: Kansas City, pp. 261-277, 1997.
81. **Alberts DS**, Liu PY, Hannigan EV, Garcia D, Rothenberg M: The role for intraperitoneal chemotherapy in the management of ovarian cancer. In: **Ovarian Cancer 5**, Sharp F, Blackett T, Berek J, Bast R (eds). ISIS Medical Media: Oxford, pp. 333-340, 1998.
82. Martinez ME, Marshall JR, **Alberts DS**: Dietary fiber, carbohydrates, and cancer. In: **Nutritional Oncology**, Heber D, Blackburn GL, Go VL (eds). Academic Press: San Diego, pp. 185-194, 1999.
83. Marshall JR, **Alberts DS**: Future strategies for the medical prevention of colorectal cancer. In: **Colorectal Cancer: Molecular Mechanisms, Premalignant State and Its Prevention** (Falk Symposium 109, Titisee, Germany, Oct. 14-15, 1998), Schmiegel W, Schlömerich J (eds). Kluwer Academic Publishers: Hingham, MA, pp. 267-276, 1999.

84. **Alberts DS**, Garcia DJ, Fisher E, Liu PY: Southwest Oncology Group experience with intraperitoneal chemotherapy of ovarian cancer. In: **Regional Chemotherapy: Clinical Research and Practice**, Markman M (ed). Humana Press: Totowa, NJ, pp. 179-191, 2000.
85. **Alberts DS**, Speicher LA, Garcia DJ, Dorr RT, Von Hoff DD: Pharmacology and therapeutics in gynecologic cancer. In: **Principles and Practice of Gynecologic Oncology (3rd edition)**, Hoskins WJ, Perez CA, Young RC (eds). Lippincott Williams and Wilkins: Philadelphia, PA, pp. 425-492, 2000.
86. **Alberts DS**, Garcia DJ, Delforge AE: Intraperitoneal chemotherapy. In: **Cancer Treatment, 5th Edition**, Haskell CM, Berek JS (eds). W.B. Saunders Company: Philadelphia, PA, pp. 232-235, 2001.
87. Martinez ME, Giovannucci E, **Alberts DS**: Prevention of colorectal cancer: Epidemiological evidence and chemoprevention. In: **Atlas of Clinical Oncology: Cancer of the Lower Gastrointestinal Tract**, Willet CG (ed.). BC Decker Inc: Hamilton, ON, pp. 7-32, 2001.
88. **Alberts DS**, Loescher LJ: Cancer prevention and screening, risk assessment. In: **Everyone's Guide to Cancer Therapy, 4th edition**, Dollinger M (ed). Andrews McMeel Publishing: Kansas City, MO, pp. 325-342, 2002.
89. Stratton MS, Stratton SP, Ranger-Moore J, Einspahr JG, Bowden GT, **Alberts DS**: Strategies in skin cancer chemoprevention. In: **Cancer Chemoprevention Volume 2: Strategies for Chemoprevention**, Kelloff GJ, Hawk ET and Sigman CC (eds). Humana Press, 2005.
90. Stratton MS, Stratton SP, Dionne SO, Thompson P, Jongewaard IN, Hakim I, Dilley T, Garland L, Ranger-Moore J, **Alberts DS**: Treatment of carcinogenesis. In: **Principles of Molecular Oncology, 2nd edition**, Bronchud MH, Foote MA, Giaccone G, Olopade O, Workman P (eds). Humana Press, Totowa, NJ, 2004 pp 607-674.
91. **Alberts DS**, Barakat RR, Daly M, Method MW, Benbrook DM, Boggess JF, Brewer MA, Brinton LA, Castle PE, Davanipour Z, Garcia FAR, Hanley MG, Hess LM, Hines JF, Keleghan J, Lucci J, Minasian L, Muller C, Mutter GL, Rader JS, Rodriguez G, Sobel E, Walker JL: Prevention of Gynecologic Malignancies. In: **Gynecologic Cancer: Controversies in Management**, Gershenson, Gore, McGuire, Quinn, Thomas (eds). Elsevier Press, Philadelphia, 2004.
92. **Alberts DS**, Hess LM, Von Hoff DD, Dorr RT: Pharmacology and therapeutics in gynecologic cancer. In: **Principles and Practice of Gynecologic Oncology**. Hoskins, Perez, Young, Barakat, Markman, Randall (eds). 4th Edition, Lippincott, Williams and Wilkins, Philadelphia, 2005.
93. Stratton MS, Stratton SP, Ranger-Moore J, Einspahr J, Bowden GT, **Alberts DS**: Strategies in Chemoprevention of Nonmelanoma Skin Cancer. In: **Cancer Chemoprevention, vol. 2: Strategies for Cancer Chemoprevention**. Kelloff GJ, Hawk ET, Sigman CC (eds), Humana Press Inc.: Totowa, NJ, 2005.
94. **Alberts DS**, Walker J, Rodriguez G, Garcia F, Mutter GL, Plaxe S, Carlson J, Hensley M, Trimble C, Hess LM, Greene MH, Method MM and Barakat RR: Prevention of gynecologic cancer. In: **GOG Monograph. 7th Edition**, DiSaia PJ (ed), In Press, 2006.
95. **Alberts DS**: Intraperitoneal Chemotherapy for Advanced Ovarian Cancer: Finally, a Standard of Care! In: **Intraperitoneal Therapies for Ovarian and Other Intraperitoneal Cancers**. Helm WC (ed), In Press, 2006.
96. **Alberts D**, Walker J, Barakat R: Prevention of gynecologic cancer. In: **The Gynecologic Oncology Group: Report of 35 Years of Excellence in Clinical Research**, pp 60-72, 2006.
97. Stratton MS, Stratton SP, Bowden T, **Alberts DS**: Organ specific cancer control, nonmelanoma. In: **A Publication of the American Society of Clinical Oncology, Chapter 25**, In press, 2007.
98. **Alberts DS**, Hess LM: Introduction to cancer prevention. In: **Fundamentals of Cancer Prevention, 2nd Edition**; **Alberts DS** and Hess LM (eds.), Springer-Verlag, 2008.
99. Lluria-Prevat M, **Alberts DS**: Skin cancer prevention. In: **Fundamentals of Cancer Prevention**, **Alberts DS** and Hess LM (eds), Springer-Verlag: New York, 2005.

100. Jeter JM, **Alberts DS**: Cancer risk assessment, screening, and prevention. In: *Everyone's Guide to Cancer Therapy: How Cancer is Diagnosed, Treated and Managed Day to Day*, Ko AH, Dollinger M, Rosenbaum EH (eds), Andrews McMeel Publ., 2008.
101. Jeter JM, **Alberts DS**: Difluoromethylornithine: The Proof is in the Polyamines. An invited perspective on CAPR-12-0233, A Phase III Skin Cancer Chemoprevention Study of DFMO: Longterm Follow-up of Skin Cancer Events and Toxicity. In Press, *Cancer Prevention Research*, 2012.
102. Hess LM, Chambers SK, **Alberts DS**: Role of Intraperitoneal Chemotherapy for Ovarian Cancer. In: *Principles & Practice of Oncology Updates, 8th Edition*. DeVita V, Lawrence T and Rosenberg S (eds.) Lippincott Williams & Wilkins, 2008.
103. Bowden GT, **Alberts DS**: Targeting UVB Medicated Signal Transduction Pathways for the Chemoprevention of Squamous Cell Carcinoma. In: *Chemoprevention of Squamous Cell Carcinoma*, Springer, 2009.
104. Romagnolo D. Bioactive Compounds and Cancer. In Press. Springer-Verlag, 2010.
105. Bowden GT and **Alberts DS**. Targeting UVB Mediated Signal Transduction Pathways for the Chemoprevention of Squamous Cell Carcinoma. In *Signaling Pathways in Squamous Cancer*. (Glick, Adam B; Waes, Carter Van, Eds.) 2011.
106. **Alberts DS**, Calvert H, Lloria-Prevatt M, Sugarbaker P, Monk BJ. Pharmacology and therapeutics in gynecologic cancer in: *Principles and Practice of Gynecologic Oncology, 6th edition* , Barakat, Berchuck, Markman, Randell, eds. 2013.

F. EDITORIALS

1. Aapro MS, **Alberts DS**: Dexamethasone as an antiemetic in patients treated with cisplatin. *N Engl J Med* 305:520, 1981.
2. Salmon SE, **Alberts DS**, Meyskens FL Jr, Moon TE: Human tumor stem cell assay (letter). *N Engl J Med* 308:1478, 1983.
3. Salmon SE, Meyskens FL Jr, **Alberts DS**: Comparison of assays used for *in vitro* chemosensitivity testing of human tumours. *Br J Cancer* 50:725, 1984.
4. Meyskens FL Jr, Moon TE, **Alberts DS**, Ritenbaugh C: The risk of cancer and serum vitamin A and E and carotenoids (letter). *N Engl J Med* 311:121, 1984.
5. **Alberts DS**: Editorial. *Invest New Drugs* 3:81-84, 1985.
6. Plezia PM, **Alberts DS**: Integrated approach to cancer pain treatment. *Hosp Therapy* 10:20-25, 1985.
7. **Alberts DS**: Mitoxantrone: It's development and role in clinical practice (commentary). *Oncology*, 1989.
8. **Alberts DS**: Intraperitoneal chemotherapy: A new treatment approach for ovarian cancer (letter). *Arizona Cancer Center's Clinical Research Newsletter* pp. 1-2, 1989.
9. **Alberts DS**, Kirkwood JM: Therapeutic modalities. *Curr Opin Oncol* 2:1105-1108, 1990.
10. Muggia FM, **Alberts DS**: Intraperitoneal therapy in ovarian cancer: Time's not up. *J Clin Oncol* 9(8):1510-1, 1991.
11. **Alberts DS**: Prediction of drug resistance in cancer chemotherapy (commentary). *Oncology* September, 1991.
12. **Alberts DS**: Intraperitoneal therapy. Adis International Limited, Auckland, New Zealand, 1991.
13. **Alberts DS**: Prevention of colon cancer: Fat, fiber, and fantasy. Adis International Limited, Auckland, New Zealand, 1991.
14. **Alberts DS**: Best papers on ovarian cancer - 1991. *Cancer Invest* 10:603-604, 1992.

15. Potter JD, **Alberts DS**, et al: Report of group A of the American Cancer Society Research Workshop on cancer and nutrition: Panel on human studies. *Cancer Res* 53(Suppl): 2449s-2451s, 1993.
16. Giuliano A, **Alberts D**: Cancer prevention among US Hispanics. *Arch Intern Med* 154:1057-1058, 1994.
17. Clark LC, **Alberts DS**: Selenium and cancer: Risk or protection? *J Natl Cancer Inst* 87:473-475, 1995.
18. Marshall JR, **Alberts DS**, Sampliner RE: Colon cancer reduction: Questions about implementation of proven techniques. *Arch Intern Med* 157:1919-1920, 1997.
19. **Alberts DS**: Tumor heterogeneity and extreme drug resistance: Meet your match! *Cancer J Sci Am* 4:10-11, 1998.
20. **Alberts DS**: In memoriam: Sydney E. Salmon, MD—As a scientist. *ASCO News* 12(1):34-35, 2000.
21. **Alberts DS**, Martinez ME, Roe DJ, Marshall JR, Sampliner RE, Hamilton SR, Issa JP, Batta AK, Salen G: Diet and colon cancer: Strike out the bran (editorial reply). *Gastroenterology* 119:590-591, 2000.
22. **Alberts DS**, Martinez ME, Marshall JR: High-fiber diet and colorectal adenomas. *N Engl J Med* 343:738, 2000.
23. **Alberts DS**: Boosting clinical trial enrollments. *Prim Care Cancer*, 2002.
24. Martinez ME, Marshall JR, **Alberts DS**: Commentary to “Calcium supplements have no significant impact on colorectal adenoma recurrence, but fiber may increase recurrence risk” by Bonithon-Kopp C et al. *Evidence-based Oncology*, 2002.
25. **Alberts DS**, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB: Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come! *J Clin Oncol* 20:3944-3946, 2002.
26. Bleyer A, **Alberts DS**: Re: Sodium thiosulfate in cisplatin overdose by Erdlenbruch B et al., *Med Pediatr Oncol* 2002;38:349-352 (letter to the editor). *Med Pediatr Oncol* 40:413, 2003.
27. Potter JD, **Alberts DS**: An “Odd Couple” to lead CEBP. *Cancer Epidemiol Biomarkers Prev* 12:1, 2003.
28. **Alberts DS**: Intraperitoneal chemotherapy for stage III ovarian cancer (reply to letter to the editor). *J Clin Oncol* 21:957-958, 2003.
29. Metz DC, **Alberts DS**: Gastrointestinal cancer prevention in the United States: the road ahead. *Cancer Epidemiol Biomarkers Prev* 12(2):81-3, 2003.
30. Jacobs ET, Martinez ME, **Alberts DS**: Research and public health implications of the intricate relationship between calcium and vitamin D in the prevention of colorectal neoplasia. *J Natl Cancer Inst* 95:1736-1737, 2003.
31. Potter JD, **Alberts DS**: One year and counting: a status report from John and Dave. *Cancer Epidemiol Biomarkers Prev* 13:1, 2004.
32. Jacobs B, Martinez EM, **Alberts DS**: Response to Dr. Heaney. *J Natl Cancer Inst* 96(10):806, 2004.
33. **Alberts DS**: Case discussion #1, 2nd Int Gynecol Cancer Society Tumor Board, International Gynecologic Cancer Society, 2004.
34. **Alberts DS**: Letter to the Editor: Response to “Two Steps Forward in the Treatment of Colorectal Cancer” by Mayer RN, *N Engl J Med* 350:2406-8, 2004.
35. Fruehauf JP, **Alberts DS**: In vitro drug resistance versus chemosensitivity: two sides of different coins. (letter to the editor: Response to ASCO Technology Assessment: Chemotherapy Sensitivity and Resistance Assays). *J Clin Oncol* 23(15):3641-3, 2005.
36. **Alberts DS**, Potter JD: The State of CEBP 2005. In: *Cancer Epidemiology, Biomarkers and Prevention* 14(1):1, 2005.
37. **Alberts DS**, Potter JD, Martinez E, Hess, LM, Stopeck A, Lance P: What happened to the coxibs on the way to the cardiologist? *Cancer Epidemiology, Biomarkers Prev* 14(3):555-6, 2005.

38. Greenberg ER, **Alberts DS**, Potter JD: What should we do now about H. pylori? *Cancer Epidemiology, Biomarkers and Prevention* 14(8):1851-2, 2005.
39. Chambers SK, **Alberts DS**, Hatch KD: RESPONSE: Re: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes in optimally debulked advanced ovarian cancer: a randomized clinical trial. *JNCI* 97(21):1622-1623, 2005.
40. Stratton SP, Stratton MS, and **Alberts DS**: Promising agents for chemoprevention of skin cancer. In: *Updates and Developments in Oncology*. *Current Oncology* 13(5):185-186, 2006.
41. **Alberts DS**: Second cancers are killing us! In: *Cancer Epidemiol Biomarkers Prev Focus: Second Primary Cancers* 15(11):2019, 2006.
42. Goodman G, Meyskens F, **Alberts DS**: Retinol, vitamins and cancer prevention, 25 years of learning and relearning. Invited Editorial, *J Clin Oncol*, 2008 Nov 3 [Epub ahead of print]. PMID 18981460.
43. **Alberts DS**. "High time" for a phase III, dosing schedule trial in U.S. women. *Oncology News*, 2010.
44. Milner JA and Romagnolo D. (Ed). **Alberts DS** and Lloria-Prevatt, M. In: *Bioactive Compounds and Cancer*, *Humana Press*, 2010
45. **Alberts DS**, Crano SL. "Personalized Medicine in Oncology: An oncologist and his patient team up to share their major success against all odds." *Southern California Clinician*, 2012.

G. PAMPHLETS/MONOGRAPHS

1. **Alberts DS**: Alkeran[®] (melphalan). Burroughs Wellcome Co., 1986.
2. **Alberts DS**, Dresser RK, Frogge MH, Goodman M, Gralla RJ, Greco FA, Kessler JF, Legha SS, Miller S, Nirenberg A, Noell L, Plezia PM, Purl S, Valdivieso M, Vogl SE, Williams SD: Outpatient administration of platinol[®] (cisplatin for injection). Bristol-Myers Oncology Division, 1987.
3. **Alberts DS**, Dresser RK, Goodman M, Gralla RJ, Greco FA, Griffin J, Kessler JF, Legha SS, Miller S, Nirenberg A, Noell L, Plezia PM, Purl S, Valdivieso M, Vogl SE, Williams SD: Office administration of platinol[®] (cisplatin for injection). Bristol-Myers Oncology Division, 1987.
4. **Alberts DS**, Peng YM, McCloskey TM, Dalton WS, Bowden GT: Monograph for Novantrone: Mechanisms of action and pharmacokinetics of Novantrone after intravenous and intraperitoneal therapy. Lederle Laboratories, 1988.
5. **Alberts DS**: Carboplatin in the treatment of ovarian cancer. Bristol-Myers, 1988.
6. **Alberts DS**, Dalton WS: Novantrone: Mechanism of action and drug resistance. Lederle Laboratories, 1988.
7. **Alberts DS**: Paraplatin[®] (carboplatin for injection) in the treatment of ovarian cancer. Bristol Myers Company, 1989.
8. Aisner J, **Alberts DS**, Dalke P, Martin G, Ozols RF, Whitacre MY, Xistris D, Yarbo CH: Guide to outpatient administration of paraplatin[®] (carboplatin for injection). Bristol-Myers Squibb Company, 1990.
9. **Alberts DS**, Garcia D: Advances in the treatment of colon cancer. The Arizona Cancer Center's Clinical Research Newsletter, August, 1990.
10. **Alberts DS**, Hannigan E, Surwit E, et al: The cost of adverse reactions to the platinum analogues cisplatin and carboplatin. Bristol-Myers, 1990.
11. Kreisle WH, **Alberts DS**: Mitoxantrone in the treatment of acute leukemia. *Contemporary Oncology*, 1991.

12. **Alberts DS**, Braly PS, Surwit EA, Sutton GP: Optimal dosing of carboplatin in ovarian cancer. Bristol-Myers, 1992.
13. Earnest DL, Hixson LJ, **Alberts DS**: Piroxicam and other cyclooxygenase inhibitors: Potential for cancer chemoprevention. Proc Bladder Chemoprevention Conf, NCI, 1992.
14. Pinkel D, Schilsky RL, Saral R, Armitage JO, **Alberts DS**: Current clinical guide. Burroughs Wellcome, 1992.
15. Pinkel D, Schilsky RL, Saral R, Armitage JO, **Alberts DS**: Current clinical guide including investigational applications. Burroughs Wellcome, 1992.
16. Dorr RT and **Alberts DS**: Use of estimated creatinine clearance for dose adjustments with renally eliminated anticancer agents. Bristol-Myers Squibb Company, 1993.
17. **Alberts DS**, Gabrilove JL: Colony-stimulating factors and their expanding role in chemotherapy. Triclinica Communication Inc, 1993.
18. **Alberts DS**, Garcia DJ: Management of ovarian cancer: An overview. Bristol-Myers Squibb Company, 1993.
19. Barlogie B, Kyle RA, Salmon S, **Alberts DS**, McIntyre OR, Dunbar CE: IV alkeran melphalan hydrochloride for injection: Proceedings of a roundtable discussion. Burroughs Wellcome, 1993.
20. **Alberts DS**, Garcia DJ: Phase III studies of cancer chemopreventive agents: Is there reason to remain optimistic? ASCO Ed Book, Dallas, TX, May 14-17, pp. 20-23, 1994.
21. Ozols RF, **Alberts DS**, Hoskins WJ, McGuire WP: Ovarian cancer: An updated management overview. Bristol-Myers Squibb Company, 1994.
22. Clark LC, Giuliano A, Walsh B, de Zapien JG, **Alberts DS**, Meister J, Mason TJ: The Santa Cruz County community health survey. Arizona Dept. Health Services, 1994.
23. **Alberts DS**, Vargas PA: Chemoprevention of colon cancer. ASCO Ed Book, Los Angeles, CA, May 20-23, pp. 322-328, 1995.
24. **Alberts DS**: Wheat bran fiber: Colorectal cancer prevention potential. Clinical Research News Arizona Physicians 7(3), 1996.
25. **Alberts DS**: Management of recurrent ovarian cancer. Bristol-Myers Squibb Company, 1996.
26. **Alberts DS**: Foreword: Single Agent STEALTH liposomal doxorubicin in cancer. Current status and future applications. Proc Experts Roundtable Meeting, Tucson, AZ, Nov 22, 1996.
27. **Alberts DS** and Koeller J: Cisplatin and carboplatin's use in oncology practice: review of clinical and economic issues. Bristol-Myers Squibb Company, 1997.
28. **Alberts DS**, Bukowski RM, Vermorken JB, Budd GT (Editorial Board): Profiles in patient management with ethyol[®] (issues 1 and 2). Schering-Plough Pharmaceuticals, 1998.
29. **Alberts DS**: Advanced clinical trial design: The use of surrogate end point biomarkers in cancer chemoprevention clinical trials. ASCO Education Book, Atlanta, GA, May 15-18, 1999.
30. **Alberts DS**, Cella D, Hensley ML: Ethyol[®] (amifostine): Preventing and treating neuropathy. Ross Communications, in press, 2002.
31. Aldige CR, **Alberts DS**, Berdebes J, Blanchard JS, Bond JH, Levin B, Wender R: Confronting colorectal cancer: Action steps for change (Dialogue for Action, October 2002). Cancer Research Foundation of America, 2002.
32. **Alberts DS**, Burger RA, Coleman RL, Herzog TJ, Thigpen JT: Management of Gynecologic Cancers. Treatment Toxicities and the Role of Cytoprotection in Pelvic Malignancies: A CME Monograph. Proc. 2005 Pelvic Malignancies Advisory Panel, pgs. 7-24. The Center for Medical Knowledge, Inc. ajacobson@cmknowledge.com, November 1, 2005.

H. ABSTRACTS

1. **Alberts DS**, Bachur NR, Holtzman JL: Distribution and excretion of daunomycin (D) in man. AACR, San Francisco, CA, March 23-25, 1969. Proc Am Assoc Cancer Res 10:3 (#9), 1969.
2. **Alberts DS**, Serpic AA, Thompson WL: Hypocalcemia complicating acute leukemia. American Federation for Clinical Research, Atlantic City, NJ, May 3-4, 1969. Clin Res 17:399, 1969.
3. **Alberts DS**, Salmon SE: Multiple myeloma (MM) tumor cell kinetics and a new approach to cancer chemotherapy. AACR, Atlantic City, NJ, April 11-13, 1973. Proc Am Assoc Cancer Res 14:51 (#203), 1973.
4. **Alberts DS**, Golde DW: Perturbation of DNA synthesis in multiple myeloma (MM) cells following cell-cycle-nonspecific (CCNS) chemotherapy. Proc Am Assoc Cancer Res 15:111, 1974.
5. **Alberts DS**, van Daalen Wetters T: Phenobarbital inhibits cyclophosphamide antitumor activity. American Federation for Clinical Research, Atlantic City, NJ, May 3-4, 1975. Clin Res 23:335A, 1975.
6. **Alberts DS**, van Daalen Wetters T: Allopurinol potentiates cyclophosphamide Antileukemic activity. Proc Am Assoc Cancer Res 16:84, 1975.
7. **Alberts DS**, Salmon SE: Adriamycin-BCNU (A-B): Effective therapy for myeloma (MM) relapsing on alkylating agents. Proc Am Assoc Cancer Res 17:123, 1976.
8. van Daalen Wetters T, **Alberts DS**, Wood DA: Rubidazole (R) versus adriamycin (A): Studies of their efficacy ratio (ER) in the spleen colony assay (SCA) system. Proc Am Assoc Cancer Res 17:127, 1976.
9. **Alberts DS**, Gray J: *In vivo* effects of cyclophosphamide and adriamycin on mouse tumor cell cycle parameters using flow microfluorometry analysis. Flow Microfluorometry Workshop, Cancer Treat Rep 60:1981, 1976.
10. **Alberts DS**, Gray J: The *in vivo* effects of cytoxan and adriamycin on mouse tumor cell cycle parameters using FMF analysis, 1977.
11. **Alberts DS**: Adjuvant immunotherapy of ovarian cancer: A preliminary report. Proc Int Conf Adjuvant Therapy of Cancer, Tucson, AZ, 1977.
12. **Alberts D**, Chang S, Melnick L, Himmelstein K, Walson P, Gross J, Salmon S: Melphalan (M) disposition in man. Proc Am Assoc Cancer Res 18:508, 1977.
13. **Alberts DS**, Lynch PJ: Cutaneous plasmacytomas in myeloma: Relationship to tumor cell burden. Proc AMA, 1977.
14. Chang SY, Melnick LR, **Alberts DS**: HPLC analysis of L-PAM and its application to pharmacokinetics, degradation, and plasma protein binding. Am Chem Soc, Medicinal Chemistry Division 173:78, 1977.
15. **Alberts D**, Chen HS, Liu R, Chen J, Mayersohn M, Perrier D, Moon T, Gross J, Broughton A, Salmon S: Systemic absorption of bleomycin (BLEO) after intracavitary (IC) administration. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 19:77, 1978.
16. **Alberts DS**, Chang SY, Chen HSG, Gross JF, Walson PD, Moon TE, Salmon SE: Variability of melphalan (M) absorption in man. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 19:334, 1978.
17. Salmon SE, Hamburger AW, Soehnlen BJ, Schmidt HJ, **Alberts DS**: Primary bioassay of ovarian carcinoma stem cells. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 19:231, 1978.
18. Struck RF, Peng YM, Chen HS, **Alberts DS**: Cancer drug-supportive drug interactions. Effects of phenobarbital (PB) and allopurinol (AP) on plasma levels of cyclophosphamide (CPA) and its major metabolites in the mouse. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 19:30, 1978.
19. **Alberts D**, Peng YM, Moon T, Strohm G, Payne C, Bressler R: Carnitine prevention of adriamycin toxicity in mice. Proc Int Congress Pharmacology, Paris, France, July 16-21, 1978.

20. Chang SY, Larcom BJ, **Alberts DS**, Larsen B, Walson PD, Sipes IG: Mass spectrometric analysis of chlorambucil, its degradation products and metabolites in biological samples. Am Chem Soc, Medicinal Chemistry, 1978.
21. **Alberts DS**, Chang SY, Larcom BJ, Chen HSG, Larsen B, Sipes IG: Pharmacokinetics and metabolism of chlorambucil in man: A preliminary report. Proc Brit Assoc Surg Onc, London, England, Feb. 22-23, 1979.
22. **Alberts DS**, Chang SY, Chen HSG, Evans TL, Moon TE: Systemic availability of oral melphalan. Proc Brit Assoc Surg Onc, Cancer Treat Rev 6:51, 1979.
23. Peng YM, **Alberts DS**, Wood DA: Antitumor effects and pharmacokinetics of continuous infusion (Con) vs. intermittent (Int) bleomycin (Bleo). Proc Am Soc Clin Oncol and Am Assoc Cancer Res 20:50, 1979.
24. **Alberts DS**, Chen HSG, Moon TE, Cetas TC, Hall JN: Whole-body hyperthermia (heat)-cis-platinum (pt) synergism in a mouse tumor model. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 20:35, 1979.
25. **Alberts DS**, Peng YM: Effective simulation of the minimum cytotoxic concentrations of continuous infusion (CI) bleomycin (BLEO) with multiple subcutaneous injections (MSC) in cancer patients. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 20:432, 1979.
26. Salmon SE, Soehnen BJ, Durie BGM, **Alberts DS**, Meyskens FL, Chen HSG, Moon TE: Clinical correlations of drug sensitivity in tumor stem cell assay. Proc Am Soc Clin Oncol 20:340 (#C-202), 1979.
27. **Alberts D**, Chen G, Chang S, Mason N, Benz D, Larcom B, Gierke K: Melphalan toxicity and disposition following renal dysfunction in dogs, 1979.
28. **Alberts DS**: Prolongation of survival in ovarian cancer patients with chemoimmunotherapy: A SWOG study, 1979.
29. **Alberts DS**, Chen HSG, Salmon SE: A predictive *in vitro* tumor stem cell assay for anticancer drug activity in ovarian cancer patients. World Conf Clin Pharm Therap, Wembley, England, Aug. 3-9, 1980.
30. Salmon SE, **Alberts DS**, Meyskens FL Jr, Durie BGM, Jones SE, Soehnen BJ, Young L: A new concept: *In vitro* phase II trial with the human tumor stem cell assay (HTSCA). Proc Am Soc Clin Oncol and Am Assoc Cancer Res 21:329, 1980.
31. Ahmann FR, Meyskens FL Jr, Jones SE, Durie BGM, **Alberts DS**, Salmon SE: A broad phase II trial of AMSA with *in vitro* stem cell culture drug sensitivity correlation. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 21:369, 1980.
32. Dorr RT, **Alberts DS**, Wood DA: Prevention of intradermal (ID) adriamycin (A) skin toxicity in the mouse. Proc Am Assoc Cancer Res 21:299, 1980.
33. **Alberts DS**, Salmon SE, Chen HSG, Moon TE, Surwit SE, Soehnen BJ, Young L: *In vitro* detection of cross-resistance (XR) and sensitivity (S) in relapsing ovarian cancer (OV) with the human tumor stem cell assay (HTSCA). Proc Am Soc Clin Oncol and Am Assoc Cancer Res 21:181, 1980.
34. **Alberts DS**, Salmon SE, Chen HSG, Surwit EA, Moon TE: Correlative and predictive accuracy of the human tumor stem cell assay (HTSCA) for anticancer drug activity in ovarian (OV) cancer patients (PTS). Proc Am Soc Clin Oncol and Am Assoc Cancer Res 21:431, 1980.
35. Goodman GE, Chang SY, **Alberts DS**: The antitumor activity of melphalan and its hydrolysis products. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 21:301 (#1207), 1980.
36. Dana B, **Alberts DS**: Combination chemoimmunotherapy of advanced renal carcinoma (RC) with adriamycin (ADR), bleomycin (BLEO), vincristine (VCR), cyclophosphamide (CXT), plus BCG. AFCR, May, 1980.
37. **Alberts DS**, Salmon SE, Surwit EA, Chen HSG, Moon TE, Meyskens FL Jr: Combination chemotherapy (CRx) *in vitro* with the human tumor stem cell assay (HTSCA). Proc Am Soc Clin Oncol and Am Assoc Cancer Res 22:153, 1981.

38. Moon TE, Salmon SE, **Alberts DS**, Chen HSG, Durie BGM, Meyskens FL Jr: Quantitative analysis of the human tumor stem cell assay (HTSCA) and the degree of association with clinical response. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 22:348, 1981.
39. Meyskens FL Jr, Gilmartin E, Chase E, **Alberts D**, Surwit E, Jones SE, Salmon SE: A broad phase II trial of 13-cis-retinoic acid in advanced cancer. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 22:370, 1981.
40. Goodman GE, Einspahr JG, Leigh SA, Chen HSG, Davis TP, Meyskens FL, Chang SY, **Alberts DS**: High performance liquid chromatographic analysis and human pharmacokinetics of 13 cis-retinoic acid. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 22:212, 1981.
41. Peng YM, **Alberts DS**, Davis TP, Wood D: High performance liquid chromatography (HPLC) of 9,10-anthracenedicarboxaldehyde bis [(4,5-dihydro-1H-imidazol-2-yl) hydrazone] dihydro-chloride (ADCA) - Physicochemical properties and pharmacokinetics. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 22:606, 1981.
42. Struck RF, El Dareer SM, **Alberts DS**, Mason N, Chen G, Peng YM: Comparative pharmacokinetics of cyclophosphamide (CPA) and its alkylating metabolites in mouse blood after intravenous (I.V.) or oral (P.O.) administration. Proc Am Soc Clin Oncol and Am Assoc Cancer Res 22:832, 1981.
43. Struck RF, Tillery K, **Alberts DS**: Qualitative and quantitative comparison of the major alkylating metabolites of cyclophosphamide in human blood after intravenous or oral administration. ASPET/PSC, Calgary, Alberta, 1981.
44. **Alberts DS**: Phase I clinical investigation of 9-10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl) hydrazone] dihydrochloride (bisantrene) with correlative *in vitro* human tumor clonogenic assay. NCI-EORTC New Drugs Cancer Therapy, Brussels, Oct. 15-17, 1981.
45. **Alberts DS**, Salmon SE: Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. NCI-EORTC New Drugs Cancer Therapy, Brussels, Oct. 15-17, 1981.
46. **Alberts DS**, Salmon SE: Pharmacologic studies of anticancer drugs using the human tumor stem cell assay. NCI-EORTC New Drugs Cancer Therapy, Brussels, Oct. 15-17, 1981.
47. Aapro MS, **Alberts DS**: Effectiveness of high-dose dexamethasone (DX) with or without neuroleptics in the prevention of nausea and vomiting induced by cis-dichlorodiammineplatinum and other chemotherapeutic drugs. UICC, Oct. 28-31, 1981.
48. **Alberts DS**, Chen HSG, Young L, Moon TE, Leigh SA, Surwit EA, Salmon SE: Improved survival for relapsing ovarian cancer (OV CA) patients (PTS) using the human stem cell assay (HTSCA) to select chemotherapy (CRx). NCI-EORTC, Brussels, Oct. 15-17 and Proc Am Soc Clin Oncol and Am Assoc Cancer Res 22:462 (#C-504), 1981.
49. **Alberts DS**, Mackel C, Salmon SE: Use of the human tumor stem cell assay (HTSCA) to prospectively select patients for phase I and II clinical trails of bisantrene (BIS). Int Conf Modulation and Mediation Cancer by Vitamins, Tucson, AZ, 1981.
50. Goodman GE, **Alberts DS**, Einspahr JG, Davis TP, Leigh SA, Meyskens FL: Pharmacokinetics of 13-cis-retinoic acid (13-cRA) in patients with advanced cancer. Int Conf Modulation and Mediation Cancer by Vitamins, Tucson, AZ, 1981.
51. **Alberts DS**, Peng YM, Davis TP: Comparative pharmacology of mitoxantrone and bisantrene. NCI-EORTC New Drugs Cancer Therapy, Brussels, Oct. 15-17, 1981.
52. **Alberts DS**, Surwit E: Guidelines for curative adjuvant therapy of advanced epithelial ovarian cancer (OV CA). NCI-EORTC New Drugs Cancer Therapy, Brussels, Oct. 15-17, 1981.
53. **Alberts DS**, Surwit EA: Mitomycin-C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix. NCI-EORTC New Drugs in Cancer Therapy, Brussels, Oct. 15-17, 1981 and Int Synopses, 1982.

54. Surwit EA, Meyskens FL Jr, Graham V, Dorr R, Chvapil M, Droegemueller W, **Alberts DS**: Chemoprevention of intraepithelial neoplasia of the cervix with locally applied β -trans retinoic acid: A phase I/II trial. ASPO, 1981.
55. Salmon SE, Durie BGM, **Alberts DS**, Meyskens FL, Young L: Primary cloning of human tumour stem cells. Cell Kinetics Society, Pacific Grove, CA, March 4-5, 1981. Cell Tissue Kinetics 15:112, 1982.
56. Peng YM, Ormberg D, Davis TP, **Alberts DS**: Bisantrone (B) and mitoxantrone (M) physiochemical properties and *in vitro* metabolism by a rapid HPLC analysis. AACR, St. Louis, MO, April 28-May 1, 1982. Proc Am Assoc Cancer Res 23:202 (#795), 1982.
57. Aapro MS, **Alberts DS**: Effectiveness of high-dose oral dexamethasone (DX) in the prevention of nausea (N) and vomiting (V) induced by cis-platinum and other chemotherapeutic drugs. UICC, Seattle, WA, 1982.
58. Aapro M, Mackel C, **Alberts D**, Woolfenden J: Phase II cardiotoxicity study of mitoxantrone hydrochloride using exercise radionuclide evaluation of the left ventricular cardiac ejection fraction (LVEF). ASCO, St. Louis, MO, April 25-27, 1982. Proc Am Soc Clin Oncol 1:14 (#C-55), 1982.
59. Ludwig R, **Alberts DS**, Miller TP, Salmon SE, Wood DA: Schedule dependency (SD) of anticancer drugs in the human tumor stem cell assay (HTSCA). AACR, St. Louis, MO, April 28-May 1, 1982. Proc Am Assoc Cancer Res 23:183 (#718), 1982.
60. **Alberts DS**, Peng YM, Davis TP: Comparative pharmacology of mitoxantrone and bisantrene. Proc ASCPT, Lake Buena Vista, FL, p. 2, 1982. AACR, St. Louis, MO, April 28-May 1, 1982. Proc Am Assoc Cancer Res 23:125 (#491), 1982.
61. Aapro MS, Salmon SE, **Alberts DS**: Schedule dependent synergism of vinblastine (VLB) and cloned leukocyte interferon A (IFL-rA). AACR, St. Louis, MO, April 28-May 1, 1982. Proc Am Assoc Cancer Res 23:184 (#725), 1982.
62. Dorr RT, **Alberts DS**, Woods MW: Vinca alkaloid ulceration: Experimental mouse model and effects of local antidotes. AACR, St. Louis, MO, April 28-May 1, 1982. Proc Am Assoc Cancer Res 23:109 (#428), 1982.
63. Goodman GE, **Alberts DS**, Meyskens FL, Peng YM, Beaudry J, Leigh S, Chang SY: Pharmacokinetics and phase I clinical trial of retinol (R) in cancer patients. AACR, St. Louis, MO, April 28-May 1, 1982. Proc Am Assoc Cancer Res 23:129 (#508), 1982.
64. Meyskens FL Jr, Aapro MS, Surwit EA, **Alberts DS**: Clinical studies of vitamin A and its synthetic derivatives in cancer prevention and treatment at the University of Arizona. Int Conf Modulation and Medication Cancer by Vitamins, Tucson, AZ, 1982.
65. Meyskens FL Jr, Aapro M, Surwit EA, **Alberts DS**, Moon TE, Brooks RJ, Levine NS: Clinical studies of retinoids in cancer prevention and treatment. Int Conf Modulation and Medication Cancer by Vitamins, Tucson, AZ, 1982.
66. **Alberts DS**, Surwit EA: Improved survival for relapsing ovarian cancer (OV CA) patients using the human tumor stem cell assay (HTSCA) to select chemotherapy (CRx). UICC, Seattle, WA, 1982.
67. Bowden GT, Garcia D, Peng YM, **Alberts DS**: Molecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxaldehyde bis [(4,5-dihydro-1H-imidazol-2-yl) hydrazone] dihydro-chloride (CL 216,942). UICC, Seattle, WA, 1982.
68. Peng YM, **Alberts DS**, Ormberg D, Einspahr JG: *In vivo* and *in vitro* metabolism of the new anticancer agent bisantrene (B) using HPLC and human tumor clonogenic assay. Proc Am Assoc Cancer Res, San Diego, CA, May 25-28, 24:256 (#1009), 1983.

69. Aapro MS, Plezia PM, **Alberts DS**, Graham V, Wilson V, Surwit EA, Jones SE, Moon TE: Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone (DEX) vs. high-dose metoclopramide (MCP). ASCO, San Diego, CA, May 22-24, 1983. Proc Am Soc Clin Oncol 2:93 (#C-364), 1983.
70. Surwit EA, **Alberts DS**, Aristizabal S, Deatherage KJ, Heusinkveld R: Treatment of primary and recurrent, advanced squamous cell cancer of the cervix with mitomycin-C + vincristine + bleomycin (MOB) plus cisplatin (PLAT). ASCO, San Diego, CA, May 22-24, 1983. Proc Am Soc Clin Oncol 2:153 (#C-596), 1983.
71. Plezia PM, **Alberts DS**, Aapro MS, Kessler JF, Graham V, Wilson V, Surwit EA: Immediate termination of intractable cisplatin induced vomiting (V) with an intensive 5-drug antiemetic regimen. ASCO, San Diego, CA, May 22-24, 1983. Proc Am Soc Clin Oncol 2:93 (#C-363), 1983.
72. Meyskens F Jr, Graham V, Chvapil M, Dorr R, **Alberts D**, Surwit E: Phase I chemoprevention trial of β -all-trans-retinoic acid for mild and moderate cervical dysplasia (CIN I and II) delivered locally via a cervical cap and collagen sponge. ASCO, San Diego, CA, May 22-24, 1983. Proc Am Soc Clin Oncol 2:156 (#C-610), 1983.
73. Minor D, Allen R, **Alberts D**, Peng YM: Pharmacokinetics of isolated limb perfusion with heat and melphalan for melanoma. ASCO, San Diego, CA, May 22-24, 1983. Proc Am Soc Clin Oncol 2:239 (#C-936), 1983.
74. Russell DH, Ellingson JD, Davis TP, **Alberts DS**, Surwit EA: Separation of the polyamines and acetyl-derivatives by a single automated amino acid analyzer technique: Implications as cancer markers. ASCPT, San Diego, CA, March 9-11, 1983. Clin Pharmacol Ther 33:223, 1983.
75. Plezia PM, Aapro MS, **Alberts DS**, Jones SE, Surwit EA: Double-blind crossover study of the antiemetic efficacy of high-dose metoclopramide vs. high-dose dexamethasone. ASCPT, San Diego, CA, March 9-11, 1983. Clin Pharmacol Ther 33:223, 1983.
76. Surwit EA, **Alberts DS**, Jackson R, Leigh S: Multiagent chemotherapy in relapsing ovarian cancer. SGO, Scottsdale, AZ, Feb. 6-9, 1983. Gynecol Oncol 15:136-137, 1983.
77. Dorr RT, **Alberts DS**, Stone A, Salmon SE: Cold protection from intradermal (ID) doxorubicin (DOX) ulceration in the mouse. AACR, San Diego, CA, May 25-28, 1983. Proc Am Assoc Cancer Res 24:255 (#1008), 1983.
78. Aapro MS, **Alberts DS**: Lack of dexamethasone (DEX) effect on the antitumor activity of cisplatin. AACR, San Diego, CA, May 25-28, 1983. Proc Am Assoc Cancer Res 24:292 (#1156), 1983.
79. Ludwig R, **Alberts DS**, Salmon SE: Evaluation of schedule dependency of anticancer drugs in the human tumor assay. Int Conf Predictive Drug Testing Human Tumor Cells, Zurich, Switzerland, July 20-23, 1983. Int J Cell Cloning 1:276, 1983.
80. Watson R, **Alberts D**, Hicks M: Effects of 13 cis retinoic acid on cellular immune functions in normal adults. Am Aging Assoc, Washington, DC, Oct. 6-9, Age 6:138-139, 1983.
81. Kessler JF, Plezia PM, **Alberts DS**, Aapro MS, Surwit EA, Graham V, Chase J: Five-drug antiemetic combination for prevention of chemotherapy related nausea and vomiting (N/V). Proc Am Soc Clin Oncol, Toronto, ON, May 6-8, 3:104 (#C-406), 1984.
82. Dorr RT, Bowden GT, **Alberts DS**, Liddil JD: Molecular pharmacology of mitomycin-C (MMC) and a polar metabolite (PM) on mammalian DNA. Proc Am Assoc Cancer Res, Toronto, ON, May 9-12, 25:291 (#1150), 1984.
83. Einspahr J, **Alberts DS**, Struck R, Salmon SE: Comparative *in vitro* cytotoxicities of cyclophosphamide (CYCLO), its major metabolites and Asta-Werke #Z 7557 against 199 fresh human cancers. ASCO, Toronto, ON, May 6-8, 1984. Proc Am Soc Clin Oncol 3:38 (#C-148), 1984.

84. **Alberts DS**, Leigh SA, Moon TE, Surwit EA, Salmon SE: Improved survival for relapsing ovarian cancer (OV CA) patients (PTS) using the human tumor clonogenic assay (HTCA) to select chemotherapy (CRx): An update. ASCO, Toronto, ON, May 6-8, 1984. Proc Am Assoc Cancer Res 25:176 (#695), 1984.
85. Bowden GT, Peng YM, **Alberts DS**: Comparative molecular pharmacology of the anthracene anticancer drugs bisantrene and mitoxantrone. AACR, Toronto, ON, May 9-12, 1984. Proc Am Assoc Cancer Res 25:296 (#1171), 1984.
86. Peng YM, **Alberts DS**: High performance liquid chromatograph analysis (HPLC) and human pharmacokinetics of 4'-deoxydoxorubicin (DEOXYDOX). AACR, Toronto, ON, May 9-12, 1984. Proc Am Assoc Cancer Res 25:165 (#654), 1984.
87. **Alberts DS**, Peng YM, Fisher B: Minimal melphalan (LPAM) systemic availability (SA): A potential cause for failure of adjuvant breast cancer therapy trials. ASCO, Toronto, ON, May 6-8, 1984. Proc Am Soc Clin Oncol 3:38 (#C-149), 1984.
88. Surwit E, **Alberts D**, Dorr R, Weiner S, Graham V, Moon T, Meyskens F Jr: A phase II trial of trans-retinoic acid (vitamin A acid) in the treatment of cervical dysplasia (intraepithelial neoplasia). ASCO, Toronto, ON, May 6-8, 1984. Proc Am Soc Clin Oncol 3:174 (#C-678), 1984.
89. **Alberts DS**, Leigh SA, Moon TE, Surwit EA, Salmon SE: Improved survival for relapsing ovarian cancer (OV CA) patients (PTS) using the human tumor clonogenic assay (HTCA) to select chemotherapy (CRx): An update. Int Conf Human Tumor Cloning, Tucson, AZ, Jan. 3-5, 1984.
90. **Alberts DS**, Aristizabal S, Weiner S, Surwit EA: Bleomycin studies - An overview. Advances Bleomycin Therapy, San Francisco, CA, Sept., 1984.
91. **Alberts DS**: Adjuvant therapy of ovarian cancer: An overview. Int Conf Adjuvant Therapy of Cancer, 1984.
92. Surwit EA, Aristizabal SA, **Alberts DS**, Weiner SA, Deatherage KJ: Treatment of primary carcinoma of the cervix with mitomycin-C + vincristine + bleomycin (MOB) + cis-platinum (PLAT) prior to definitive radiation therapy. Int Conf Adjuvant Therapy of Cancer, 1984.
93. Dorr RT, **Alberts DS**, Bowden GT: Evaluation of mitomycin-C (MCC) antagonists *in vitro*: Correlation with molecular DNA interactions. Int Conf Human Tumor Cloning, Tucson, AZ, Jan. 3-5, 1984.
94. Dorr RT, **Alberts DS**: Interaction of cimetidine but not ranitidine with cyclophosphamide. Proc ASCPT, San Antonio, TX, March 28-30, p. 15, 1985. Clin Pharmacol Ther 37:191, 1985.
95. Dalton WS, **Alberts DS**, Cress AE, Trent J: Characterization of a mitoxantrone (DHAD) resistant human colon carcinoma cell line. Proc ASCPT, San Antonio, TX, March 28-30, p. 13, 1985. Clin Pharmacol Ther 37:189, 1985.
96. Baker L, Boutselis J, **Alberts D**, Surwit E, Hilgers R: Combination chemotherapy for patients with disseminated carcinoma of the uterine cervix. ASCO, Houston, TX, May 19-21, 1985. Proc Am Soc Clin Oncol 4:120 (#C-465), 1985.
97. Greenberg B, Ahmann F, Garewal H, Koopman C, Coulthard S, Berzes H, **Alberts D**: Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil (5-FU) and cis-platinum (CP). ASCO, Houston, TX, May 19-21, 1985. Proc Am Soc Clin Oncol 4:146 (#C-571), 1985.
98. Peng YM, **Alberts DS**, Leigh S, Serokman R, Edwards L, Davis TP, Meyskens FL Jr: Clinical toxicology and pharmacokinetics of 13-cis-retinoic acid (13cRA) administered chronically at low doses expected for cancer chemoprevention trials. AACR, Houston, TX, May 22-25, 1985. Proc Am Assoc Cancer Res 24:69 (#624), 1985. Int Conf Modulation and Mediation Cancer by Vitamins, 1985.

99. Dalton WS, **Alberts DS**, Robertone A, Peng YM, Serokman R, Braich T, Garewal H, Salmon SE: Indocyanine green (ICG) for rapid prediction of 4'-deoxydoxorubicin (esorubicin, E) pharmacokinetics, toxicity and dose selection. ASCO, Houston, TX, May 19-21, 1985. Proc Am Soc Clin Oncol 4:36 (#C-136), 1985.
100. **Alberts DS**, Mackel C, Peng YM, Dalton WS, Weiner SA, Surwit EA, Young L, Salmon SE: Comparative activity of anticancer drugs used in high dose by the intraperitoneal (IP) route for the treatment of advanced ovarian cancer (OV CA). ASCO, Houston, TX, May 19-21, 1985. Proc Am Soc Clin Oncol 4:36 (#C-137), 1985.
101. Weiner SA, Meyskens FL Jr, Surwit EA, **Alberts DS**, Levine NS: Response of human papilloma-associated diseases to retinoids (vitamin A derivatives). Proc UCLA Symp, Papilloma Viruses: Molecular and Clinical Aspects, Steamboat Springs, CO, April 8, 1985.
102. **Alberts DS**, Mackel C, Peng YM, Dalton WS, Weiner SA, Surwit EA, Young L, Salmon SE: Intraperitoneal chemotherapy of ovarian cancer: Comparative ratings of standard and experimental drugs based on *in vivo* pharmacokinetics and *in vitro* tumor sensitivity assays. Proc Int Congress Chemotherapy, Kyoto, Japan, June 23-28, 1985.
103. Weiner SA, Surwit EA, **Alberts D**, Davis J, Leigh S: Tamoxifen therapy in recurrent epithelial cancer. SGO, 1985.
104. Ho EE, Abrams C, Sievers J, **Alberts DS**: The use of bran fiber supplementation to lower colon cancer risk. Am Public Health Assoc, Washington, DC, Nov. 17-21 1985. Food Nutr Med Pediatr Oncol 13:A22, 1985.
105. **Alberts DS**, Mason NL, Surwit EA, Weiner SA, Hammond N, and Deppe G: Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: A Southwest Oncology Group study. Proc ECCO, Interferon Alpha-2 Symp, Stockholm, Sweden, June 19, 1985.
106. Dalton WS, Durie BGM, Gerlach J, Cress AE, **Alberts DS**, Ling V: Development and characterization of a new drug resistant human multiple myeloma cell line. ASH, 1985.
107. **Alberts DS**, Young L, Salmon S: Comparative activity of anti-cancer drugs administered by the intraperitoneal route for the treatment of advanced ovarian cancer. Proc Int Congress Chemotherapy, Kyoto, Japan, June 23-28, 1985.
108. Weiner S, Aristizabal S, **Alberts D**, Surwit E, Deatherage K: A phase II trial of mitomycin, vincristine, bleomycin, cis-platinum (MOBP) as neoadjuvant therapy in high risk cervical carcinoma. SGO, Feb. 3-5, 1986. Gynecol Oncol 23:249-250, 1986.
109. Protell RL, Tripp MR, Morgan TR, Kendall D, Serokman RA, **Alberts DS**: Can ornithine decarboxylase (ODC) levels presage adenoma-prone mucosa? Western Section, AFCR, Clin Res 34:31A, 1986.
110. Bozak KA, Dorr RT, **Alberts DS**: A novel *in vitro* culture system for cardiotoxic (CDTX) drug screening. Soc of Toxicology 6:305, 1986.
111. Moon TE, Ritenbaugh C, **Alberts DS**, Meyskens FL Jr: Selection of chemopreventive agents. Int Cancer Congress, Budapest, Hungary, Aug. 21-27 and Soc Preventive Oncology, March, 1986.
112. Garewal H, Sampliner R, Kogan F, Smith W, Gerner E, **Alberts D**, Kendall D: Ornithine decarboxylase (ODC) levels in Barrett's Esophagus, a pre-malignant lesion for adenocarcinoma. ASCO, Los Angeles, CA, May 4-6, 1986. Proc Am Soc Clin Oncol 5:18 (#70), 1986.
113. Dalton WS, Durie BGM, Grogan TM, Cress AE, **Alberts DS**: Cytogenetic and phenotypic analysis of a drug resistant human myeloma cell line. AACR, Los Angeles, CA, May 7-10, 1986. Proc Am Assoc Cancer Res 27:271 (#1074), 1986.
114. Peng YM, **Alberts DS**, Lim HD: High performance liquid chromatographic (HPLC) analysis of vinzolidine (VZD) and related vinca alkaloids in biological samples. AACR, Los Angeles, CA, May 7-10, 1986. Proc Am Assoc Cancer Res 27:407 (#1616), 1986.

115. **Alberts D**, Mason N, O'Toole R, Kronmal R, Hilgers R, Surwit E, Eyre H, Baker L, Boutsellis J, Rivkin S, Green B, Hannigan E: Randomized phase III trial of doxorubicin (D) + cyclophosphamide (C) + BCG vs DC + cisplatin (P) vs DC + P + BCG in stages III and IV ovarian cancer (OV CA). ASCO, Los Angeles, CA, May 4-6, 1986. Proc Am Soc Clin Oncol 5:119 (#462), 1986.
116. **Alberts DS**, Young L, Salmon SE: *In vitro* phase II trial of cisplatin vs carboplatin vs iproplatin against ovarian cancer (OV CA). ASCPT, Clin Pharmacol Ther 39:177, 1986.
117. Struck RF, Horne K, Phillips JG, Peng YM, **Alberts DS**: Plasma levels and AUC data for the antitumor-active metabolites of cyclophosphamide (CPA) in cancer patients treated intravenously (i.v.) or orally (p.o.) with cyclophosphamide. AACR, Los Angeles, CA, May 7-10, 1986. Proc Am Assoc Cancer Res 27:167 (#663), 1986.
118. **Alberts DS**, Deuser KD, Young L, Clark B, Moon TE, Salmon SE: *In vitro* chemosensitivity (CS) and survival of patients (PTS) with previously untreated, stages III & IV ovarian cancer (OV). AACR, Los Angeles, CA, May 7-10, 1986. Proc Am Assoc Cancer Res 27:415 (#1649) 1986. WAGO, Monterey, CA, May 21-24, 1986.
119. Wunz TP, Dorr RT, Tunget CL, Einspahr J, Milton S, **Alberts DS**: New antitumor agents containing the anthracene nucleus. Am Chemistry Soc, Anaheim, CA, and Santa Fe Graduate Medicinal Chemistry Mtg, June, 1986.
120. Sampliner R, Garewal H, Kogan F, Smith W, Gerner E, **Alberts D**, Kendall D: Elevated ornithine decarboxylase levels in Barrett's esophagus. AGA, Gastroenterology 90:1613, 1986.
121. Protell RL, Tripp MR, Morgan TR, Kendall D, Serokman RA, **Alberts DS**: Will ornithine decarboxylase (ODC) levels predict adenoma-prone patients? AGA, Gastroenterology 90:1591, 1986.
122. **Alberts D**, Young L, Clark B, Salmon S: *In vitro* studies of new agents for the treatment of ovarian cancer. Chemotherapy Foundation, New York, Nov. 12-14, 1986. Cancer Inv 4:491, 1986.
123. Dalton WS, **Alberts DS**, Cress AE, Trent J: Characterization of a resistant human colon carcinoma cell line. Int Workshop Chromosomes in Solid Tumors, Tucson, AZ, March 3-5, 1985. Cancer Genet 19:189, 1986.
124. Plezia PM, **Alberts DS**, Kessler JF, Wilson V: Randomized crossover comparison of high-dose intravenous metoclopramide (HDMCP) vs a 5-drug antiemetic regimen. Proc ASCPT, Orlando, FL, p. 6, 1987. Clin Pharmacol Ther 41:160, 1987.
125. **Alberts DS**, Surwit EA, O'Toole R, Kronmal R, Salmon SE: Stage III, optimal disease ovarian cancer relatively resistant to adjuvant cisplatin chemotherapy *in vitro* and *in vivo*. Int Conf Adjuvant Therapy of Cancer, March 11-15, and WAGO, Tucson, AZ, May 13-16, 1987.
126. Dalton W, Gleason M, McCloskey T, Durie B, **Alberts D**: Reversal of drug resistance in human multiple myeloma (MM) with verapamil (VER): Design of a clinical study based on *in vitro* testing using a drug resistant myeloma cell line. ASCO, Atlanta, GA, May 17-19, 1987. Proc Am Soc Clin Oncol 6:31 (#119), 1987.
127. Garewal H, Sampliner R, Steinbronn K, **Alberts D**, Gerner E: Ornithine decarboxylase levels in Barrett's esophagus: Correlation with dysplasia. AGA, Chicago, IL, May 10-13, 1987. Gastroenterology 92:1400, 1987.
128. **Alberts DS**, Einspahr J, Peng YM, Spears P: Dipyridamole (D) potentiation of FUDR antitumor activity. Proc ASCPT, Orlando, FL, p. 93, 1987. Clin Pharmacol Ther 41:247, 1987.
129. Peng YM, Lim H, Dalton WS, **Alberts DS**: Marked alteration in membrane transport and intracellular accumulation of vinblastine (VBS) in multi-drug resistant (MDR) human myeloma cells selected for resistance to doxorubicin (DOX). AACR, Atlanta, GA, May 20-22, 1987. Proc Am Assoc Cancer Res 28:277 (#1094), 1987.

130. **Alberts DS**, Wunz T, Remers W, Einspahr J, Dorr RT, Liu R, Salmon SE: Fresh human tumors (Fresh HT) but not human tumor cell lines (TC lines) accurately predict the *in vitro* activity of a series of anthracene compounds in tumor bearing mice. AACR, Atlanta, GA, May 20-22, 1987. Proc Am Assoc Cancer Res 28:420 (#1664), 1987.
131. Schwartz J, **Alberts D**, Einspahr J, Peng YM, Spears P: Dipyridamole (D) potentiation of FUDR activity against human colon cancer *in vitro* and in patients. ASCO, Atlanta, GA, May 17-19, 1987. Proc Am Soc Clin Oncol 6:83 (#325), 1987.
132. **Alberts D**, Surwit E, Peng YM, McCloskey T, Graham V, McDonald L, Roe D: Phase I-II and pharmacokinetic study of mitoxantrone by intraperitoneal administration. ASCO, Atlanta, GA, May 17-19, 1987. Proc Am Soc Clin Oncol 6:115 (#453), 1987.
133. Taylor CW, Salmon SE, **Alberts DS**, Robertone AB, Peng YM: Phase I study of intravenous vinzolidine. ASCO, Atlanta, GA, May 17-19, 1987. Proc Am Soc Clin Oncol 6:22 (#81), 1987.
134. Plezia PM, **Alberts DS**, McDonald L, McCloskey T, Peng YM, Wendt AG: Oral Idarubicin (I): Evaluation of food effects and consistency of absorption. ASCO, Atlanta, GA, May 17-19, 1987.
135. Davis LE, Plezia PM, **Alberts DS**, Greenberg BR, Garewal HS, Schwartz SE, Fairchild C: BMY-25801: An effective single-agent antiemetic for cisplatin-induced nausea and vomiting. Am College Clinical Pharmacy, July 19-22, 1987.
136. Bellamy WT, Dorr RT, Dalton WS, **Alberts DS**: Elevated glutathione levels in multidrug resistant human myeloma cells and its relationship to drug resistance. Western Pharmacology Society, Tucson, AZ, Jan. 10-15, 1988.
137. **Alberts DS**, Peng YM, Plezia P, Sayers S, Xu MJ, Davis TP: Serum and tissue pharmacology of vitamin A and β -carotene. Int Conf Prevention Human Cancer: Chemoprevention, Tucson, AZ, Jan. 12-15, 1988.
138. Garewal H, Gerner E, Sampliner R, **Alberts D**, Roe D: Ornithine decarboxylase and polyamine levels in patients with Barrett's esophagus. Int Conf Prevention Human Cancer: Chemoprevention, Tucson, AZ, Jan. 12-15, 1988.
139. Peng YM, Xu MJ, Lim H, Dalton W, **Alberts D**: Pharmacokinetics of N-4-Hydroxyphenyl-retinamide (4HPR) and effect of oral 4HPR administration (PO 4HPR) on plasma retinol (ROH) levels in cancer patients. Int Conf Prevention Human Cancer: Chemoprevention, Tucson, AZ, Jan. 12-15, 1988.
140. Garewal H, Gerner E, Sampliner R, **Alberts D**: Lack of correlation between ornithine decarboxylase activity and polyamine levels in Barrett's esophagus. Western Section, AFCR, 1988. Clin Res 36:169A, 1988.
141. **Alberts DS**, Surwit EA, Mason-Liddil N, Stock-Novack D, O'Toole RV, Hannigan EV, Green S: Phase III study of IP cisplatin (P) + IV Cyclophosphamide (C) vs IV P + IV C in patients with stage III, optimal disease ovarian cancer: A SWOG-ECOG-GOG Intergroup Trial. Int Conf Intracavitary Chemotherapy, San Diego, CA, Feb. 25-27, 1988.
142. **Alberts DS**, Shimm D, Surwit EA, Graham V, Monk BJ: Intraperitoneal (IP) mitomycin C with and without whole abdominal hyperthermia (Heat) in the treatment of peritoneal carcinomatosis following second-look surgery. Int Conf Intracavitary Chemotherapy, San Diego, CA, Feb. 25-27, 1988.
143. **Alberts DS**, Surwit EA, Peng YM, McCloskey T, Rivest R, Graham V, McDonald L, Roe D: Phase I clinical and pharmacokinetic study of mitoxantrone by intraperitoneal administration. Int Conf Intracavitary Chemotherapy, San Diego, CA, Feb. 25-27, 1988.
144. Surwit EA, **Alberts DS**, Graham V, McDonald L, Davis A, Buzaid A, Hersh E: Phase I and pharmacokinetic study of IP rTNF plus rIFN-g. Int Conf Intracavitary Chemotherapy, San Diego, CA, Feb. 25-27, 1988.

145. Plezia PM, **Alberts DS**, McDonald L, McCloskey T, Peng YM, Wendt AG: Oral Idarubicin (I): Evaluation of food effects and consistency of absorption. ASCPT, San Diego, CA, March 9-11, 1988. Clin Pharmacol Ther 43:161, 1988.
146. Shipp NG, Dorr RT, **Alberts DS**: Myocyte culture system for evaluation of cardiotoxic antitumor agents. FASEB J 2:A1818, 1988.
147. Meyskens FL Jr, Garewal HS, **Alberts DS**, Ritenbaugh C, Earnest D: Chemoprevention of gut epithelial malignancy. Premalignant Lesions Esophagus and Colon, Birmingham, AL, April 21-22, 1988.
148. Presant CA, Turner AF, Chaudhuri T, Neal GD, Weiss G, Baum M, Barrett J, Roberts J, Parbhoo S, Hilson A, LaFrance N, Abeloff M, **Alberts D**, Surwit EA, Woolfenden J, Hiltz S, Preiss SJ, Crossley RJ, Williams L, Proffitt RT: Successful localization of human tumors (T) by In-III liposomes/lipid vesicles (LV) initial report of an international multi-institutional study. ASCO, New Orleans, LA, May 22-24, 1988. Proc Am Soc Clin Oncol 7:43 (#166), 1988.
149. Taylor CW, **Alberts DS**, Ketcham MA, Peng YM, Satterlee WG: A phase I and pharmacokinetic study of LY186641 (LY). ASCO, New Orleans, LA, May 22-24, 1988. Proc Am Soc Clin Oncol 7:60 (#226), 1988.
150. Smaldone L, Fairchild C, Rozenzweig M, Apro M, Sartiano G, Plezia P, **Alberts D**: Dose-range evaluation of BMY-25801, a non-dopaminergic antiemetic. ASCO, New Orleans, LA, May 22-24, 1988. Proc Am Soc Clin Oncol 7:280 (#1086), 1988.
151. Garewal H, Gerner E, **Alberts D**, Sampliner R: Ornithine decarboxylase in a premalignant lesion (Barrett's Esophagus): Lack of correlation of increased activity with polyamine levels. ASCO, New Orleans, LA, May 22-24, 1988.
152. Plezia PM, Davis LE, **Alberts DS**, Davis A, Garewal HS, Greenberg BR, Smaldone L, Fairchild C: BMY-25801: An effective single agent antiemetic (A) for cisplatin (C)-induced nausea (N) and vomiting (V). ASCO, New Orleans, LA, May 22-24, 1988. Proc Am Soc Clin Oncol 7:294 (#1143), 1988.
153. Taylor CW, Salmon SE, Satterlee WG, **Alberts DS**, Robertone AB, Peng YM: Intravenous vinzolidine (IV VZL): A phase I and pharmacokinetic study. AACR, New Orleans, LA, May 25-28, 1988. Proc Am Assoc Cancer Res 29:325 (#1292), 1988.
154. Struck RF, **Alberts DS**, Plezia P, Phillips JG, Mason-Liddil N, McDonald L: Effect of the antiulcer drug ranitidine on the pharmacokinetics and hematologic toxicity of cyclophosphamide and its cytotoxic metabolites in patients. AACR, New Orleans, LA, May 25-28, 1988. Proc Am Assoc Cancer Res 29:187 (#743), 1988.
155. Peng YM, Dalton WS, **Alberts DS**, Booth A, Ponder R, Wargin W, Tuttle R: Pharmacokinetics (PK) and phase I clinical trial of the arylmethylaminopropanediol (AMAP) crisnatol (CRIS, BW A770U), a highly lipid soluble drug which distributes into the CSF. AACR, New Orleans, LA, May 25-28, 1988. Proc Am Assoc Cancer Res 29:194 (#769), 1988.
156. Einspahr J, **Alberts DS**, Gleason M, Dalton WS, Leibovitz A: Pharmacologic pitfalls in the use of the MTT (versus human tumor clonogenic - HTCA) assay to quantitate chemosensitivity of human tumor cell lines. AACR, New Orleans, LA, May 25-28, 1988. Proc Am Assoc Cancer Res 29:492 (#1956), 1988.
157. Bellamy WT, Dorr RT, Dalton WS, Meltzer P, **Alberts DS**: The role of glutathione (GSH) as a potential detoxification system in multidrug resistant (MDR) human myeloma cells. AACR, New Orleans, LA, May 25-28, 1988. Proc Am Assoc Cancer Res 29:317 (#1259), 1988.
158. **Alberts DS**: Adjuvant therapy after second-look exploratory laparotomy in patients with ovarian cancer and minimal residual or no evidence of disease. Current Issues and Future Directions Clinical Development Biologicals, Rancho Mirage, CA, Oct. 13-16, 1988.

159. Modiano M, Pond G, Holdsworth M, Plezia P, **Alberts D**: Phase I and pharmacokinetic (PK) study of selective intraarterial chemoembolization (CE) with Angiostat[®] collagen, CDDP, mitomycin, adriamycin for metastatic colorectal carcinoma to the liver. The University of Arizona Experience. Western Section, AFCR, Feb. 7-10, 1989. Clin Res 37:143A, 1989.
160. Guan XY, **Alberts D**, Burges AC, Thompson FH, Trent JM: Chromosomal analysis of 90 cases of ovarian carcinoma. Workshop Chromosomes in Solid Tumors, Tucson, AZ, Feb. 26-28, 1989. Cancer Genet 41:291, 1989.
161. Liu Y, Leibovitz A, **Alberts D**, Thompson FH, Trent JM: Cytogenetic findings in 36 cases of colorectal tumors. Workshop Chromosomes in Solid Tumors, Tucson, AZ, Feb. 26-28, 1989. Cancer Genet 41:284, 1989.
162. Holdsworth M, Plezia P, Taylor C, **Alberts D**, Peng YM, McCloskey T, Hamilton M, Satterlee W: Pharmacokinetics (PK) related to toxicity for a novel arylsulfonyleurea (AS) anticancer agent. ASCPT, Nashville, TN, March 8-10, 1989. Clin Pharmacol Ther 45:136, 1989.
163. Earnest D, Hixson L, Sim W, Ahnen D, **Alberts D**: Piroxicam as an agent to inhibit colonic neoplasia. AGA, Washington, DC, May 14-17, 1989. Gastroenterology 96:A134, 1989.
164. **Alberts D**, Green S, Hannigan E, O'Toole R, Mason-Liddil N, Surwit E, Stock-Novack D, Goldberg R, Malviya V, Nahhas W: Improved efficacy of carboplatin (CarboP)/ cyclophosphamide (CPA) vs cisplatin (CisP)/CPA: Preliminary report of a phase III, randomized trial in stages III-IV, suboptimal ovarian cancer (OV CA). WAGO, San Francisco, CA, May 17-20, 1989. ASCO, San Francisco, CA, May 21-23, 1989. Proc Am Soc Clin Oncol 8:151 (#588), 1989.
165. Green JB, Green S, **Alberts DS**, O'Toole R, Surwit EA, Noltimier JW: Carboplatin therapy in advanced endometrial cancer: A Southwest Oncology Group study. ASCO, San Francisco, CA, May 21-23, 1989. Proc Am Soc Clin Oncol 8:155 (#605), 1989.
166. Taylor C, Hersh E, Plezia P, **Alberts D**, McCloskey T, Wiggins C, Ahmann F, King D, Rudolph A: A phase I and pharmacokinetic study of recombinant tumor necrosis factor (rTNF) and doxorubicin (DOX). ASCO, San Francisco, CA, May 21-23, 1989. Proc Am Soc Clin Oncol 8:183 (#712), 1989.
167. Weiss G, Green S, Stock-Novack D, **Alberts DS**, Guidice R: Phase II trial of cisplatin (CP) and 5-fluorouracil (5FU) with or without allopurinol (ALL) for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: A Southwest Oncology Group study. ASCO, San Francisco, CA, May 21-23, 1989. Proc Am Soc Clin Oncol 8:158 (#616), 1989.
168. Brady ME, Dandekar KA, Pfeffer M, Sartinano GP, **Alberts DS**, Plezia P, Smaldone L: Pharmacokinetics of batanopride (BMY-25801). A new antiemetic in cancer patients. ASCO, San Francisco, CA, May 21-23, 1989. Proc Am Soc Clin Oncol 8:330 (#1285), 1989.
169. Modiano M, Holdsworth M, **Alberts D**, Pond G, Plezia P: Control of hepatic metastases from colorectal carcinoma with selective intraarterial chemoembolization (CE) with Angiostat[®] collagen, CDDP, mitomycin and adriamycin. The University of Arizona Experience. ASCO, San Francisco, CA, May 21-23, 1989. Proc Am Soc Clin Oncol 8:105 (#408), 1989.
170. Meyers F, **Alberts DS**, Spaulding M, Garewal H, Flam M, Allen D: Phase I/II study of Fluosol[®]/oxygen in combination with weekly 5-fluorouracil (5FU) in metastatic colorectal carcinoma. AACR, San Francisco, CA, May 24-27, 1989. Proc Am Assoc Cancer Res 30:256 (#1020), 1989.
171. Bellamy W, Dorr R, Bair K, **Alberts D**: Cytotoxicity and mechanism of action of 3-arylmethylaminopropanediols (AMAPS). AACR, San Francisco, CA, May 24-27, 1989. Proc Am Assoc Cancer Res 30:562 (#2236), 1989.
172. Kendall D, **Alberts D**, Peng YM: Activity of tetraplatin isomers against cisplatin sensitive and resistant human tumor cell lines. AACR, San Francisco, CA, May 24-27, 1989. Proc Am Assoc Cancer Res 30:469 (#1864), 1989.

173. **Alberts D**, Einspahr J, Sipes IG: *In vitro* cytotoxicity of a novel DNA minor groove binding anticancer agent (U-73,975) against doxorubicin sensitive and resistant human tumor cell lines. AACR, San Francisco, CA, May 24-27, 1989. Proc Am Assoc Cancer Res 30:492 (#1957), 1989.
174. **Alberts D**, Buller M, Einspahr J, Rees-McGee S, Ramanujam P, Aickin M, Earnest D, Phelps J, Pethigal P, Ritenbaugh C, Atwood J, Wilbur L, Meyskens F: Dietary wheat bran (WB) fiber supplementation significantly reduces [³H]-thymidine crypt organ labeling index (LI) in rectal mucosal biopsies from patients with resected colorectal cancers (Colon CA). AACR, San Francisco, CA, May 24-27, 1989. Proc Am Assoc Cancer Res 30:258, (#1026) 1989.
175. Plezia PM, **Alberts DS**, Sayers SM, Xu MJ, Peng YM, Ritenbaugh C: Evaluation of plasma and skin concentrations of β -carotene (BC), retinol (ROH), and retinyl palmitate (RP) in normal subjects receiving daily oral doses of BC for 9 months. Int Assoc Vitamin and Nutritional Oncology, June 26-29, 1989.
176. Atwood JR, Giordano L, Sheehan E, Benedict J, **Alberts D**, Meyskens FL: Health behavior questionnaire: Short form. Clinical Research: Biophysical and Psychosocial Instrumentation. UA College Nursing and Beta Mu Chapter, Sigma Theta Tau, Tucson, AZ, Oct. 11-13, 1989.
177. Meakem T, Unger E, Pond G, Stejskal T, Modiano M, **Alberts DS**: CT findings after hepatic chemoembolization. Radiologic Society of North America, Chicago, IL, Nov. 26-Dec. 1, 1989.
178. Shipp NG, Dorr RT, **Alberts DS**: Differential mechanisms of doxorubicin and mitoxantrone cardiotoxicity. Soc of Toxicology, Miami Beach, FL, Feb. 12-16, 1990.
179. Surwit EA, Childers JM, **Alberts DS**, Graham V: Short-term dose-intensive adjuvant therapy with cisplatin for advanced ovarian carcinoma. Int Conf Adjuvant Therapy of Cancer, Tucson, AZ, March 7-10, 1990.
180. **Alberts DS**: Adjuvant therapy of epithelial ovarian cancer. Int Conf Adjuvant Therapy of Cancer, Tucson, AZ, March 7-10, 1990.
181. Garewal HS, Meyskens F, **Alberts D**, Friedman S, Pitcock J: Potential role of vitamin A related compounds in oral cancer. Int Conf Adjuvant Therapy of Cancer, Tucson, AZ, March 7-10, 1990.
182. Earnest D, Hixson L, Einspahr J, **Alberts D**: Piroxicam as prevention against colonic neoplasia: Absence of deleterious effect on colon epithelial regeneration. Proc ASG, San Antonio, TX, May 13-16, 1990.
183. Hixson L, Einspahr J, **Alberts D**, Earnest D: Effect of bowel preparation on rectal [³H]-thymidine labeling index. Am Assoc Study Liver Diseases, San Antonio, TX, May 13-16, 1990. Gastroenterology 98:A286, 1990.
184. Leong SPL, Xu MJ, **Alberts DS**, Wang TF, Peng YM, Hersh EM, Taylor CW, Fanta P, Salmon SE: Chemosensitivity of human melanoma to cisplatin and heat at doses achievable by isolated hyperthermic perfusion. ASCO, Washington, DC, May 20-22, 1990. Proc Am Soc Clin Oncol 9:277 (#1073), 1990.
185. Hannigan E, **Alberts D**, Green S, O'Toole R, Mason-Liddil N, Surwit E, Stock-Novack D, Goldberg R, Malviya V, Nahhas W, Canetta R, Thomas R: Assessment of treatment costs for carboplatin and cisplatin. ASCO, Washington, DC, May 20-22, 1990. Proc Am Soc Clin Oncol 9:337 (#1305), 1990.
186. Lam K, **Alberts D**, Peng YM, Brodar F, Booth A, Matias B, Modiano M, Tuttle R, Lucas S: Phase I and pharmacokinetic study of BW502U83 (an arylmethylaminopropanediol) in cancer patients. ASCO, Washington, DC, May 20-22, 1990. Proc Am Soc Clin Oncol 9:68 (#264), 1990.
187. Salmon SE, Liu R, **Alberts DS**, Ahmann AH, Taylor C, Hersh EM, Surwit EA, Steinbronn D, Leong SPL: Predicted antitumor activity of suramin in ovarian cancer and metastatic melanoma. ASCO, Washington, DC, May 20-22, 1990. Proc Am Soc Clin Oncol 9:68 (#263), 1990.
188. **Alberts DS**, Liu PY, Hannigan E, Surwit EA, O'Sullivan J, Garcia D, Richardson M, Williams S, Young J, O'Toole R: Relationship between serum CA-125 levels at chemotherapy courses 3 and 6 and the outcome of second-look surgery status in advanced ovarian cancer. AACR, Washington, DC, May 23-26, 1990. Proc Am Assoc Cancer Res 31:189 (#1121), 1990.

189. Einspahr J, **Alberts DS**, McGee D, Davidson J, Hixson L, Earnest D, Oishi N: Evaluation of the reproducibility of [³H]-thymidine labeling index determinations in crypt organ culture in normal subjects and patients with resected colorectal adenomas and cancers. AACR, Washington, DC, May 23-26, 1990. Proc Am Assoc Cancer Res 31:233 (#1380), 1990.
190. Xu MJ, Peng YM, Liu Y, **Alberts DS**, Plezia PM, Sayers SM: Effect of chronic oral administration of β -carotene on plasma α -tocopherol concentrations in normal subjects. AACR, Washington, DC, May 23-26, 1990. Proc Am Assoc Cancer Res 31:126 (#748), 1990.
191. Poplin E, Redman B, Smith H, Balcerzak S, **Alberts D**: SWOG 8825-intravenous melphalan and GM-CSF: A phase I study. AACR, Washington, DC, May 23-26, 1990. Proc Am Assoc Cancer Res 31:204 (#1213), 1990.
192. Modiano M, Plezia P, Becker S, **Alberts D**, Fairchild C, Smaldone L: Randomized double-blind crossover trial of batanopride (BMY-25801) vs. metoclopramide (MTC) in patients (pts) receiving cisplatin (CDDP) chemotherapy. AACR, Washington, DC, May 23-26, 1990. Proc Am Assoc Cancer Res, Washington, DC, May 23-26, 31:181 (#1078), 1990.
193. Taylor CW, Plezia PM, McCloskey TM, **Alberts DS**, Luo Y, Rudolph AR, Salmon SE, Hersh EM: Tumor necrosis factor and doxorubicin: A phase I clinical trial based on *in vitro* antitumor synergy and a pharmacokinetic interaction between the two agents. Combining Biologic Response Modifiers with Cytotoxics in Treatment Cancer: Developing Rational Approach to New Therapy, Baltimore, MD, 1990.
194. Xu MJ, Peng YM, Liu Y, **Alberts DS**: Platinum determination in biological samples by Zeeman Atomic Absorption Spectrophotometry. ANABIOTECH, 1990.
195. Earnest DL, Hixson LJ, Rappaport WD, Finley PR, Einspahr J, **Alberts DS**: Treatment with low-dose NSAID: Potential chemoprevention against colonic neoplasia. Am College Surgeons Scientific Exhibit, Oct. 8-11, 1990.
196. Smaldone L, **Alberts D**, Aapro M, Al-Sarraf M, Cavalli F, Vokes E, Carr B, Rozenzweig M: Randomized double-blind crossover comparison of batanopride (BMY-25801) and metoclopramide (MTC) in patients receiving cisplatin-based chemotherapy (CT). ESMO, 1990.
197. Kunz KR, Remers WA, Iyengar BS, Dorr RT, **Alberts DS**: Mitomycin QSAR. Santa Fe Graduate Medicinal Chemistry Conf, St. John's College, NM, July 6-8, 1990.
198. **Alberts DS**, Taylor C, Matias B, Ketcham M, Nichols H, Satterlee W, Grindy G, Seitz D, Nolte G: Phase II trial of sulofenur (LY186641) in patients with previously treated, advanced ovarian cancer. UICC, Hamburg, West Germany, Aug. 21, 1990.
199. **Alberts DS**: Intraperitoneal alpha-interferon for ovarian cancer. Interferon in 90's: Decade of Decisions, Phoenix, AZ, Oct. 18-21, 1990.
200. Thompson FH, Liu Y, **Alberts DS**, Nahhas W, Trent J, Salmon SE: Mosaicism for Turner's syndrome (45,X/46,XX) diagnosed after cytogenetic study of an ovarian tumor. Int Workshop Chromosomes in Solid Tumors, Feb. 24-26, 1991.
201. **Alberts DS**: Primary prevention of colorectal cancer through dietary modification. ACS National Conf, New Orleans, LA, March 20-22, 1991.
202. Giordano L, Atwood J, Sennott-Miller L, **Alberts D**, Earnest D: Strategies for adherence enhancement in cancer prevention trials. ASPO, Seattle, WA, April 10-12, 1991.
203. Bassford T, Hauck L, Santa Cruz V, Rosenberg R, Modiano M, **Alberts D**: Experience with a cancer prevention clinic. ASPO, Seattle, WA, April 10-12, 1991.
204. **Alberts DS**: Wheat bran fiber and calcium trials in polyp patients. ASPO, Seattle, WA, April 10-12, 1991.
205. Earnest D, Ritenbaugh C, Emerson S, **Alberts D**, Hixson L, Rees-McGee S, Atwood J, Clark L, Meyskens F: Putative risk factors for colon cancer: Lack of significant associations in patients with sporadic adenomatous colon polyps. AFCR, Seattle, WA, 1991. Clin Res 39:177A, 1991.

206. **Alberts DS**, Garcia D, Roe D, Fanta P, Liu R, Salmon S: Lack of tetraplatin cross resistance with cisplatin against epithelial ovarian cancers obtained from more than 70 patients with advanced disease. AACR, Houston, TX, May 15-18, 1991. Proc Am Assoc Cancer Res 32:409 (#2434), 1991.
207. Peng YS, Peng YM, Dalton WS, **Alberts DS**, Dyke RW: Binding of vincristine, vinblastine and vindesine to human α - & β -globulins, globulins, albumin and serum *in vitro*. AACR, Houston, TX, May 15-18, 1991. Proc Am Assoc Cancer Res 32: 329 (#1955), 1991.
208. Dorr RT, **Alberts DS**, Sami SM, Remers WA: Consistent cytotoxic activity in multidrug resistant tumors for azonafide, a new anthracene analog of amonafide. AACR, Houston, TX, May 15-18, 1991. Proc Am Assoc Cancer Res 32:408 (#2424), 1991.
209. Bishop MR, **Alberts DS**, McKenzie RS, McCloskey TM, Sosman JA, Fisher RI, Stiff PJ: High dose mitoxantrone with autologous bone marrow transplantation can clinically achieve plasma levels active against ovarian cancer cells *in vivo*. AACR, Houston, TX, May 15-18, 1991. Proc Am Assoc Cancer Res 32:177 (#1054), 1991.
210. McKenzie RS, **Alberts DS**, Bishop MR, McCloskey T, Sosman JA, Dolan JR, Koch D, Fisher RI, Stiff PJ: Phase I trial of high dose cyclophosphamide (CY), mitoxantrone (MX), and carboplatin (CB) with autologous bone marrow transplantation (ABMT) in female malignancies: Pharmacologic levels of mitoxantrone and high response rate in refractory ovarian cancer. ASCO, Houston, TX, May 19-21, 1991. Proc Am Soc Clin Oncol 10:186 (#605), 1991.
211. Truesdel C, Muggia FM, **Alberts DS**, Liu PY, O'Sullivan J, Wallace D: CA-125: A predictor of outcome from intraperitoneal (IP) therapy in Southwest Oncology Group (SWOG) Study 8835. ASCO, Houston, TX, May 19-21, 1991. Proc Am Soc Clin Oncol 10:195 (#644), 1991.
212. **Alberts D**, Miranda E, Dorr R, Nichols N, Ketcham M, MacNeal W, Hatch K, Surwit E, Childers J, Taylor C, Ahmann R, Salmon S: Phase II and pharmacokinetic (PK) and human tumor cloning assay (HTCA) study of suramin in advanced ovarian cancer. ASCO, Houston, TX, May 19-21, 1991. Proc Am Soc Clin Oncol 10:187 (#609), 1991.
213. Shipp NG, Dorr RT, **Alberts DS**, Liebler D: Mitoxantrone cardiotoxicity *in vitro* is selectively blocked by ICRF-187. ASCO, Houston, TX, May 19-21, 1991. Proc Am Soc Clin Oncol 10:118 (#340), 1991.
214. Taylor C, Modiano M, **Alberts DS**, Marcus S, Hersh E: Combination therapy with 5-fluorouracil (5-FU), leucovorin (LCV) and interferon-alpha (IFN- α) in patients with adenocarcinoma. ASCO, Houston, TX, May 19-21, 1991. Proc Am Soc Clin Oncol 10:141 (#432), 1991.
215. Smaldone L, Al-Sarraf M, Aapro M, **Alberts D**, Cavalli F, Vokes E, Carr B, Rozenzweig M: Randomized double-blind crossover comparison of batanopride (BMY-25801) and metoclopramide (MTC) in patients receiving cisplatin-based chemotherapy (CT). ASCO, Houston, TX, May 19-21, 1991. Proc Am Soc Clin Oncol 10:342 (#1211), 1991.
216. Einspahr J, Hixson L, **Alberts D**, Durbin D, Pennie K, Davidson J, McGee D, Garewal H: Comparison of [3 H]-thymidine ([3 H]-THYD) and BrdU labeling index (LI) in human colorectal mucosa. AGA, New Orleans, LA, May 19-22, 1991. Gastroenterology 100:A359, 1991.
217. Earnest DL, Hixson LJ, Blackwell G, Finley PR, Einspahr J, Ritenbaugh C, Atwood JR, **Alberts DS**, McGee D: Treatment with low dose piroxicam reduces colonic mucosal PGE₂ without increasing epithelial cell proliferation: Potential for chemoprevention against colonic neoplasia. AGA, New Orleans, LA, May 19-22, 1991. Gastroenterology 100:A359, 1991.
218. Earnest DL, **Alberts D**, Emerson S, Einspahr J, Hixson L, Rees-Magee S, Ritenbaugh C, Atwood J: [3 H]-Thymidine labeling index (LI) and other putative risk factors for colon cancer: Lack of significant associations in patients with sporadic adenomatous colon polyps. AGA, New Orleans, LA, May 19-22, 1991.

219. Meyskens FL Jr, Pelot D, Meshkinpour H, Gerner EW, Emerson S, **Alberts DS**: Effect of difluoromethylornithine (DFMO) on rectal mucosa polyamine content of subjects with prior colonic polyps. Am College Gastroenterology, Boston, MA, Oct. 14-16, 1991.
220. Surwit E, Childers J, Hatch K, **Alberts D**: Short-term, single-agent cisplatin chemotherapy as first-line treatment for stage III ovarian carcinoma. SGO, March 15-18, 1992. Gynecol Oncol 45:108, 1992.
221. Buller D, Modiano M, Meister J, de Zapien J, Lash S, Villar-Werstler P, Hunsaker F, **Alberts D**: A community survey on cervical cancer screening among young Hispanic women in the southwest. ASPO, Bethesda, MD, March 14-16, 1992.
222. Ratain MJ, Von Hoff DD, **Alberts DS**, Foster BJ, Earhart RH: Phase I trial program for adozelesin (U-73,975). Proc NCI-EORTC, March, 1992.
223. Peng YM, Peng YS, Lin Y, Tan H, Childers JM, Moon TW, Garewal H, **Alberts DS**: Micronutrient contents in paired tissue and plasma samples from normal and high risk subjects and cancer patients. AACR, San Diego, CA, May 20-23, 1992. Proc Am Assoc Cancer Res 33:286 (#1707), 1992.
224. **Alberts D**, Rees-McGee S, Einspahr J, Mason-Liddil N, Giordano L, Phelps J, Ramanujam P, Bellapravalu S, Patel J, Bettinger L, Kogan F, Earnest D, Ritenbaugh C, Atwood J, Story J, Hillier A, Davidson J, Clark L, McGee D: Double-blind, placebo controlled study of wheat bran fiber (WBF) vs calcium carbonate (CALC) in patients with resected adenomatous polyps. AACR, San Diego, CA, May 20-23, 1992. Proc Am Assoc Cancer Res 33:207 (#1242), 1992.
225. Dorr RT, Remers WA, Sami S, **Alberts DS**: Structure-activity relationships for anthracene derivatives of amonafide termed azonafides. AACR, San Diego, CA, May 20-23, 1992. Proc Am Assoc Cancer Res 33:523 (#3129), 1992.
226. Aickin M, Ritenbaugh C, Woolf K, Graver E, Rees-McGee S, Sampliner R, **Alberts D**: A general method of adjusting dietary data to obtain stable estimates of usual intake. Int Conf Dietary Assessment Methods, 1992.
227. **Alberts DS**, Garcia D, Fanta P, Liu R, Roe D, Salmon SE: Comparative cytotoxicities of taxol & taxotere *in vitro* against fresh human ovarian cancers. ASCO, San Diego, CA, May 17-19, 1992. Proc Am Soc Clin Oncol 11:226 (#719), 1992.
228. Garewal H, Pitcock J, Friedman S, **Alberts D**, Meyskens F, Ramsey L, Peng YM, Girodias K: Beta-carotene in oral leukoplakia. ASCO, San Diego, CA, May 17-19, 1992. Proc Am Soc Clin Oncol 11:141 (#386), 1992.
229. Plezia P, Modiano M, **Alberts D**, Bertoli L, Yielding A, Einsberg P, Khojasteh A, Gandara D, Heck K, Hahne W: A double-blind, randomized, parallel study of two doses of intravenous (IV) MDL 73, 147EF in patients (PTS) receiving high dose cisplatin (CDDP)-containing chemotherapy (CT). ASCO, San Diego, CA, May 17-19, 1992. Proc Am Soc Clin Oncol 11:407 (#1425), 1992.
230. Modiano M, Villar-Werstler P, Lash S, Meister J, de Zapien J, Buller D, **Alberts D**: Increasing enrollment of minorities into clinical trials through community involvement. ASCO, San Diego, CA, May 17-19, 1992. Proc Am Soc Clin Oncol 11:147 (#409), 1992.
231. Remers WA, Sami SM, Dorr RT, **Alberts DS**: 1, 2-dihydro-3H-Dibenz (DEH) isoquinoline-1, 3-diones, new antitumor agents related to amonafide. Int Symp Medicinal Chemistry, Basel, Switzerland, Sept., 1992.
232. **Alberts DS**: Chemoprevention of colorectal cancer. Proc Chemoprevention Foundation Mtg, Nov., 1992.
233. Dorr RT, **Alberts DS**: Multidrug resistance to mitomycin C: Experimental background and pilot clinical trials with megestrol acetate as a modulator. Int Symp Mechanism Multidrug Resistance, Oct., 1992.
234. Earnest DL, Hixson LJ, Fennerty MB, **Alberts DS**: NSAIDs for prevention of colon cancer: Early studies with piroxicam in humans. Int Conf Prevention Human Cancer: Nutrition and Chemoprevention Controversies, Tucson, AZ, June 3-6, 1992.

235. **Alberts DS**, Sampliner R, Einspahr J, Mason-Liddil N, Rees-McGee S, Ritenbaugh C, Sennott-Miller L, Giordano L, Roe D, McGee D, Emerson S, Clark L, Earnest D, and the Phoenix Metropolitan Gastroenterologists: Colon cancer prevention - the argument for fiber. *Int Conf Prevention Human Cancer: Nutrition and Chemoprevention Controversies*, Tucson, AZ, June 3-6, 1992.
236. Surwit E, Childers J, Hatch K, **Alberts D**: Nonadjuvant chemotherapy for advanced ovarian carcinoma. *SGO*, Feb. 7-10, 1993. *Gynecol Oncol* 49:134, 1993.
237. Liu Y, Salmon S, Weinstein R, **Alberts DS**, Thompson FH: Clonal chromosomal abnormalities in a case of ovarian teratoma. *Int Workshop Chromosomes in Solid Tumors*, Jan. 10-12, 1993.
238. Thompson FH, Liu Y, **Alberts D**, Fox S, Emerson J, Salmon SE, Taetle R, Trent JM: Evidence for specific, simple numeric abnormalities as primary karyotypic changes in ovarian carcinoma. *Int Workshop Chromosomes in Solid Tumors*, Jan. 10-12, 1993.
239. Einspahr J, **Alberts D**, Earnest D, Hixson L, Davidson J, Roe D, Blackwell G: Comparison of tritiated thymidine, BrdU, and PCNA labeling indices in normal mucosal rectal biopsies from subjects with resected colorectal cancer. *AACR*, Orlando, FL, May 19-22, 1993. *Proc Am Assoc Cancer Res* 34:552 (#3287), 1993.
240. Modiano M, Taylor C, Brooks R, Wiggins C, Power J, **Alberts D**: Etoposide (E), Leucovorin (L), 5-fluorouracil (F), and interferon- α 2A (I) (ELFI) is an active treatment for high-risk or advanced pancreatic or gastric adenocarcinoma. *ASCO*, Orlando, FL, May 16-18, 1993. *Proc Am Soc Clin Oncol* 12:203 (#604), 1993.
241. Xu MJ, **Alberts DS**, Goldman R, Smeester D, Peng YM: Analysis and storage stability of polyamines in human skin. *AACR*, Orlando, FL, May 19-22, 1993. *Proc Am Assoc Cancer Res*, Orlando, FL, May 19-22, 34:552 (#3288), 1993.
242. Powell MB, Hyman P, Zawadski L, Brown K, Balmain A, **Alberts D**, Bowden GT: Increased pigmentation and melanocytic hyperplasia in transgenic mice. *AACR*, Orlando, FL, May 19-22, 1993. *Proc Am Assoc Cancer Res* 34:122 (#725), 1993.
243. Meister J, Modiano M, Buller D, Zapien J, Lash S, Santa Cruz V, Villar-Werstler P, **Alberts D**: Juntos contra el cancer: A Hispanic health community program improves cancer screening rates and access to care for Mexican-American women in the southwest. *ASCO*, Orlando, FL, May 16-18, 1993. *Proc Am Soc Clin Oncol* 12:170 (#476), 1993.
244. Meyskens FL Jr, Surwit E, Moon TE, Davis J, **Alberts DS**: A placebo-controlled, randomized phase III trial of locally-applied β -trans retinoic acid (vitamin A acid, RA) in cervical intraepithelial neoplasia (CIN): Favorable effect on CIN II (moderate dysplasia). *ASCO*, Orlando, FL, May 16-18, 1993. *Proc Am Soc Clin Oncol* 12:167 (#465), 1993.
245. **Alberts DS**: Adjuvant therapy of ovarian cancer. *Int Conf Adjuvant Therapy of Cancer*, Tucson, AZ, March 10-13, 1993.
246. **Alberts DS**, Modiano MR, Shamdas GJ, Childers J, Surwit E, Hatch K, Pruett L, Garcia D, Lippman SM: Phase II trial of 13-cis-retinoic acid (13-cRA) plus interferon- α 2A (IFN) for advanced, heavily treated squamous cell carcinoma of the cervix (SCCC). *ASCO*, Orlando, FL, May 16-18, 1993. *Proc Am Soc Clin Oncol* 12:266 (#852), 1993.
247. **Alberts D**, Hixson L, Krutzsch M, Einspahr J, Brendel K, Paranka N, Baier M, Emerson S, Pamukcu R: Antiproliferative effect of nonsteroidal anti-inflammatory drugs (NSAIDS) against HT-29 colon cancer cells. *AACR*, Orlando, FL, May 19-22, 1993. *Proc Am Assoc Cancer Res* 34:557 (#3320), 1993.
248. Hixson L, **Alberts D**, Krutzsch M: Piroxicam inhibits proliferation in colon adenomatous polyp explants. *AGA*, Boston, MA, May, 1993.
249. Narce-Valente S, Powell MB, Culling-Berglund A, Cartmel B, **Alberts DS**: ADP-ribosyl transferase (ADPRT) activity, actinic keratosis (AK), and nonmelanoma skin cancer (NMSC). *ASPO*, 1993.

250. Moon TE, Surwit E, Meyskens FL, Davis J, Dorr R, **Alberts DS**: The evaluation of topically-applied retinoic (vitamin A) acid in the regression of cervical intraepithelial neoplasia. ASPO, 1993.
251. **Alberts DS**: Strategies for the prevention of colon cancer. CCPC, Berlin, Germany, April 28-30, 1993.
252. Garewal H, Meyskens F, Katz R, Friedman S, Morse D, **Alberts DS**, Ritenbaugh C: Beta-carotene and other antioxidant nutritional agents in oral leukoplakia. CCPC, Berlin, Germany, April 28-30, 1993.
253. Moon TE, Levine N, Cartmel B, Bangert J, Peng YM, **Alberts DS**: The evaluation of vitamin A and retinoids in the chemoprevention of skin cancer. CCPC, Berlin, Germany, April 28-30, 1993. Proc CCPC p. 84 (#57), 1993.
254. Meyskens F, Surwit E, Childers J, Moon T, Shell M, Davis J, **Alberts DS**: Phase III randomized trial of trans-retinoic acid to prevent progression of cervical intraepithelial neoplasia (CIN): Would new biomarkers have helped along the way? CCPC, Berlin, Germany, April 28-30, 1993. Proc CCPC p. 45 (#20), 1993.
255. Meyskens FL Jr, Gerner E, Emerson S, Pelot D, Boyle J, **Alberts D**, Dutton C: Phase IIA trial of DFMO and its effect on polyamine levels in buccal mucosal cells and rectal colonic biopsies. CCPC, Berlin, Germany, April 28-30, 1993. Proc CCPC p. 133 (#105), 1993.
256. Meyskens F, Kopecky K, Surwit E, Childers J, Moon T, Davis J, **Alberts DS**: Phase III randomized trials of retinoids to prevent progression of chronic myelogenous leukemia (CML) in chronic phase and cervical intraepithelial neoplasia (CIN). CCPC, Berlin, Germany, April 28-30, 1993.
257. Taylor C, Modiano M, Garrison L, List A, **Alberts D**, Hersh E, Taetle R: Pixy plus carboplatin (C) and adriamycin (A) in patients with advanced gastrointestinal (GI) malignancy. ASCO, Orlando, FL, May 16-18, 1993. Proc Am Soc Clin Oncol 12:195 (#569), 1993.
258. Thompson FH, Liu Y, **Alberts D**, Taetle R, Trent JM: Cytogenetic findings in 51 colorectal carcinomas: Correlations with sample site. ASHG, New Orleans, LA, Oct. 5-9, 1993. Am J Hum Genet 53(Suppl): #376, 1993.
259. Ritenbaugh CK, Aickin MG, **Alberts DS**, Story J, Sampliner R, Atwood J, Meyskens F Jr: Short vs. long term effects of wheat bran fiber and calcium intakes on fecal bile acids. Int Congress Nutritional Sciences, Adelaide, Australia, Sept. 26-30, 1993.
260. Liu Y, Salmon S, Weinstein R, **Alberts D**, Thompson FH: Clonal chromosomal abnormalities in a case of ovarian teratoma. Cancer Genet Cytogenet 66:161, 1993.
261. Thompson FH, Liu Y, **Alberts D**, Fox S, Emerson J, Salmon SE, Taetle R, Trent JM: Evidence for specific, simple numeric abnormalities as primary karyotypic changes in ovarian carcinoma. Cancer Genet Cytogenet 66:161, 1993.
262. Taetle R, **Alberts DS**, Brooks DJ, Ihle J, Pargamus E, Woodward S: Expression of EV1 proto-oncogene RNA in ovarian cancer. ASH, St. Louis, MO, Dec. 3-7, 1993.
263. Vargas PA, **Alberts DS**: Prevenzione primaria del carcinoma coloretale mediante corretta alimentazione. Oncology Digest (Italian) 3:20-21, 1993.
264. **Alberts DS**, Hixson L: Nonsteroidal anti-inflammatory drugs as chemopreventive agents. Advances Biology and Therapy Colorectal Cancer, Houston, TX, Nov. 4-7, 1993.
265. Nelson MA, Einspahr J, Balfour C, Wymer J, Welch K, Salasche S, Bangert J, Grogan T, **Alberts DS**: Mutations in the p53 gene in pre-cancerous actinic keratosis lesions and human epithelial skin cancers. Soc of Toxicology, 1994.
266. Dorr RT, Sami S, Remers WA, **Alberts DS**, Salmon SE, Hersh EM: The azonafide series of anthracenes with activity in multidrug resistant (MDR) tumors. NCI-EORTC, 1994.
267. Remers WA, Dorr RT, Sami SM, Solyom AS, **Alberts DS**: Quantitative structure-activity relationships of azonafide analogues. AACR, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:337 (#2009), 1994.

268. Dorr RT, Remers WA, **Alberts DS**, Salmon SE, Hersh EM: Activity of a substituted anthracene, AMP-53, in sensitive and multidrug resistant tumors in vitro and in vivo. AACR, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:(#2166), 1994.
269. Brooks DJ, Russell M, Woodward S, **Alberts DS**, Taetle R: Expression of EVII RNA in ovarian cancer and normal ovary. AACR, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:(#3280), 1994.
270. Einspahr J, **Alberts D**, Aickin M, Welch K, Bangert J, Salasche S, Grogan T, Nelson M: Evaluation of P53 protein expression in actinic keratosis, adjacent, and normal-appearing skin samples. AACR, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:622 (#3708), 1994.
271. **Alberts D**, Hixson L, Ahnen D, Bogert C, Einspahr J, Brendel K, Gross P, Paranka N, Burt R, Pamukcu R: Do non-steroidal anti-inflammatory drugs (NSAIDs) inhibit rat azoxymethane (AOM) colon carcinogenesis through inhibition of colonic mucosal prostaglandin synthesis? AACR, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:632 (#3766), 1994.
272. Clark DA, Taylor JE, **Alberts DS**, Davis TP: Inhibition of human small cell lung cancer growth by growth factor receptor antagonists and protease inhibitors. AACR, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:379 (#2261), 1994.
273. Nelson MA, Einspahr J, Balfour C, Wymer J, Welch K, Salasche S, Bangert J, **Alberts DS**: Mutations in the p53 and H-ras genes in human actinic keratosis lesions and squamous cell cancers. AACR, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:337 (#3707), 1994.
274. Xu MJ, Peng YM, Gensler H, **Alberts DS**: Determination of alpha-tocopherol and its esters in mouse skin by HPLC. AACR, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:627 (#3741), 1994.
275. Ahnen D, Hixson L, **Alberts D**, Brendel K, Gross P, Paranka N, Burt R, Pamukcu R: Sulindac, and its sulfone metabolite (FGN-1), both inhibit rat colon carcinogenesis but neither inhibit colonic proliferation. AACR, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:(#3763), 1994.
276. Holubec H, Earnest D, Jolley C, Einspahr J, **Alberts D**, Allen C, Brasitus T: Effect of a chemopreventive dose of ursodeoxycholic acid on colonic mucosal markers of cancer risk. AGA, New Orleans, LA, May 15-18, 1994.
277. Muggia F, **Alberts D**, Liu P, Terada K, Wallace D: Intraperitoneal (IP) mitoxantrone vs. intraperitoneal floxuridine in ovarian cancer patients with minimal residual disease after second-look surgery, a randomized phase II pilot. ASCO, Dallas, TX, May 14-17, 1994. Proc Am Soc Clin Oncol 13:249 (#782), 1994.
278. Stini W, Chen Z, **Alberts D**, Ritenbaugh C, Sampliner R, Aikin M, Vargas P, Woolf K: Relationships of bone mineral content, body fat and fat-free mass in elderly subjects. Experimental Biology, 1994.
279. **Alberts DS**, Einspahr J, Aickin M, Bogert C, Earnest D, Roe D, Powell M, Finley P: Validation of proliferation indices and prostaglandin concentrations as surrogate endpoint biomarkers in rectal mucosal biopsies. Quantitative Pathology Chemoprevention Cancer, San Diego, CA, Feb. 9-13, 1994.
280. **Alberts DS**, Emerson J, Thompson F, Taetle R, Trent J, Grogan T, Liu-Xu Y, Frutiger Y, Fanta P, Running K, Federico M, Salmon S: Studies of the pathogenesis and prognosis of previously untreated, epithelial type ovarian cancer. NIH Consensus Conf, Bethesda, MD, April 5-7, 1994.
281. **Alberts D**, Hixson L, Ahnen D, Bogert C, Einspahr J, Brendel K, Gross P, Paranka N, Burt R, Pamukcu R: Do non-steroidal anti-inflammatory drugs (NSAIDs) inhibit rat azoxymethane (AOM) colon carcinogenesis through inhibition of colonic mucosal prostaglandin synthesis? Proc World Congress Gastroenterology, Los Angeles, CA, Oct. 2-7, 1994.
282. Bell IR, Ritenbaugh C, **Alberts DS**, Peterson JM, Schwartz GE: Discrepancies between self-reported food frequency and diet diary histories as a function of personality trait shyness: Implications for epidemiological studies of diet and disease. Am College Nutrition, Oct., 1994.

283. **Alberts DS:** Nonsteroidal anti-inflammatory drugs in colon cancer prevention. *Cancer Chemo Agents*, Princeton, NJ, Oct. 18-22, 1994.
284. Aickin M, Ritenbaugh C, Graver E, Woolf K, **Alberts D:** The biases created by dietary instruments can be corrected. *Int Conf Dietary Assessment Methods*, 1995.
285. Ritenbaugh C, Aickin M, Woolf K, Graver E, **Alberts D:** Use of a food frequency questionnaire for eligibility screening in clinical trials. *Int Conf Dietary Assessment Methods*, 1995.
286. Taetle R, Emerson J, Trent J, Thompson F, Weinstein R, Leong S, Dalton W, Emerson S, **Alberts D:** Overview of results obtained in the Cytogenetics Oncology Program Project (COPP). *Solid Tumor Cytogenetics Workshop*, 1995.
287. Nelson MA, **Alberts DS:** Effect of topically administered α -DFMO in patients with established solar keratoses in randomized clinical trial. *Soc of Toxicology*, Baltimore, MD, March 5-9, 1995.
288. **Alberts DS**, Krutzsch M, Wymer J, Liddil J, Dvorakova K, Einspahr J, Running K, Dorr RT: Experimental rationale for 24 vs 3 hour (Hr) paclitaxel infusion schedules in the treatment (Rx) of advanced ovarian cancer (OVCA). *AACR*, Toronto, ON, March 18-22, 1995. *Proc Am Assoc Cancer Res* 36:363 (#2164), 1995.
289. Xu MJ, Peng YM, **Alberts DS:** A new precolumn derivatization method for determination of α -difluoromethylornithine and ornithine in biological specimens by HPLC. *AACR*, Toronto, ON, March 18-22, 1995. *Proc Am Assoc Cancer Res* 36:592 (#3524), 1995.
290. Nelson MA, Thompson FH, Emerson J, **Alberts DS**, Taetle R: Chromosome band 1p36 abnormalities in ovarian cancers. *AACR*, Toronto, ON, March 18-22, 1995. *Proc Am Assoc Cancer Res* 36:552 (#3290), 1995.
291. Speicher LA, Krutzsh M, Wymer J, **Alberts DS**, Capizzi RL: Amifostine does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. *AACR*, Toronto, ON, March 18-22, 1995. *Proc Am Assoc Cancer Res* 36:290 (#1727), 1995.
292. Tricot G, **Alberts DS**, Roe D, Dorr RT, Vesole DH, Jagannath S, Barlogie B: High dose melphalan (MEL) and renal function in multiple myeloma (MM). *ASH*, 1995.
293. Thompson FH, Liu Y, Emerson J, **Alberts D**, Trent JM, Nelson M, Taetle R: 1p36 structural abnormalities and t(1;17) in ovarian carcinoma. *Int Workshop Chromosomes in Solid Tumors*, Tucson, AZ, Feb. 19-21, 1995
294. Thompson FH, Yang JM, Liu Y, Trent JM, Guan XY, Emerson J, **Alberts DS**, Nelson M, Taetle R: Structural alterations of chromosome 19 in ovarian cancer: G-band, and fish studies. *Int Workshop Chromosomes in Solid Tumors*, Tucson, AZ, Feb. 19-21, 1995.
295. Garewal H, Meyskens F, Katz RV, Friedman S, Morse DE, **Alberts D**, Girodias K: Beta-carotene produces sustained remissions in oral leukoplakia: Results of a 1 year randomized, controlled trial. *ASCO*, Los Angeles, CA, May 20-23, 1995. *Proc Am Soc Clin Oncol* 14:496 (#1623), 1995.
296. **Alberts DS**, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young J, Franklin EW, Clarke-Pearson D, Malviya VK, DuBeshter B, Hoskins W, Adelson M, Alvarez RD, Vogl S, O'Sullivan J, Garcia DJ, Sparks D, Rothenberg ML: Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG Intergroup study (INT 0051). *ASCO*, Los Angeles, CA, May 20-23, 1995. *Proc Am Soc Clin Oncol* 14:273 (#760), 1995.
297. Liu PY, **Alberts DS**, Federico M, Hannigan EV, Garcia DJ, Rothenberg ML, Dorr RT: CA-125 concentration 8 weeks after treatment initiation independently predicts survival in patients with advanced epithelial ovarian cancer: A Southwest Oncology Group (SWOG) study. *ASCO*, Los Angeles, CA, May 20-23, 1995. *Proc Am Soc Clin Oncol* 14:266 (#735), 1995.

298. Muggia F, Liu PY, **Alberts DS**, Terada K, Belt RJ, Schmidt HJ, Pollack TW, Weiser EB, Blayney D, Wallace D, O'Toole R: Elevated serum CA-125: An adverse prognostic factor for survival in epithelial ovarian cancer (EOC) with minimal residual disease after second-look laparotomy (SLL). ASCO, Los Angeles, CA, May 20-23, 1995. Proc Am Soc Clin Oncol 14:270 (#750), 1995.
299. Ahnen D, Piazza G, **Alberts D**, Paranka N, Burt R, Pamukcu R: Sulindac sulfide (SS) and sulfone (FGN-1) both inhibit the growth of colon cancer cell lines by inducing apoptosis. AGA, San Diego, CA, May 14-17, 1995. Gastroenterology 108:A443, 1995.
300. Ahnen D, **Alberts D**, Hixson L, Paranka N, Burt R, Pamukcu R: The sulfone metabolite of sulindac (FGN-1) inhibits rat colonic carcinogenesis but does not inhibit either prostaglandin synthesis or colonic proliferation. AGA, San Diego, CA, May 14-17, 1995. Gastroenterology 108:A444, 1995.
301. Earnest D, Holubec H, Einspahr J, Jolley C, **Alberts D**, Ahnen D, Brasitus T: Lack of correlation between colonic epithelial cell proliferation and drug-induced inhibition of colon cancer in rats treated with azoxymethane. AGA, San Diego, CA, May 14-17, 1995. Gastroenterology 108:A463, 1995.
302. Powell MB, Gregus J, Gause P, Bowden GT, **Alberts D**: Transgenic mice expressing human T24 Ha-ras in pigmented cells: A model for melanoma development. Joint Conf AACR & Japanese Cancer Assoc, Feb., 1995.
303. **Alberts DS**, Krutzsch M, Wymer J, Speicher L, Capizzi RL: Evaluation of effect of the active metabolite of amifostine (AMI), WR-1065, on the cytotoxicity of anticancer drugs against human ovarian cancer. ECCO, Paris, France, Oct. 29-Nov. 2, 1995. Eur J Cancer 31A(Suppl 5):5106, 1995.
304. Dorr RT, McLean S, **Alberts DS**, Speicher L, Capizzi RL: Selective cardioprotection of rat heart myocytes exposed to DNA intercalating agents using amifostine (AMI) and its dephosphorylated metabolite, WR-1065. ECCO, Paris, France, Oct. 29-Nov. 2, 1995. Eur J Cancer 31A(Suppl 5):5123, 1995.
305. **Alberts DS**, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young J, Franklin EW, Clarke-Pearson D, Malviya VK, DuBeshter B, Hoskins W, Adelson M, Alvarez RD, Vogl S, O'Sullivan J, Garcia DJ, Sparks D, Rothenberg ML: Phase III study of IP cisplatin plus IV cyclophosphamide vs IV cisplatin plus IV cyclophosphamide in optimal disease stage III ovarian cancer: An Intergroup study 0051 (SWOG-GOG-ECOG). Proc SGO, p. 40 (#1), New Orleans, LA, Feb. 10-14, 1996.
306. **Alberts DS**, Dorr RT, Aickin M, Quinn J, Goldman R, Nelson M, Xu MJ, Peng YM, Bozzo P, Gensler H: Positive randomized, double blinded, placebo controlled study of topical difluoromethylornithine (DFMO) in the chemoprevention of skin cancer. ASCO, Philadelphia, PA, May 18-21, 1996. Proc Am Soc Clin Oncol 15:172 (#342), 1996.
307. Piazza G, Mehta R, **Alberts D**, Burt R, Pamukcu R, Ahnen D: Antineoplastic activity of sulindac does not require cyclooxygenase inhibition. AACR, Washington, DC, April 20-24, 1996. Proc Am Assoc Cancer Res 37:279 (#1901), 1996.
308. **Alberts DS**, Reid M, Aickin M, Xie T, Martinez ME, Ritenbaugh C, Vargas P, Earnest D, Sampliner R: Cigarette smoking and colorectal adenoma recurrence at repeat colonoscopy. AACR, Washington, DC, April 20-24, 1996. Proc Am Assoc Cancer Res 37:254 (#1731), 1996.
309. Xu MJ, **Alberts DS**, Peng YM, Liu Y, Canfield LM: Simultaneous analysis of plasma retinol, retinyl palmitate, δ -, γ -, α -tocopherols and six major carotenoids by isocratic non-aqueous reversed-phase HPLC method. AACR, Washington, DC, April 20-24, 1996. Proc Am Assoc Cancer Res 37:277 (#1887), 1996.
310. Einspahr J, **Alberts D**, Aickin M, Welch K, Bozzo P, Levine N, Grogan T: Evaluation of proliferating cell nuclear antigen (PCNA) as a biomarker of skin cancer risk. AACR, Washington, DC, April 20-24, 1996. Proc Am Assoc Cancer Res 37:269 (#1836), 1996.
311. Batta AK, Salen G, Pamukcu R, **Alberts D**, Earnest D, Ahnen D: Sulindac and its sulfone derivative inhibit colon cancer via modification of intestinal bile acids. AGA, San Francisco, CA, May 19-22, 1996. Gastroenterology 110:A490, 1996.

312. Xie T, Aickin M, **Alberts D**: A truncated poisson regression model with applications to occurrence of adenomatous polyps. *Am Stat Assoc*, 1996.
313. **Alberts DS**: Adjuvant therapy of ovarian cancer. *Int Conf Adjuvant Therapy of Cancer*, Scottsdale, AZ, March 13-16, 1996.
314. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, **Alberts DS**: The nutritional prevention of cancer with selenium 1983-1993: A randomized clinical trial. *Proc ASPO*, Bethesda, MD, March 23, 1996.
315. Batta AK, Salen G, Gibson J, Holubec H, **Alberts D**, Earnest D: Metabolism of 6-fluorouroursodeoxycholic acid (FUD) in the rat: Reduced bacterial 7-dehydroxylation, increased biliary enrichment and conversion to Δ^{22} -derivative. *Am Assoc Study Liver Diseases*, Chicago, IL, Nov. 8-12, 1996.
316. **Alberts DS**, Heddens DK, Garcia DJ, Williams SD, Hannigan EV, Hoskins WJ, O'Toole R, Quade J, O'Sullivan J: Chemotherapy-induced anemia and packed red blood cell (PRBC) transfusions in advanced ovarian cancer patients enrolled in a phase III study of cisplatin plus cyclophosphamide. *ASH*, Orlando, FL, Dec. 6-10, 1996. *Blood* 88(10, Suppl 1, Pt 2):8b (#2760), 1996.
317. Batta AK, Salen G, Earnest D, **Alberts D**, Pamukcu R, Ahnen D: Sulindac (Sul) and sulindac sulfone (FGN-1) may inhibit colon cancer via modification of intestinal bile acids. *Int Bile Acids Mtg*, Freiburg, Germany, Oct. 22-24, 1996.
318. Yang JM, Kwee YM, Taetle R, Wymer JA, **Alberts DS**, Guan XY, Trent JM, Miki T, Nelson MA: The human of ECT2 (epithelial cell transforming gene 2) mapping on chromosome 3q26.1-3q26.2 is amplified in ovarian cancer cells. *Int Workshop Chromosomes and Solid Tumors*, Tucson, AZ, 1997.
319. Einspahr J, **Alberts D**, Warneke J, Hart N, Bozzo P, Quinn J, Grogan T: p53, bcl-2, and apoptosis as useful surrogate endpoint biomarkers (SEBs) in human skin carcinogenesis. *AACR*, San Diego, CA, April 12-16, 1997. *Proc Am Assoc Cancer Res* 38:528 (#3546), 1997.
320. Xu XC, Einspahr J, Nelson M, Warneke J, **Alberts D**, Lotan R: Differential expression of retinoic acid receptor β in actinic keratosis, adjacent skin, and non sun-exposed skin. *AACR*, San Diego, CA, April 12-16, 1997. *Proc Am Assoc Cancer Res* 38:86 (#575), 1997.
321. Weiss GR, Liu PY, **Alberts DS**, Gandara DR, Baker LH, Hynes HE: A randomized phase II trial of 13-*cis*-retinoic acid (CRA) or all-*trans*-retinoic acid (ATRA) plus interferon alpha 2A (IFN) for metastatic or recurrent squamous/adenosquamous carcinoma of the uterine cervix: A Southwest Oncology Group study. *ASCO*, Denver, CO, May 17-20, 1997. *Proc Am Soc Clin Oncol* 16:355a (#1268), 1997.
322. Rothenberg ML, Pazdur R, Rowinsky EK, Cohn AL, **Alberts DS**, Petit RG, Miller LL, Elfring GL, Murphy TC, Mayer RJ: A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer (CRC). *ASCO*, Denver, CO, May 17-20, 1997. *Proc Am Soc Clin Oncol* 16:266a (#944), 1997.
323. Holubec H, Earnest D, Batte A, Salen G, **Alberts D**, Gibson J: Chemopreventive effects of 6-fluoro ursodeoxycholic acid on azoxymethane-induced aberrant crypt foci in rat colon. *AGA*, Washington, DC, May 11-14, 1997. *Gastroenterology* 112:A579, 1997.
324. Nelson MA, Contreras V, Holubec H, Payne C, **Alberts D**, Earnest DL: Studies on the mechanism of growth inhibition of aberrant crypt foci by ursodeoxycholic acid. *AGA*, Washington, DC, May 11-14, 1997. *Gastroenterology* 112:A626, 1997.
325. DiSario JA, **Alberts DS**, Tietze CC, Khullar SK, Bohman VD, Larsen BR, Hixson LJ, Samowitz WS, Reading JC, Buys SS, Dawson R, Burt RW: Sulindac induces regression and prevents progression of sporadic colorectal adenomas. *AGA*, Washington, DC, May 11-14, 1997. *Gastroenterology* 112:A555, 1997.
326. Young RC, Brady MF, Nieberg RM, Long HJ, Mayer A, Lentz SS, Hurteau J, **Alberts DS**: Randomized clinical trial of adjuvant treatment of women with early (FIGO I-IIA high risk) ovarian cancer - GOG #95. *Int Gynecologic Cancer Society*, Fukuoka, Japan, Oct., 1997.

327. Batta AK, Salen G, **Alberts D**, Reid M, Morales T, Earnest D: Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, suppresses the proportion of deoxycholic acid in the water soluble fraction in human stool. AGA/AASLD, Chicago, IL, Nov. 7-11, 1997.
328. Surwit EA, Childers JM, **Alberts DS**: Survival and morbidity of neoadjuvant chemotherapy compared to primary cytoreductive surgery in advanced ovarian cancer. SGO, Gynecol Oncol 68:122 (#205), 1998.
329. Taetle R, Aickin M, Yang JM, Panda L, Emerson J, Roe D, **Alberts DS**, Thompson F, Wisner L, Davis J, Trent J: Non-random chromosome breakpoints in ovarian carcinomas are associated with impaired survival. AACR, New Orleans, LA, March 28-April 1, 1998. Proc Am Assoc Cancer Res 39:413 (#2808), 1998.
330. Ritenbaugh C, Aickin M, Taren D, Graver E, Einspahr J, Bogert C, Hart N, Sampliner R, Earnest D, **Alberts D**: Colon crypt cell labeling index is associated with food intake patterns. AACR, New Orleans, LA, March 28-April 1, 1998. Proc Am Assoc Cancer Res 39:89 (#606), 1998.
331. Heddens DK, **Alberts DS**, Garcia DJ, Hannigan EV, Rothenberg ML: Factors associated with platinum-induced anemia in ovarian cancer (OVCA) patients (PTS) in Southwest Oncology Group (S) studies. ASCO, Los Angeles, CA, May 16-19, 1998. Proc Am Soc Clin Oncol 17:359a (#1387), 1998.
332. **Alberts DS**, Taetle R, Frutiger E, Heddens D, Laptalo L, Einspahr J, Gilmore D, Grogan T: Multidrug resistance (MDR-1) expression as an independent risk factor for poor survival in optimal stage III ovarian cancer (OVCA). ASCO, Los Angeles, CA, May 16-19, 1998. Proc Am Soc Clin Oncol 17:351a (#1356), 1998.
333. Markman M, Bundy B, Benda J, **Alberts D**, Wadler S, Fowler J, Clark-Pearson D, Carson LF: Randomized phase 3 study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): An Intergroup trial (GOG, SWOG, ECOG). ASCO, Los Angeles, CA, May 16-19, 1998. Proc Am Soc Clin Oncol 17:361a (#1392), 1998.
334. Poplin EA, Liu PY, Delmore J, Wilczynski S, **Alberts D**: Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma (SWOG 9212). ASCO, Los Angeles, CA, May 16-19, 1998. Proc Am Soc Clin Oncol 17:373a (#1436), 1998.
335. Batta AK, Salen G, Rapole KR, Batta M, **Alberts D**, Earnest D: A highly simplified method for plasma and fecal bile acid analysis in humans. Gastroenterology 114:A515 (#G2098), AGA, New Orleans, LA, May 16-22, 1998.
336. Martinez JD, Stratagoules ED, Payne CM, Batta AK, Craven MT, Reid M, **Alberts DS**, Powell AA, Powell MB, Earnest D: The tumor promoter deoxycholic acid induces apoptosis while the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Gastroenterology 114:A396 (#G1615), AGA, New Orleans, LA, May 16-22, 1998.
337. Earnest DL, Reid M, Heddens D, Batta AK, Salen G, **Alberts DS**, Morales T: Treatment with 600 mg/day of ursodeoxycholic acid maximally suppresses the proportion of deoxycholic acid in fecal water. AGA, New Orleans, LA, May 16-22, 1998. Gastroenterology 114:A588 (#G2413), 1998.
338. Martinez ME, Matzman T, Marshall JR, Einspahr J, Reid M, Guillen-Rodriguez J, van Leeuwen B, Ahnen DJ, **Alberts DS**: Association between cigarette smoking and k-ras mutations in colorectal adenomas. Society of Epidemiologic Research, Chicago, IL, June 24-26, 1998. Am J Epidemiol 147:S69 (#276), 1998.
339. Marshall JR, Martinez ME, Bogert CL, Heddens D, Blackwell G, **Alberts DS**, Earnest DL: Physical activity and PGE₂ levels in rectal mucosa. Society of Epidemiologic Research, June, 1998.
340. **Alberts DS**: Chemoprevention of cancer pathological, biochemical and molecular endpoints. Gene Environment Interactions: Emerging Issues, Technologies and Biologic Paradigms, Austin, TX, Dec. 2-5, 1998.

341. Thomson CA, Giuliano AR, **Alberts DS**, Bogert C, Kight MA: The effect of a high fruit and vegetable, low fat diet on urinary 8-hydroxy-2-deoxyguanosine excretion in women previously treated for breast cancer. *Cancer Survivorship: Research Challenges and Opportunities for the New Millennium*, Bethesda, MD, March 8-9, 1999.
342. Peters WA III, Liu PY, Barrett R, Gordon W Jr, Stock R, Berek JF, DiSaia PJ, Souhami L, Grigsby P, **Alberts DS**: Cisplatin, 5-fluorouracil, plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy. Report of a phase III Intergroup study. SGO, San Francisco, CA, March 20-24, 1999. *Gynecol Oncol* 72:443 (#1), 1999.
343. Markman M, Bundy B, Benda J, **Alberts DS**, Wadler S, Fowler J, Clarke-Pearson DL, Carson LF: Randomized trial of standard dose intravenous (iv) cisplatin/paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal (ip) cisplatin. A Gynecologic Oncology Group study. SGO, San Francisco, CA, March 20-24, 1999. *Gynecol Oncol* 72:445 (#9), 1999.
344. Maltzman T, Knoll K, Martinez ME, Byers T, Marshall J, Reid M, Einspahr J, Hart N, Bhattacharyya AB, Bogert C, Sampliner R, **Alberts D**, Ahnen D: Association of Ki-ras mutations and polyp characteristics. AACR, Philadelphia, PA, April 10-14, 1999. *Proc Am Assoc Cancer Res* 40:42 (#279), 1999.
345. Martinez ME, Marshall JR, Einspahr J, Reid ME, Sampliner R, Maltzman T, Ahnen D, Ambrosone CB, Thompson P, Kadlubar FF, **Alberts DS**: Cigarette smoking, N-acetyltransferase 2, and Ki-ras mutations in adenomatous polyps. AACR, Philadelphia, PA, April 10-14, 1999. *Proc Am Assoc Cancer Res* 40:242-243 (#1609), 1999.
346. Wiese FW, Einspahr JG, Warneke JA, Snead GR, Martinez ME, **Alberts DS**, Kadlubar FF, Thompson PA: Variation in Cox-2 expression levels in colorectal tumors by subsite of origin. AACR, Philadelphia, PA, April 10-14, 1999. *Proc Am Assoc Cancer Res* 40:330 (#2184), 1999.
347. Heddens DK, Reid ME, Earnest DL, Batta AK, Krutzsch MF, Snead GR, Booth AR, Marshall JR, Salen G, **Alberts DS**: Measurement of bile acids in experimental clinical settings: The reliability and validity of blood and fecal water assays. AACR, Philadelphia, PA, April 10-14, 1999. *Proc Am Assoc Cancer Res* 40:342 (#2263), 1999.
348. Marshall JR, Earnest D, Martinez ME, Heddens D, Bogert C, Roe D, Einspahr J, **Alberts DS**: Changes in rectal mucosal PGE-2 levels in response to piroxicam treatment. AACR, Philadelphia, PA, April 10-14, 1999. *Proc Am Assoc Cancer Res* 40:433 (#2860), 1999.
349. Xu MJ, Peng YM, Goldman R, Warneke J, Dorr R, **Alberts DS**: Photoprotective effect of α -tocopherol on polyamine metabolism in human skin. AACR, Philadelphia, PA, April 10-14, 1999. *Proc Am Assoc Cancer Res* 40:530 (#3495), 1999.
350. Einspahr J, **Alberts D**, Warneke J, Bozzo P, Basye J, Grogan T, Nelson MA, Bowden GT: Relationship between p53 mutation, expression, and apoptosis in UV-induced human skin carcinogenesis. AACR, Philadelphia, PA, April 10-14, 1999. *Proc Am Assoc Cancer Res* 40:530-531 (#3497), 1999.
351. Marshall JR, Martinez ME, Graver E, Whitaker R, Wolf K, Ritenbaugh C, **Alberts DS**: Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. ASPO, Houston, TX, March 14-16, 1999.
352. Reid ME, Martinez ME, Bhattacharyya A, Marshall JR, Roe D, van Leeuwen JB, Sampliner RE, **Alberts DS**: Smoking and adenomatous polyp characteristics. ASPO, Houston, TX, March 14-16, 1999.
353. Batta AK, Salen G, Batta P, **Alberts D**, Earnest D: Simultaneous capillary gas-liquid chromatographic determination of sterols and bile acids in human stool without prior isolation. *Gastroenterology* 116:A4 (#G0014), AGA, Orlando, FL, 1999.
354. Young RC, Brady MF, Nieberg RM, Long HJ, Mayer A, Lentz SS, Hurteau J, **Alberts DS**: Randomized clinical trial of adjuvant treatment of women with early (Figo-I-IIA high risk) ovarian cancer—GOG #95. ASCO, Atlanta, GA, May 15-18, 1999. *Proc Am Soc Clin Oncol* 18:357a (#1376) 1999.

355. Rothenberg ML, Liu PY, Nahhas WA, Weiss GR, Schroder LE, Elias L, Wilczynski S, Winakur G, **Alberts DS**: A phase II trial of vinorelbine in relapsed and refractory ovarian cancer—A Southwest Oncology Group study (SWOG-9324). ASCO, Atlanta, GA, May 15-18, 1999. Proc Am Soc Clin Oncol 18:383a (#1480), 1999.
356. Pandit L, Liu PY, Muggia FM, Felix JC, Hawes D, Paradelo JC, Terada KY, Cote RJ, **Alberts DS**: Concordance of pre- and post-chemotherapy p53 immunostaining, and its prognostic significance in epithelial ovarian cancer (EOC) receiving intraperitoneal (IP) consolidation: A Southwest Oncology Group study (SWOG 9521). ASCO, Atlanta, GA, May 15-18, 1999. Proc Am Soc Clin Oncol 18:382a (#1475), Atlanta, GA, May 15-18, 1999.
357. Roe DJ, Guillen-Rodriguez J, Marshall JR, Sampliner RE, **Alberts DS**: Reality versus design: Analysis of adenomatous polyp recurrence in a randomized chemoprevention trial. Joint Statistical Meeting, Aug., 1999.
358. Marshall JR, Reid ME, **Alberts DS**: Chemoprevention education in an interdisciplinary cancer prevention training program. AACE, Cleveland, OH, Oct. 7-10, 1999.
359. Batta AK, Rapole RK, Salen G, Heddens D, Snead G, Krutzsch M, **Alberts D**, Earnest D: Bacterially derived more hydrophilic bile acids are concentrated in aqueous phase of human stool. AASLD/IASL, 1999. Hepatology 30:525A (#1459), 1999.
360. **Alberts D**, Sibley L, Hallum A, Stratton-Custis M, Garcia D, Gleason-Guzman M, Salmon S, Santabarbara P, Niesor E, Floret S, Bentzen C: Phase I, pharmacokinetic and correlative tumor kinetic studies of SR-45023A, a novel, oral anticancer drug. Molecular Targets and Cancer Therapeutics, Washington, DC, Nov. 16-19, 1999.
361. Rothenberg ML, Liu PY, Weiner SA, Hunter V, Tiersten A, Kohler PC, Hannigan EV, Wilczynski S, **Alberts DS**: Phase II trial of oral altretamine for women with stage III epithelial ovarian cancer in clinical complete remission: A Southwest Oncology Group study (S9326). Proc SGO Abstract# 131, San Diego, CA, Feb. 5-9, 2000. Gynecol Oncol 76:263-264 (#126), 2000.
362. Gold MA, Walker JL, Berek JS, Hallum AV, Garcia DJ, **Alberts DS**: Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: Results of a multi-center phase II trial in patients with advanced gynecologic malignancies. Proc SGO Abstract# 162, San Diego, CA, Feb. 5-9, 2000. Gynecol Oncol 76:279 (#183), 2000.
363. Kadlubar FF, DeLongchamp R, Gross M, Anderson K, Martinez E, **Alberts D**, Lang N, Thompson P, Hogan M, Sinha R: Common genetic polymorphisms that affect individual cancer susceptibility. Keystone Symposium, Molecular Epidemiology: A New Tool in Cancer Prevention, Taos, NM, Feb. 10-15, 2000.
364. **Alberts DS**: Introduction to primary prevention. Colorectal Cancer: Underrecognized and Undertreated, Washington, DC, March 17-18, 2000.
365. **Alberts DS**, Martinez ME, Roe DJ, Guillen-Rodriguez J, Marshall JR, van Leeuwen B, Reid M, Ritenbaugh C, Parish D, Koonce K, Fales L, Vargas P: Phase III trial of the effect of a high fiber cereal supplement on colorectal adenoma recurrence. AACR, San Francisco, CA, April 1-5, 2000. Proc Am Assoc Cancer Res 41:475 (#3030), 2000.
366. Gapstur SM, Gann PH, Chatterton R, Colangelo L, Barron-Simpson R, Guillen-Rodriguez J, Roe DJ, Einspahr JG, **Alberts DS**: Hormonal responses to a dietary wheat bran fiber supplement in men. AACR, San Francisco, CA, April 1-5, 2000. Proc Am Assoc Cancer Res 41:475-476 (#3033), 2000.
367. Thomson CA, **Alberts DS**, Ritenbaugh CK, Marshall JR, Giuliano AR: The effect of a high fruit and vegetable, low fat diet on urinary 8OHdG in women previously treated for breast cancer. AACR, San Francisco, CA, April 1-5, 2000. Proc Am Assoc Cancer Res 41:476 (#3035), 2000.
368. Damle B, Kaul S, Sonnichsen D, Ferreira I, **Alberts D**, Brooks D, Stewart D, Pazdur R: Effect of food on the oral bioavailability of UFT and leucovorin in patients. AACR, San Francisco, CA, April 1-5, 2000. Proc Am Assoc Cancer Res 41:492 (#3138), 2000.

369. Stratton SP, Zhao D, Hart NK, **Alberts DS**, Dorr RT: Lack of effect of topical epigallocatechin gallate (EGCG) ointment on UVB-induced mouse skin carcinogenesis *in vivo*. AACR, San Francisco, CA, April 1-5, 2000. Proc Am Assoc Cancer Res 41:531 (#3387), 2000.
370. Martinez ME, Marshall JR, Guillen-Rodriguez J, Sampliner R, **Alberts DS**: Risk factors for colorectal adenoma recurrence. AACR, San Francisco, CA, April 1-5, 2000. Proc Am Assoc Cancer Res 41:558 (#3557), 2000.
371. Marshall JR, Martinez ME, Reid M, Guillen-Rodriguez J, Sampliner R, **Alberts DS**: Occurrence of proximal without distal adenomatous polyps following colonoscopy and adenoma ablation. AACR, San Francisco, CA, April 1-5, 2000. Proc Am Assoc Cancer Res 41:558 (#3558), 2000.
372. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, **Alberts DS**, Howell SB: MLH1 and MSH2 expression and correlation with prognostic factors in ovarian cancer. AACR, San Francisco, CA, April 1-5, 2000. Proc Am Assoc Cancer Res 41:728 (#4623), 2000.
373. Chlebowski RT, Blackburn G, Winters B, Elashoff R, Wynder E, Goodman M, **Alberts D**, Thompson C, Oken M, Shapiro A, Nixon D: Long term adherence to dietary fat reduction in the Women's Intervention Nutrition Study (WINS). ASCO, New Orleans, LA, May 20-23, 2000. Proc Am Soc Clin Oncol 19:78a (#302), 2000.
374. **Alberts DS**, Rothenberg ML, Liu PY, Weiner SA, Hunter VJ, Tiersten A, Kohler PC, Hannigan EV, Wilczynski S: Altretamine (Hexalen) consolidation for patients with stage III epithelial ovarian cancer in clinical complete remission: A Southwest Oncology Group trial (S9326). ASCO, New Orleans, LA, May 20-23, 2000. Proc Am Soc Clin Oncol 19:384a (#1520), 2000.
375. Reynolds TC, **Alberts D**, Gershenson D, Gleich L, Glisson B, Hanna E, Huang L, Hung MC, Kenady D, Ueno N, Villaret D, Yoo G. Activity of E1a in human clinical trials. ASCO, New Orleans, LA, May 20-23, 2000. Proc Am Soc Clin Oncol 19:461a (#1809), 2000.
376. Sampliner RE, **Alberts DS**, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen B, Reid ME, Ritenbaugh C, Parrish D, Koonce KK, Fales LK: Effect of wheat bran fiber supplement on colorectal adenoma recurrence. Gastroenterology 118(Suppl 2, Part 1):A187 (#1202), AGA Meeting, San Diego, CA, May 21-24, 2000.
377. Earnest DL, Einspahr JG, Krutzsch MF, Kramer CB, Heddens DK, Roe D, Calaluze R, Marshall JR, **Alberts DS**: Suppression of cyclooxygenase does not have an early effect on rectal epithelial cell proliferation. AGA Meeting, San Diego, CA, May 21-24, 2000. Gastroenterology 118(Suppl 2, Part 1):A273 (#1554), 2000.
378. Batta AK, Salen G, Molokwu GO, **Alberts D**, Earnest D: More hydrophilic bacterial bile acid metabolites are concentrated in the aqueous phase of human stool. AGA Meeting, San Diego, CA, May 21-24, 2000. Gastroenterology 118(Suppl 2, Part 1):A448 (#2462), 2000.
379. Hakim I, Hartz V, Weisgerber U, Balentine D, Harris R, Paetau-Robinson I, Graver E, Whitacre R, **Alberts D**: Development of a tea questionnaire, database and computer program for assessing tea polyphenols intake. 4th International Conference on Dietary Assessment Methods, Tucson, AZ, Sept. 17-20, 2000.
380. Hakim I, Hartz V, Graver E, Whitacre R, **Alberts D**: Development of a questionnaire and a database for assessing dietary d-limonene intake. 4th International Conference on Dietary Assessment Methods, Tucson, AZ, Sept. 17-20, 2000.
381. Thomson C, Rock C, **Alberts D**, Kight M, Green T, Giuliano A, Pierce J: Correlations between diet and urinary 8OHdG excretion among breast cancer survivors participating in a dietary intervention study. 4th International Conference on Dietary Assessment Methods, Tucson, AZ, Sept. 17-20, 2000.
382. Lavey RS, Liu PY, Greer BE, Pui CC, Robinson WR, Monk BJ, Wynn RB, Conrad ME, **Alberts D**: Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy (RT) and cisplatin for stage IIB-IVA carcinoma of the cervix: A Southwest Oncology Group study. ESTRO 19 (European Society for Therapeutic Radiology and Oncology), Istanbul, Turkey, Sept. 20-23, 2000.

383. Batta AK, Powell AA, Sivadas H, Salen G, La Rue J, Earnest DR, **Alberts DS**, Martinez JD: Effect of hydrophobicity of bile acids and their conjugation on apoptosis and growth arrest in colon cells. Falk Meeting, 2000.
384. Earnest DL, Martinez JD, Batta AK, Salen G, Gerner EW, **Alberts DS**: Increasing the ursodeoxycholate (UDC): Deoxycholate (DCA) ratio in model fecal water solutions enhances apoptosis of colon cancer cells. Possible mechanism for cancer chemoprevention effect of UDC. American College of Gastroenterology Scientific Meeting, New York, NY, Oct. 13-18, 2000. *Am J Gastroenterol* 95:2532-2533 (#417), 2000.
385. Powell MB, Lluria-Prevatt M, Morreale J, Kaper F, **Alberts D**, Giaccia AJ: Chemoprevention of melanoma: Effects of perillyl alcohol on Ras signaling pathways. American Cancer Society-Schilling Research Conference: Molecular Targets for Cancer Prevention, October 26-29, 2000.
386. **Alberts DS**: Chemoprevention to save our skins. Experimental Skin Carcinogenesis Conference, Tucson, AZ, Nov. 9-11, 2000.
387. Foote JA, Giuliano AR, Harris RB, Ritenbaugh C, Roe D, **Alberts DS**: Dietary risks in skin basal and squamous cell carcinoma. Experimental Skin Carcinogenesis Conference, Tucson, AZ, Nov. 9-11, 2000.
388. Kaper F, Lluria-Prevatt M, Morreale J, **Alberts D**, Giaccia AJ, Powell MB: Chemoprevention of melanoma: Effects of perillyl alcohol on Ras signaling pathways. NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, Nov. 7-10, 2000. *Clin Cancer Res* 6:4486s (#104), 2000.
389. Einspahr J, **Alberts D**, Hart N, Nelson M, Bowden T: p53 mutation and p53 overexpression as intermediate biomarkers in the chemoprevention of skin cancer. Oncogenomics: Dissecting Cancer Through Genome Research, Tucson, AZ, January 25-27, 2001.
390. Martinez ME, Einspahr J, Issa JP, Giuliano A, Kadlubar F, **Alberts DS**: The effect of 677 C to T mutations in the methylenetetrahydrofolate reductase gene, folate intake, and plasma homocysteine on adenoma recurrence. Oncogenomics: Dissecting Cancer through Genome Research, Tucson, AZ, January 25-27, 2001.
391. Lavey RS, Liu PY, Greer BE, Pui CC, Robinson WR, Monk BJ, Wynn RB, Conrad ME, **Alberts DS**: Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy (RT) and cisplatin for stage IIB-IVA carcinoma of the cervix: A Southwest Oncology Group (SWOG) study. SGO, Nashville, TN, March 3-7, 2001.
392. Martinez ME, Sampliner R, Marshall JR, Bhattacharyya AB, Reid ME, **Alberts DS**: Adenoma characteristics at baseline colonoscopy as risk factors for recurrence of advanced adenomas. ASPO, New York, NY, March 11-13, 2001. *Cancer Epidemiol Biomarkers Prev* 10:157, 2001.
393. Xu MJ, Stratton SP, **Alberts DS**: A method for determination of curcumin in biological specimens by RP-HPLC. AACR, New Orleans, LA, March 24-28, 2001. *Proc Am Assoc Cancer Res* 42:21 (#113), 2001.
394. Martinez ME, Giuliano AR, Marshall JR, Kramer CB, **Alberts DS**: Plasma homocysteine and recurrence of adenomatous polyps. AACR, New Orleans, LA, March 24-28, 2001. *Proc Am Assoc Cancer Res* 42:153 (#821), 2001.
395. Thomson CA, Giuliano AR, Rock CL, Marshall JR, Green TK, **Alberts DS**: Anthropometric and body composition changes among breast cancer survivors consuming a high vegetable, fruit and fiber, low fat diet. AACR, New Orleans, LA, March 24-28, 2001. *Proc Am Assoc Cancer Res* 42:310 (#1670), 2001.
396. Einspahr JG, **Alberts DS**, Saboda K, Hart N, Nelson M, Bowden GT: Topical DFMO, a promising chemoprevention agent in non-melanoma skin cancer, modulates p53, polyamines, and actinic keratoses. AACR, New Orleans, LA, March 24-28, 2001. *Proc Am Assoc Cancer Res* 42:464 (#2497), 2001.
397. Lluria-Prevatt MC, Morreale J, **Alberts D**, Giaccia A, Powell MB: Chemoprevention of melanoma: Effects of perillyl alcohol on ras signaling pathways. AACR, New Orleans, LA, March 24-28, 2001. *Proc Am Assoc Cancer Res* 42:465 (#2504), 2001.

398. **Alberts DS**, Hallum AV, Hatch KD, Stratton-Custis M, Carrier A, De Loera J, Gleason-Guzman M, Von Hoff DD, Garcia DJ, Santabarbara P, Niesor E, Bentzen CC, Floret S: Phase I, pharmacokinetic and *in vitro* chemosensitivity studies of Apomine (SR-45023A), a novel oral anticancer drug. AACR, New Orleans, LA, March 24-28, 2001. Proc Am Assoc Cancer Res 42:833 (#4475), 2001.
399. Scudder SA, Liu PY, Smith HO, Wilczynski SP, Hannigan EV, **Alberts DS**: Paclitaxel (PCT) and carboplatin (C) with amifostine (A) in advanced or recurrent endometrial cancer: a Southwest Oncology Group trial (S9720). ASCO, San Francisco, CA, May 12-15, 2001. Proc Am Soc Clin Oncol 20:205a (#819), 2001.
400. Martinez ME, Kadlubar F, Issa JP, Thompson P, Hogan H, **Alberts DS**: Gene/environmental interactions related to colon cancer. Cancer and the Environment: Gene-Environment Interactions, National Academy of Sciences, Washington, DC, May 17, 2001.
401. **Alberts DS**: Chemoprevention to save our skins. Carcinogenesis and Cancer Prevention: Non-melanoma and Melanoma Skin Cancer, Newport Beach, CA, June 22-24, 2001.
402. **Alberts D**, Fruehauf JP: Maximizing chemoresistance testing data for the clinician. 1st Symposium of the International Society for Chemosensitivity Testing in Oncology, Homburg/Saar, Germany, September 14-15, 2001. Anticancer Drugs 12(8):A12, 2001.
403. **Alberts DS**, Floret S, Bentzen C, Carrier A, Denis LJ, Hammond LA, Hao D, Kinsey A, Niesor E, Ochoa L, Schwartz G, Simmons C, Smith S, Rugg T, Rowinsky EK, Tolcher AW: Pharmacokinetic evaluation and determination of the recommended phase II dose and schedule of oral APOMINE™, a novel FXR nuclear receptor activator, in patients with advanced solid tumors. Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications (AACR-NCI-EORTC International Conference), Miami Beach, FL, October 29-November 2, 2001. Clin Cancer Res 7(Suppl):3734s (#399), 2001.
404. **Alberts DS**, Powell MB, Carrier A, Lopez AM, Hersh E, Kinsey A, Smith S, Niesor EJ, Bentzen CL: Apomine, a novel biophosphonate ester with preclinical and clinical activity in the prevention and treatment of melanoma. Chemotherapy Foundation Symposium XIX: Innovative Cancer Therapy for Tomorrow, New York, NY, November 7-10, 2001.
405. Gawad C, Gallegos A, Einspahr J, **Alberts DS**: The use of cDNA microarray to characterize alterations in gene expression of HaCaT keratinocytes after treatment with UV or DFMO. Western Regional Meeting, Carmel, CA, February, 6-9, 2002. J Invest Med 50:24A (#127), 2002.
406. Hess LM, Heddens DS, Earnest DL, Einspahr J, Roe D, **Alberts DS**: Adherence assessment in a chemoprevention clinical trial: what are we measuring? ASPO, Bethesda, MD, March 10-12, 2002.
407. Krouse RS, Einspahr JG, Martinez ME, Danenberg PV, Danenberg KD, Bhattacharyya AB, **Alberts DS**: COX-2 expression in colorectal adenomas: A possible association with transformation into carcinoma. Society of Surgical Oncology Annual Meeting, Denver, CO, March 14-17, 2002.
408. Markman M, Liu PY, Wilczynski S, Monk BJ, Copeland L, **Alberts D**: Phase 3 randomized trial of 12 vs. 3 months of single agent paclitaxel in patients with advanced ovarian cancer who attained a clinically-defined complete response to platinum/paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. SGO, Miami Beach, FL, March 16-20, 2002.
409. **Alberts DS**, Einspahr J, Krutzsch M, Lin P, Hess L, Heddens D, Roe D, Sampliner R, Salen G, Batta AK: Fecal bile acid concentrations in a subpopulation of the wheat bran fiber colon polyp trial. AACR, San Francisco, CA, April 6-10, 2002. Proc Am Assoc Cancer Res 43:122 (#615), 2002.
410. Einspahr JG, Krouse RS, Park JM, Moore MW, Danenberg PV, Danenberg KD, Bhattacharyya AK, Martinez ME, **Alberts DS**: Association between COX-2 expression, colorectal adenoma characteristics, and adenoma recurrence. AACR, San Francisco, CA, April 6-10, 2002. Proc Am Assoc Cancer Res 43:123 (#616), 2002.

411. Reid ME, Lillico A, Marshall JR, Martinez ME, **Alberts DS**: A pilot case-control study of plasma selenium levels and colorectal adenoma recurrence. AACR, San Francisco, CA, April 6-10, 2002. Proc Am Assoc Cancer Res 43:568 (#2819), 2002.
412. Martinez ME, O'Brien TG, Gerner EW, Guo Y, Boorman D, Einspahr JG, **Alberts DS**: Pronounced reduction in adenoma recurrence by ornithine decarboxylase polymorphism and aspirin use. AACR, San Francisco, CA, April 6-10, 2002. Proc Am Assoc Cancer Res 43:850 (#4214), 2002.
413. Stratton MS, Warneke JA, Goldman RF, Miller RC, Liu Y, Einspahr JG, Thompson DB, Bartels PH, **Alberts DS**: Measurement of chemopreventive efficacy of oral vitamin A with nuclear morphometry. AACR, San Francisco, CA, April 6-10, 2002. Proc Am Assoc Cancer Res 43:1006 (#4988), 2002.
414. Powell MB, **Alberts DS**, Lluria-Prevatt M, Carrier A, Lopez AM, Hersh E, Kinsey A, Smith S, Niesor EJ, Bentzen CL: Preclinical and clinical activity of Apomine, a novel biophosphonate ester, in the prevention and treatment of melanoma. AACR, San Francisco, CA, April 6-10, 2002. Proc Am Assoc Cancer Res 43:1007 (#4992), 2002.
415. Stratton SP, Saboda K, Brooks CA, Bozzo P, Salasche SJ, Warneke JA, Miller RC, Dorr RT, Einspahr JG, Roe DJ, Levine NS, **Alberts DS**: Phase IIa study of safety, tolerance, and sun protection factor of topical EGCG ointment in subjects with Fitzpatrick type II-III skin. AACR, San Francisco, CA, April 6-10, 2002. Proc Am Assoc Cancer Res 43:1143 (#5663), 2002.
416. Foote JA, Giuliano AR, Harris RB, Roe D, Ritenbaugh C, **Alberts DS**: Alcohol intake and risk of nonmelanoma skin cancer. AACR, San Francisco, CA, April 6-10, 2002.
417. **Alberts DS**, Wolf J, Muntz H, Hatch K, Carrier A, Eggert S, Heald A: A phase 1, dose-escalation trial of E1A gene transfer with chemotherapy for treatment of advanced ovarian cancer. ASCO, Orlando, FL, May 18-21, 2002. Proc Am Soc Clin Oncol 21:18a (#69), 2002.
418. Rothenberg ML, Liu P, Wilczynski S, Braley PS, Wadler S, Stuart G, Hannigan EV, Bonebrake AJ, **Alberts DS**, Markman M: Excellent 2-year survival in women with optimally-debulked ovarian cancer treated with intraperitoneal and intravenous chemotherapy: A SWOG-ECOG-NCIC study (S9619). ASCO, Orlando, FL, May 18-21, 2002. Proc Am Soc Clin Oncol 21:203a (#809), 2002.
419. Markman M, Liu PY, Wilczynski SP, Monk BJ, Copeland LJ, **Alberts DS**: Impact of 12 monthly courses of single agent paclitaxel in patients with advanced ovarian cancer (OC) who attained a clinically-defined complete response to platinum/paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group phase 3 randomized trial. ASCO, Orlando, FL, May 18-21, 2002.
420. **Alberts DS**: Building a cancer prevention and control research program in a cancer center from the ground up. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Behavioral Prevention Research, Clinical Prevention Trials, Science and Public Policy, Boston, MA, October 14-18, 2002. Cancer Epidemiol Biomarkers Prev 11(Suppl):1249s, 2002.
421. Ranger-Moore JR, Bartels PH, Thompson D, Bozzo P, Einspahr J, Liu Y, Saboda K, Hart N, Duckett L, **Alberts DS**: Karyometric analysis of actinic damage in unexposed and sun-exposed skin and in actinic keratoses in untreated individuals. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Behavioral Prevention Research, Clinical Prevention Trials, Science and Public Policy, Boston, MA, October 14-18, 2002. Cancer Epidemiol Biomarkers Prev 11(Suppl):1185s (#B309), 2002.
422. **Alberts DS**, Einspahr J, Frank D, Stratton MS, Xu X, Liu Y, Thompson DB, Ranger-Moore J, Bartels PH: Cost- and time-efficient evaluation of chemoprevention agent efficacy. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Behavioral Prevention Research, Clinical Prevention Trials, Science and Public Policy, Boston, MA, October 14-18, 2002. Cancer Epidemiol Biomarkers Prev 11(Suppl):1197s (#C120), 2002.
423. **Alberts DS**: Treatment of intraepithelial neoplasia. EORTC-NCI-AACR Conference: Molecular Targets and Cancer Therapeutics, Frankfurt, Germany, November 19-22, 2002.

424. Trimble C, Silverberg S, Mutter GL, Kurman R, Kauderer J, Curtin J, **Alberts D**, Zaino R: Reproducibility of the diagnosis of atypical endometrial hyperplasia (a Gynecologic Oncology Group study). Proc. SGO 88:184, 2003, New Orleans, LA, January 31-February 4, 2003.
425. **Alberts DS**, Martinez ME, Roe D, Einspahr JG, Guillen J, Clouser M, Krutzsch M, Batta AK, Salen G, Lance P: Proving the bile acid hypothesis for colon carcinogenesis: Mature results from a phase III chemoprevention trial of ursodeoxycholic acid versus placebo to prevent colorectal adenoma recurrence. ASCO, Chicago, IL, May 31-June 3, 2003. Proc Am Soc Clin Oncol 22:91 (#363), 2003.
426. Curtis AV, Einspahr JG, Buckmeier JA, Bangert JL, Bozzo PD, **Alberts DS**: Differential expression of cleaved caspase-3 in normal skin and non-melanoma skin cancer. AACR, Washington, DC, July 11-14, 2003. Proc Am Assoc Cancer Res 44(2nd edition):569-570 (#R2894), 2003.
427. Samimi G, Varki NM, Wilczynski S, Safaei R, **Alberts DS**, Howell SB: Expression of the copper transporter ATP7A is associated with poor survival of ovarian cancer patients treated with platinum drugs. AACR, Washington, DC, July 11-14, 2003. Proc Am Assoc Cancer Res 44(2nd edition):807 (#4037), 2003.
428. Martinez ME, Reid M, Einspahr J, Parker F, **Alberts DS**: Validity of self-reported smoking status and change in smoking status among participants in a chemoprevention trial. AACR, Washington, DC, July 11-14, 2003. Proc Am Assoc Cancer Res 44(2nd edition):892 (#R4497), 2003.
429. **Alberts DS**: Cancer treatment versus cancer prevention: Identical disciplines with different wrappers. AACR-Joseph H. Burchenal Clinical Research Award Lecture. AACR, Washington, DC, July 11-14, 2003. Proc Am Assoc Cancer Res 44(2nd edition):1385-1387, 2003.
430. Bishop MC, Gopal AV, **Alberts DS**: Hope has a name: Sunstone healing center. Quality of Life III: Translating the Science of QOL Assessment into Clinical Practice. An Example-driven Approach for Practicing Clinicians and Clinical Researchers. Scottsdale, AZ, October 2-4, 2003. Clin Ther 25(Suppl D):D39-D40 (#26), 2003.
431. Lavey RS, Liu PY, Greer BE, Robinson WR, Pui CC, Wynn RB, Conrad ME, Jiang C, Markman M, **Alberts DS**: Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting, Salt Lake City, UT, October 19-23, 2003. Int J Radiat Oncol Biol Phys 57(2 Suppl):S190-S191 (#110), 2003.
432. Thomson CA, Newton T, Crane T, Jackson K, Stroster J, Giuliano A, **Alberts DS**: Intake of cruciferous vegetables among adults in a validation study for the Arizona Cruciferous Vegetable Food Frequency Questionnaire. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Clinical Prevention Trials, Behavioral Prevention Research, Science and Public Policy, Phoenix, AZ, October 26-30, 2003. Cancer Epidemiol Biomarkers Prev 12(Suppl):1277s (#A104), 2003.
433. Martinez ME, Lanza E, **Alberts DS**, Schatzkin A, Jacobs E, Einspahr J, Green S, Reid ME, Ratnasinghe L, Gunter EW: Blood selenium and colorectal adenoma recurrence: pooled analyses from the Wheat Bran Fiber trial and the Polyp Prevention trial. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Clinical Prevention Trials, Behavioral Prevention Research, Science and Public Policy, Phoenix, AZ, October 26-30, 2003. Cancer Epidemiol Biomarkers Prev 12(Suppl):1280s (#A114), 2003.
434. Buckmeier JA, Einspahr JG, Hart NK, Bozzo P, Bangert JL, Fruehauf JP, Richardson M, **Alberts DS**: Differential expression of VEGF, CD31, CD105 and p53 in benign nevi, dysplastic nevi and primary melanoma. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Clinical Prevention Trials, Behavioral Prevention Research, Science and Public Policy, Phoenix, AZ, October 26-30, 2003. Cancer Epidemiol Biomarkers Prev 12(Suppl):1281s (#A119), 2003

435. Rial NS, Einspahr JG, Buckmeier JA, Krouse RS, Ismail A, Bhattacharyya AK, Prasad A, Kepler CY, Pollock MR, Allen AN, **Alberts DS**: Candidate biomarkers in colorectal cancer progression. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Clinical Prevention Trials, Behavioral Prevention Research, Science and Public Policy, Phoenix, AZ, October 26-30, 2003. *Cancer Epidemiol Biomarkers Prev* 12(Suppl):1282s-1283s (#A123), 2003.
436. Brewer M, Ranger-Moore J, **Alberts D**, Thompson D, Liu Y, Davis J, Baruch A, Bartels PH: Exploratory study of ovarian intraepithelial neoplasia. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Clinical Prevention Trials, Behavioral Prevention Research, Science and Public Policy, Phoenix, AZ, October 26-30, 2003. *Cancer Epidemiol Biomarkers Prev* 12(Suppl):1285s (#A132), 2003.
437. **Alberts DS**, Garcia F, Davis JR, Liu Y, Thompson D, Bartels PH: A karyometric approach to the characterization of atypical endometrial hyperplasia with and without co-occurring adenocarcinoma. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Clinical Prevention Trials, Behavioral Prevention Research, Science and Public Policy, Phoenix, AZ, October 26-30, 2003. *Cancer Epidemiol Biomarkers Prev* 12(Suppl):1306s (#B113), 2003.
438. Ranger-Moore J, Bozzo P, **Alberts DS**, Einspahr J, Liu Y, Thompson D, Stratton MS, Stratton SP, Bartels PH: Karyometry of nuclei from actinic keratosis and squamous cell cancer of the skin. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Clinical Prevention Trials, Behavioral Prevention Research, Science and Public Policy, Phoenix, AZ, October 26-30, 2003. *Cancer Epidemiol Biomarkers Prev* 12(Suppl):1330s-1331s (#C109), 2003.
439. Huffman TM, Einspahr JG, Buckmeier JA, Kepler CY, Allen AN, **Alberts DS**: Modulation of ultraviolet radiation B induced Wnt-signaling by perillyl alcohol in human keratinocytes. AACR Conference Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Clinical Prevention Trials, Behavioral Prevention Research, Science and Public Policy, Phoenix, AZ, October 26-30, 2003. *Cancer Epidemiol Biomarkers Prev* 12(Suppl):1344s (#C163), 2003.
440. Walling E, Frank DH, Thompson P, Davis J, Thompson D, Bartels PH, Ranger-Moore J, Kim C, Warneke J, Crane T, **Alberts DS**, Thomson C: Nuclear chromatin characteristics of breast epithelial cells obtained by ductal lavage. 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003.
441. Martinez E, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Guo Y, Boorman D, Einspahr J, **Alberts DS** and Gerner EW: Aspirin use and the ornithine decarboxylase polymorphism reduce risk of colorectal neoplasia through polyamine metabolism. NCI SPORE Meeting, Bethesda, MD 2003.
442. Im SS, Monk BJ, Wang J, Stock RJ, Peters WA 3rd, Liu PY, Barrett RJ 2nd, Berek JS, Souhami L, Grisby P, Gordon W, **Alberts DS**: Rethinking the use of chemotherapy and radiation after radical hysterectomy: A clinical-pathologic analysis of SWOG 8797/GOG 109. *Proc. Society of Gynecologic Oncologists (SGO)* 92:396(#8), 2004. Annual Meeting on Women's Cancer, San Diego, CA, February 7-11, 2004.
443. Brewer MA, Ranger-Moore J, **Alberts DS**, Hatch K, Thompson D, Liu Y, Davis J, Baruch A, Bartels PH: Exploratory study of ovarian intraepithelial neoplasia. Society of Gynecologic Oncologists (SGO) 2004 Annual Meeting on Women's Cancer, San Diego, CA, February 7-11, 2004.
444. Smith HO, Jiang C, Weiss GR, Hallum AV 3rd, Liu PY, Miller AM, Gandara DR, Markman M, **Alberts DS**: Tirapazamine plus cisplatin in advanced or recurrent squamous or adenosquamous carcinoma of the uterine cervix: A phase II study of the Southwest Oncology Group (SWOG). Society of Gynecologic Oncologists (SGO) 2004 Annual Meeting on Women's Cancer, San Diego, CA, February 7-11, 2004.
445. Krouse RS, Rial NS, Einspahr JG, Buckmeier JA, Ismail A, Bhattacharyya AK, Prasad A, Kepler CY, Pollock MR, Allen AN, **Alberts DS**: Candidate biomarkers in colorectal cancer progression. Society of Surgical Oncology (SSO) Meeting, New York, NY, March 18-21, 2004.

446. Einspahr JG, **Alberts DS**, Bhattacharya AK, Martinez ME, Wilkinson J, Issa JP, Buckmeier JA, Rashid A, Houlihan P, Lance MP, Hamilton SR: Ki-ras mutations and p53 overexpression in adenomas from a phase III trial of recurrence. AACR, Orlando, FL, March 27-31, 2004.
447. Shen L, Kondo Y, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, **Alberts DS**, Hamilton SR, Issa JP: Epigenetic inactivation of MGMT defines a field defect in sporadic colorectal cancer. AACR, Orlando, FL, March 27-31, 2004.
448. Ranger-Moore J, Bartels P, Einspahr J, **Alberts D**, Frank D, Brentnall T, Lance P: The utility of karyometric analysis for detection of colorectal cancer and prediction of recurrent adenomas. Digestive Disease Week, New Orleans, LA, May 15-20, 2004.
449. Baruch AC, Davis JR, Brewer, MA, Ranger-Moore, J, **Alberts, DS**, Thompson D, Liu Y, Bartels, PH: Nuclear chromatin characteristics of surface epithelial and stromal cells in non-malignant and malignant ovaries. USCAP, 2004.
450. Larkey LK, **Alberts DS**, Lance, P, Goode DA: Strategies to improve regional colorectal cancer screening rates. Educational Conference on Cancer Prevention. Dead Sea, Israel, May 6-8, 2004.
451. Martinez ME, Thompson P, Einspahr J, Hamilton S, Jacobs E, **Alberts DS**: Genetic variant in the peroxisome proliferators-activator receptor-gamma (PPAR γ) gene as predictor of Ki-ras mutations in colorectal adenomas. NCI SPORE Meeting, Bethesda, MD 2004.
452. **Alberts DS**: Intraperitoneal therapy for stage III, optimally debulked ovarian cancer (Optimal OV CA): Isn't it about time to take the phase III trial data seriously? 10th Biennial International Gynecologic Cancer Society Meeting, Edinburgh, Scotland, October 3-7, 2004.
453. Martinez ME, Thompson P, Jacobs ET, Jiang R, **Alberts DS**: Insulin resistance syndrome, PPAR γ , and overweight/obesity status among individuals with colorectal adenomatous polyps. Proc. AACR Frontiers in Cancer Prevention, Seattle, WA, October 16-19, 2004, CEBP Suppl 13(11):176, 2004.
454. Martinez ME, Einspahr J, Jiang R, Swan S, Lance P, **Alberts D**: Ascertainment of colorectal polyp characteristics from medical records: Can data be captured with a high degree of accuracy? Proc. AACR Frontiers in Cancer Prevention, Seattle, WA, October 16-19, 2004, CEBP Suppl 13(11):170, 2004.
455. Marshall JR, Sakr W, Wood D, **Alberts D**, Tangen C, Faulkner J, Parker F, Lippman S, Thompson I, Greenwald P, Minasian L, Lieberman R, Crawford D: Selenium-based prostate cancer chemoprevention for those with prostatic intraepithelial neoplasia. AACR Frontiers in Cancer Prevention, Seattle, WA, October 16-19, 2004, CEBP Suppl 13(11):73, 2004.
456. Hess LM, Guillen J, Krutzsch M, Salen G, Batta A, Einspahr J, **Alberts DS**: A phase I multiple-dose safety and pharmacokinetic clinical study of ursodeoxycholic acid: Results of Task II. AACR Frontiers in Cancer Prevention, Seattle, WA, October 16-19, 2004, CEBP Suppl 13(11):126, 2004.
457. **Alberts DS**, Martinez E, Jacobs E, Einspahr J, Hamilton S, Issa J-P, Lance P: Large phase III clinical trials: The importance of secondary endpoint analyses. AACR Frontiers in Cancer Prevention, Seattle, WA, October 16-19, 2004.
458. Chow H-HS, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, Celaya CA, Rodney R, Hara Y, **Alberts DS**: Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. AACR Frontiers in Cancer Prevention, Seattle, WA, October 16-19, 2004, CEBP Suppl 13(11):127, 2004.
459. Harris RB, Foote JA, Hakim IA, Bronson DL, **Alberts DS**: Fatty acid composition of red blood cell membranes and risk of squamous cell carcinoma of the skin. AACR Frontiers in Cancer Prevention, Seattle, WA, October 16-19, 2004, CEBP Suppl 13(11):93, 2004.
460. Liu PY, **Alberts DS**, Monk BJ, Brady M, Markman M: Relationship between pretreatment CA-125 level and risk of relapse in advanced ovarian cancer (AOC) patients in a complete clinical response (CCR) who received "maintenance therapy." ASCO, Orlando, FL, May 13-17, 2005. Proc Am Soc Clin Oncol submitted, 2004.

461. Martinez ME, Giovannucci E, Jiang R, Henning SM, Jacobs ET, Thompson P, Smith-Warner SA, **Alberts DS**: Effect of folate fortification of the food supply on plasma folate, homocysteine, and adenoma recurrence. AACR, Anaheim, CA, April 16-20, 2005.
462. Frank D, Kim C, Ranger-Moore J, Thompson P, Thomson C, Davis, J, Bartels P, **Alerts DS**: Karyometry in breast cancer risk assessment. The Breast Cancer Intergroup of North America, 2005.
463. Hostetter G, Gooden C, Watanabe A, Kim S, Stafford P, Bittner M, Trent J, **Alberts DS**: Accessing paraffin tissues to generate molecular profiles predictive of neoplastic progression in colorectal adenomas using microarray CGH. Proc AACR, Anaheim, CA, April 16-20, 2005.
464. **Alberts DS**: Nutrition and Cancer. Frontiers in Nutritional Sciences, Tucson, AZ, October 20-21, 2005.
465. Einspahr JG, Ranger-Moore, J, Warneke J, Saboda K, Bozzo P, Xu MJ, Duckett L, Goldman R, Lin P, Buckmeier J, **Alberts DS**: Reproducibility and expression of skin biomarkers in sun-damaged skin. AACR Frontiers in Cancer Prevention Research Meeting, abstr #B14, Baltimore, MD, October 30-November 2, 2005.
466. Einspahr JG, **Alberts DS**, Hsu P, Bhattacharya M, Martinez E, Buckmeier J, Lance P, Jacobs E, Hamilton SR: Association of specific K-ras mutation and recurrence of advanced colorectal adenomas. Proc AACR, Anaheim, CA, April 2005.
467. Chow H-H S, Hakim I, Vining DR, Crowell JA, Cordova CA, Hara Y, **Alberts DS**: Effects of polyphenon E on drug and carcinogen metabolizing enzymes in healthy individuals. AACR Frontiers in Cancer Prevention Research Meeting, abstr #B69, Baltimore, MD, October 30-November 2, 2005.
468. Hostetter G, Gooden C, Watanabe A, Savage S, Kim S, Stafford P, Bittner M, Lance P, Martinez ME, Trent J, **Alberts D**: Towards utilizing archival colorectal adenomas for oligo-CGH experiments using quantitative measures of template integrity and representativity. AACR, Frontiers in Cancer Prevention Research Meeting, poster A8, Baltimore, MD, October 30-November 2, 2005.
469. Ley M, Frank D, Davis J, Degan J, Lacovora J, Kim C and the Karyometry Laboratory of **Alberts DS**: Breast endoscopy in the evaluation of individuals in a high-risk breast cancer clinic. San Antonio Breast Cancer Symposium, 2005.
470. Martinez ME, Conti D, Duggan D, Haile RW, Jacobs ET, Lance MP, Thompson PA, Watanabe R, **Alberts DS**: Lifestyle and genetic determinants of IGF-1 as risk factors for advanced colorectal neoplasia, CCFR Conference, Washington DC, 2005.
471. Fruehauf JP, Buckmeier JA, **Alberts DS**: Dysregulation of angiogenesis is associated with melanoma progression. Proc AACR, Anaheim, CA, April 2005.
472. Einspahr JG, Hess LM, Guillen J, Green SB, Lance P, Krutzsch M, Lin P, Martinez ME, Batta AK, Salen G, **Alberts DS**: Association of baseline fecal and plasma bile acids with colorectal adenoma recurrence and high-grade dysplasia in a phase III trial of colorectal adenoma recurrence. Washington, DC, AACR Annual Meeting, April 1-5, 2006.
473. Brewer MA, Ranger-Moore J, **Alberts DS**, Liu Y, Davis J, Bartels PH: Ovarian intraepithelial neoplasia. Soc Gyn Oncol, March 2006.
474. **Alberts DS**, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke D, Bradford WZ, Loutit JS, Kirn D and the GRACES Clinical Trial Consortium: A randomized phase 3 trial of interferon gamma-1b (IFN- γ 1b) versus carboplatin/paclitaxel (C/P) alone for first-line treatment of advanced ovarian (OC) and primary peritoneal carcinomas (PPC): Results from a prospectively designed analysis of progression-free survival (PFS). ASCO, Atlanta, GA, June 2-6, 2006.
475. Liu P, Moon J, **Alberts DS**, Monk BJ, Brady M, Markman M: A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy. ASCO, Atlanta, GA, June 2-6, 2006.

476. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, **Alberts D**: Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG 9701/GOG178:12 versus 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. Proc ASCO #5005, pg 256s, Atlanta, GA, June 2-6, 2006.
477. Hess LM, Tian C, Barakat R, Ozols RF and **Alberts DS**: Change in patient weight during platinum/paclitaxel-based chemotherapy for ovarian cancer: A Gynecologic Oncology Group Study. Abstr, Proc ASCO #5073 pg 18s, Atlanta, GA, June 2-6, 2006.
478. Liu PY, **Alberts DS**, Monk BJ, Brady M, Markman M: A modified disease progression criterion by CA-125 in ovarian cancer (OC) patients. ASCO, Atlanta, GA, June 2-6, 2006.
479. Jacobs E, **Alberts D**, Hollis B, Thompson P, Martinez ME: Predictors of serum 25(OH)D levels and colorectal adenoma recurrence. 13th Annual Workshop on Vitamin D, Victoria, British Columbia, Canada, April 8-12, 2006.
480. Bookman M, McGuire WP, **Alberts D**, Friedlander M, Parmar M, Colombo N, Harper P, Trimble T, Swart AM, Omura GA, Modeas C, Blessing J: 5-Arm phase III randomized trial of paclitaxel (P) and carboplatin vs combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. ASCO, Atlanta, GA, June 2-6, 2006.
481. Korde V, Krishnamurthy C, Ranger-Moore J, **Alberts DS**, Barton JK: Optical coherence tomography as an aid in chemoprevention of skin cancer. Am Soc Laser Med and Surg Annual Mtg, Proc Lasers in Surgery and Medicine 38(S18):14, 2006.
482. Martinez ME, Thompson P, Chen Z, Jiang R, **Alberts D**: Relationship between plasma and dietary markers of folate status and bone mineral density. 2nd North Am Congress Epidemiol, Seattle, WA, June 21-24, 2006.
483. Chu D, **Alberts DS**, Clouser M: Supplemental calcium and colorectal adenomas in individuals with resected colorectal carcinomas: A Southwest Oncology Group Feasibility Study. Am Assoc for Cancer Res, Frontiers in Cancer Prevention, Boston, MA, November 12-15, 2006.
484. Vale C, Tierney J and the Concomitant Chemoradiation for Cervical Cancer Meta-analysis Collaboration: Concomitant chemoradiation in cervical cancer: A meta-analysis using individual patient data from randomized clinical trials. IGCS Meeting, Santa Monica, CA, October, 2006.
485. McGuire WP, Swart AM, **Alberts D**, Friedlander M, Parmar M, Brady MF, Bookman M, Colombo N, Harper P, Trimble T, Accario C, Parham J, Roth LM, Williams S, Herzog T: Phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma. Proc ASCO, Atlanta, GA, June 2-6, 2006.
486. Chansky K, **Alberts D**, Meyskens F, Fenoglio-Preiser C, Rivkin S, Mills G, Giguere J, Goodman G, Abbruzzese J, Lippman, S: Supplemental calcium and colorectal adenomas in individuals with resected colorectal carcinomas (CRC): Results from a Southwest Oncology Group feasibility study. Proc Am Assoc for Cancer Res, Frontiers in Cancer Prevention, Boston, MA, November 12-15, 2006.
487. Jacobs ET, **Alberts DS**, Hollis BW, Martinez ME: A predictive model of 25(OH)D and colorectal adenoma recurrence. Assoc for Cancer Res, Frontiers in Cancer Prevention, Boston, MA, November 12-15, 2006.
488. **Alberts DS**: Chemoprevention to save our lives! Proc AACR International Conference on Frontiers in Cancer Prevention Research. November 12-15, 2006, Boston, MA.
489. Holterman D, Nagle RB, Bowden GT, Demeure MJ, **Alberts DS**: Exogenous α -defensin increases motility of prostate, follicular thyroid and pancreatic cancer cell lines. AACR International Conference on Frontiers in Cancer Prevention Research. November 12-15, 2006, Boston, MA.

490. Jacobs ET, **Alberts DS**, Hollis BW, Martinez ME: Predictors of serum 25(OH)D may vary by ethnicity. ASPO Meeting, November 27, 2006.
491. Thomas TL, Bozzo P, **Alberts DS**, Curiel C, Saboda K, Fruehauf J, Buckmeier J, Einspahr J: Biomarkers of angiogenesis in progression from dysplastic nevi to malignant melanoma. Soc Investig Dermatol, Philadelphia, PA, May 4, 2006.
492. Kamradt J, Einspahr J, Davis S, Anzick SL, **Alberts DS**, Krouse R, Prasad AR, Meltzer P: Comparing gene expression of histologically normal colon mucosa distant and adjacent to colorectal cancer. Proc AACR, April 2006.
493. Chow H-H S, Hakim IA, Vining DR, Crowell JA, Cordova CA, Mikhael DM, Ranger-Moore J, **Alberts DS**: Effects of green tea catechin intervention on human phase II detoxification enzymes. Proc AACR, November 2006.
494. Hostetter G, Savage S, Bittner M, Trent J, Martinez E, **Alberts D**: Sample selection strategy using microarray-based CGH to identify a recurrent gene dosage alteration common to colorectal carcinomas and adenomas. Proc AACR, November 2006.
495. **Alberts DS**, Liu PY, Wilczynski S, Clouser M, Lopez A, Lange M, Wade J, Markman M: Phase III randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy. A Southwest Oncology Group Protocol #S0200. ASCO Annual Meeting, Chicago, IL, June 1-5, 2007.
496. Einspahr JG, Stratton SS, McKenzie N, **Alberts DS**, Warneke J, Salasche S, Nagle RB, Pestano G, Meek W, Brooks C, Haubein N, Chatigny J, Bowden GT: Cross-validation of UVB signal transduction pathways in human skin. Proc. AACR, April 15-18, 2007.
497. Einspahr JG, Stratton SP, McKenzie N, **Alberts DS**, Warneke J, Salasche S, Nagle RB, Nickoloff BJ, Pestano G, Brooks C, Haubein N, Chatigny J, Lett S, Bowden GT: Acute UVB signal transduction pathways in human skin. Proc. Society of Investigative Dermatology, Los Angeles, CA, May 9-12, 2007.
498. Hsu C-H, Taylor JMG, Long Q, **Alberts DS**, Thompson PA: A weighted Kaplan-Meier approach for estimation of recurrence of colorectal adenomas. Intl Workshop on Statistical Modeling, Barcelona, Spain, July 2-6, 2007.
499. Jacobs ET, **Alberts DS**, Hollis BW, Martinez ME: Predictors of serum 25(OH)D vary by race/ethnicity. Proc. 31st Amer Society for Preventive Oncol, Houston, TX, March 2-4, 2007.
500. Marth C, **Alberts DS**, Alvarez R, Markman M, Johnson G, Bidzinski M, Kardatzke D, Bradford WZ, Loutit J, Kim D, and the GRACES Clinical Trial Consortium: A randomized phase III trial of Interferon gamma-1b (IFN- γ 1b) plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian (OC) and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival (PFS). European Society Gynecologic Oncology, October 28, 2007.
501. Hess, L, Martinez E, Hakim I, **Alberts DS**: Arizona Cancer Center: R25 cancer prevention and control postdoctoral fellowship program. National Leadership Workshop on Mentoring Women in Biomedical Careers, National Institutes of Health, Bethesda, MD, November 27-28, 2007.
502. Jacobs ET, Martinez ME, **Alberts D**, Ashbeck E, Gapstur S, Lance P, Thompson P: Plasma IGF-I is inversely associated with colorectal adenoma recurrence. Proc AACR Frontiers in Cancer Prevention Research, December 6, 2007.
503. Bosanquet AG, Kaspers GJ, Larsson R, Nagourney RA, Nygren P, Pieters R, Zwaan CM, Weisenthal LM, **Alberts DS**: Individualized tumor response (ITR) profiling for drug selection in tailored therapy: Meta-analysis of 1,929 cases of leukemia and lymphoma. Proc ASH, December 10, 2007.

504. Tiersten A, Liu PY, Smith H, Wilczynski S, Robinson W, Markman M, **Alberts D**: Phase II evaluation of neoadjuvant chemotherapy and interval debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: A Southwest Oncology Group Study. 39th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Tampa, FL, March 9-12, 2008.
505. Tiersten A, Liu PY, Smith H, Wilczynski S, Robinson W, Markman M, **Alberts D**: Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking followed by intraperitoneal chemotherapy: A Southwest Oncology Group study. Proc ASCO, Chicago, IL, May 30-June 3, 2008.
506. Martinez E, Schatzkin A, **Alberts D**, Lieberman D, Ahnen D, Robertson D, Greenberg ER, Jacobs E, Baron JA, Bond J, Smith-Warner S, Green S, Winawer S, Zauber A: A pooled analysis of adenoma and patient characteristics in relation to metachronous advanced adenoma and colorectal cancer. Proc AACR, San Diego, CA, April 12-16, 2008.
507. Martinez E, Baron JA, Schatzkin A, Robertson D, Lieberman D, Zauber A, Winawer S, Jiang R Ahnen D, Jacobs E, Smith-Warner S, **Alberts D**, Greenberg ER: Advanced colorectal neoplasia following polypectomy: A pooled analysis. Proc Digestive Diseases Week, San Diego, May 17-22, 2008.
508. Bourzac K, Olson ER, Bowden T, **Alberts DS**, Einspahr J, Galbraith DW, Seligmann B: Quantitative gene expression profiles as the basis for biomarker selection for UV damaged skin and squamous cell carcinoma. Proc ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, Hollywood, FL, October 30-November 1, 2008.
509. Chambers SK, Clouser MC, Gordon M, Janicek M, **Alberts DS**: Phase II trial of bevacizumab and erlotinib in women with refractory ovarian cancer. Annual Meeting on Women's Cancers, Soc Gyn Oncol, San Antonio, TX, February 5-8, 2009.
510. Melton TF, Olson ER, Einspahr JG, **Alberts DS**, Petricoin III EF, Bowden T: Effects of solar UV light on signaling pathway activation and protein expression in SKH-1 hairless mouse skin: Analysis by reverse phase protein microarray and immunohistochemistry. AACR 2009.
511. Chambers SK, Clouser MC, Roe DJ, Baker AF, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Wright HM, Cohen JL, **Alberts DS**: Phase II trial of bevacizumab and erlotinib in women with refractory ovarian cancer. AACR 2009.
512. Calvert V, Longo C, Einspahr J, Deng J, Liotta L, Pellicani G, Bowden GT, **Alberts D**, Curiel-Lewandrowski C, Krouse R, Prasad A, Petricoin E. Protein network analysis of SCC reveals the AK-SCC transition occurs through EGFR-driven signaling through MAPK/AKT/mTOR. AACR 2009.
513. Einspahr JG, Calvert V, Olson E, Curiel-Lewandrowski C, Longo C, Deng J, Lance L, Pellicani G, **Alberts DS**, Krouse R, Prasad A, Bowden GT, Petricoin EF. Protein network analysis of acutely UV-irradiated mouse skin and human samples representing the progression of Cutaneous SCC. SID 2009.
514. Knight DD, Liu PY, Smith HO, Wilczynski SP, Robinson WR, Markman M, Fruehauf JP, **Alberts DS**, Tiersten AD. Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: A Southwest Oncology Group Study. Western Assn Gyn Onc 2009.
515. Hess LM, Chambers SK, Hatch K, Hallum A, Janicek MF, Buscema J, Borst M, Johnson C, Slayton L, Chongpison Y and **Alberts DS**. Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. Amer Soc Clin Oncol, 2009.
516. Sekulic A, Kim SY, Hostetter G, Savage S, Einspahr JG, Prasad A, Sagerman P, **Alberts DS**, Trent JM, Bittner M., Krouse RS. Inositol polyphosphate-5-phosphatase (INPP5A) expression is frequently reduced in squamous cell carcinoma (SCC) of the skin. Amer Assn for Can Res, 2009.
517. **Alberts DS**, Jacobs E, Thompson P, Hus P, Martinez E, Lance P. Colon cancer prevention: Trials, Tribulations, and Triumphs. Amer Inst for Can Res, 2009.

518. Chambers, SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Issacs JD, Gordon AN, Wright HM, Cohen JL, **Alberts DS**. Tissue VEGF-A levels may portend increased likelihood of progression of ovarian cancer in a phase II trial of bevacizumab and erlotinib. *Soc Gyn Oncol*, 2009.
519. Marshall JR, Tangen CM, Sakr W, Wood DP, Lippman SM, Jarrard DF, **Alberts DS**, Berry DL, Crawford ED, Thompson I. Southwest Oncology Group (SWOG) trial S9917: Randomized phase 3 trial of selenium supplementation to prevent prostate cancer among men with high grade prostatic intraepithelial neoplasias (HGPIN). *Amer Soc Clin Oncol*, 2010.
520. **Alberts DS**. Should endpoints for trials in recurrent disease vary from those of first-line trials? 4th Ovarian Cancer Consensus Conference, UBC Life Sciences institute, Vancouver, BC, 2010.
521. Glazer ES, Bartels PH, Yozwiak M, Prasad AR, Bartels HG, **Alberts DS**, Krouse RS. Karyometry of Cutaneous squamous cell carcinoma discriminates between aggressive and nonaggressive phenotypes. *Soc Surgical Onc*, 2010.
522. Einspahr JG, Calvert V, **Alberts DS**, Curiel-Lewandrowski C, Warneke J, Stratton SP, Liotta L, Pellicani G, Krouse R, Prasad A, Deng J, Bowden GT, Petricoin EF. Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. *Amer Assn for Can Res*, 2010.
523. Tang D, Nevins R, Sullivan S, **Alberts DS**, Skrepnek GH. Health expenditures, disability days, and resource utilization associated with cancer in employer settings in the United States. *Intl Soc Pharmacoeconomic and Outcomes Res*, 2011.
524. Bernudez Y, Stratton SP, Bowden GT, Dong Z, Bode AM, Curiel-Lewandrowski C, Warneke J, Hurst CA, Lang JE, **Alberts DS**, Einspahr JG. Crosstalk between UV-induced PI-3 kinase/Akt/mTOR and Fyn/RSK2 Signaling Pathways: Implications in Skin Carcinogenesis. *Society of Investigational Dermatology*, 2011.
525. Chu D, Chansky K, Fenoglio-Preiser C, **Alberts D**, Meyskens F, Goodman G, Lippman S. Adenoma recurrences after resection of colorectal carcinoma (CRC). Results from the SWOG 9041 calcium chemoprevention pilot study. *Annals of Surgical Oncology* 9(1) Supple:S24(#52), 2002.
526. **Alberts DS**. Does Diet and Physical Activity Increase Progression-Free Survival in Ovarian Cancer? *Ovarain National Alliance*, 2011.
527. **Alberts DS**, Garcia FAR, Trimble CL, Kauderer J, Curtin J, Lim PC, Hess LM, Silverberg S, Zaino RJ, Yozwiak M, Bartels HG, Bartels PH. Karyometry in atypical endometrial hyperplasia: A Gynecologic Oncology Group Study, *Proceedings of the American Association for Cancer Research*, Volume 53, #4614, 2012.
528. Coleman RL, Moon J, Sood AK, Branham D, Bonebrake AJ, Anderson G, **Alberts DS**, Markman, M. Randomized phase II study of docetaxel plus vandetanib (V+D) versus docetaxel followed by vandetanib (DV) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. *American Association for Clinical Oncology*, 2012.
529. Tate WR, Skrepnek GH, **Alberts DS**. Advanced disease in ovarian cancer: Clinical and economic outcomes within hospital inpatient settings. *International Society for Pharmacoeconomics and Outcomes Research*, 2012.
530. Glazer ES, Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, **Alberts DS**, Krouse RS. The proportion of atypical nuclei and the relative frequency of highly atypical nuclei determine aggressiveness in cutaneous squamous cell carcinoma. *American College of Surgeons*, 2012.
531. Bowden GT, Einspahr JG, Curiel C, Stratton SP, Dong Z, Petricoin EF and **Alberts DS**. Thirty-Five Years with Bowden and Alberts: Down the Molecularly-Targeted Road to Skin Cancer Prevention. 10th *International Skin Carcinogenesis Conference*, 2012.

532. Glazer ES, Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, **Alberts DS** and Krouse RS. Quantitative Histopathology to Accurately Predict the Natural History of Newly Resected Skin Squamous Cell Carcinomas. 10th International Skin Carcinogenesis Conference, 2012.
533. Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, **Alberts DS**, Krouse RS. The Relative Frequency of Highly Aggressive Nuclei Determine Aggressiveness in Cutaneous Squamous Cell Carcinoma. American College of Surgeons 98th Annual Clinical Congress, Chicago, IL, 2012.
534. Glazer ES, Bartels PH, DaSilva, FD, Morgan SS, Bartels HG, Yozwiak ML, Einspahr JG, Cranmber LD, **Alberts DS**, Krouse, RS. Quantitative Histopathology identifies patients with thin melanomas that have high metastatic risk. Academic Surgical Congress, 2013.
535. Raja FA, Counsell N, Colombo N, Parmar MK, Pfisterer J, Vergote IB, Gonzalez-Martin A, Alberts DS, Ledermann JA. Platinum combination chemotherapy versus platinum monotherapy in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomized trials using individual patient data. ESMO, 2012.
536. Einspahr JG, Curiel-Lewandrowski C, Petricoin EF, Bermudez Y, Hu C, **Alberts DS**, Bowden GT, Saboda K, Calvert V, Liotta L, Stratton SP. Functional protein pathway activation mapping of normal skin exposed to solar simulated light. International Investigative Dermatology, 2013.